P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1A  PH A S E  3  R A N DOM I Z E D ,  DO U B L E -B L I N D ,  P L A C E BO -CO N T RO L L E D ,  
P A R A L L E L  G RO U P ,  M U L T I - C E N T E R  S T U D Y  TO  E V A L U A T E  TH E  E F F I C A C Y  
A N D  S A F E T Y  O F  P F -0 4 9 6 5 8 4 2  MO NO TH E R A P Y I N  S U B J E C T S  AG E D  1 2  Y E A R S  
A N D  O L D E R ,  W I TH  MO D E R A T E  TO  S E V E R E  A TO P I C  D E RM A T I T I S 
I n v e s t i g a t i o n a l  P r o d u c t  N um b e r : P F - 0 4 9 6 5 8 4 2 
I n v e s t i g a t i o n a l  P r o d u c t  N am e : N o t  a p p l i c a b l e  ( N / A ) 
U n i t e d  S t a t e s  ( U S )  I n v e s t i g a t i o n a l  N e w  
D r u g  ( I N D )  N um b e r : 
E u r o p e a n  C l i n i c a l  T r i a l s  D a t a b a s e  
( E u d r a C T )  N um b e r : 2 0 1 8 - 0 0 1 1 3 6 - 2 1 
P r o t o c o l  N um b e r : B 7 4 5 1 0 1 3 
P h a s e : C C I 
3
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 2Document History
Document Version Date Summary of Changes and Rati onale
Amendment 3 06 December 2018 For Japan and Republic of Korea only :
Similar to China, other countries in Asia,
such as Japan and Republic of Korea, have 
a high prevalence of hepatitis B surface 
antigen (HBsAg) negative, hepatitis B core 
antibody  (HB cAb) positive, and hepatitis B 
surface antibod y (HBsAb) positive 
serology . Therefore, Republic of Korea 
will adopt the same changes and Japan will 
adopt similar changes as those proposed 
for China in Amendment 2tomonitor the 
risk of hepatitis B reactiva tion.  The 
following sections of the protocol are 
affected: Schedule of Activities, 
Sections 4.2, 6.1, 6.2.7, 7.6.2, [IP_ADDRESS] and 
Appendix 1 .
For Japan only : 
Based on local request, HBsAg, HBcAb 
and HBsAb testing wil l be performed 
concurrently  at Screenin
g for all subjects 
rather than performing HBsAb as a reflex 
test only .  
Based on local practices for tuberculosis 
testing in Japan, if QuantiFERON-TB 
Gold I n-Tube (QTF -G)testing is not 
possible , the T - SPOT.TBtest performed 
at
a local laboratory is acceptable as the 
screening TB test .The following sections 
of the protocol are affected: Schedule of 
Activities, Sections 4.2, 6.1, 7.3.[ADDRESS_80775] HBV DNA above the 
lower limit of quantification (LLQ ) will be 
excluded. Subje cts who are HBV DNA 
negative or below LLQ may  be 
randomized but will have repeat HBV 
DNA testing at Week 12 (or early  
termination).
The following sections of the protocol are 
affected:
Schedule of Activities;
Section 4.2. Exclusion Criteria;
Section 6.1. Visit 1, Screening ;
Section 6.2.7. Visit 8, Day 85/Week 12 
(±3 day s) or Earl y Termination Visit
;
Table of Laboratory  Tests in 
Section 7.6.2. L aboratory Testing ;
Section [IP_ADDRESS]. Hepatitis Testing.
The protocol changes specified in Protocol 
Administrative Change Letter #1 (09 May  
2018) have been incorporated in Section 
4.[ADDRESS_80776] bullet , and 
Section 7.8.1 Pruritus Numerical Rating 
Scale (NRS) .
The protocol changes specified in Protocol 
Administrative Change Letter #2 (23 Jul 
2018) have be en incorporated in 
Appendix 3. Prohibited Concomitant 
Medications .

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 4Amendment 1 13 July  2018 Added European Clinical Trials Database 
(EudraCT) Number on the cover page.
The following changes were requested 
from the Voluntary  Harmonisation 
Procedure (VHP) for participating member 
states only  (Czech Republic, German y, 
Hungary , Latvia, Poland, United 
Kingdom) :
1.In Section 1.2.4, additional text was 
added to present the model -estimated 
proportion of subjects achieving 
EASI -[ADDRESS_80777] of abbreviations has been updated 
to include VHP.
Final Protocol 27February 2018 Not applicable (N/A)
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics 
committees (ECs).

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  5T A B L E  O F  CO N T E N T S 
L I S T  O F  T A B L E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
L I S T  O F  F I G U R E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
A P P E N D I C E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
P R O T O C O L  S UMM A R Y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 
S C H E D U L E  O F  A C T I V I T I E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8 
1 .  I N T R O D U C T I O N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4 
1 . 1 .  M e c h a n i sm  o f  A c t i o n / I n d i c a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4 
1 . 2 .  B a c k g r o u n d  a n d  R a t i o n a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5 
1 . 2 . 1 .  D r u g  D e v e l o pm e n t  a n d  R a t i o n a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5 
1 . 2 . 2 .  A t o p i c  D e rm a t i t i s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5 
1 . 2 . 3 .  N o n -C l i n i c a l  a n d  P h a s e  1  D a t a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7 
1 . 2 . 4 .  P h a s e  2 b  i n  A D  ( B 7 4 5 1 0 0 6 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7 
1 . 3 .  S umm a r y  o f  P F -0 4 9 6 5 8 4 2  C l i n i c a l  P h a rm a c o k i n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8 
1 . 3 . 1 .  P o p u l a t i o n  P h a rm a c o k i n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9 
1 . 4 .  S umm a r y  o f  B e n e f i t s  a n d  R i s k s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9 
1 . 5 .  D o s e  S e l e c t i o n  R a t i o n a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0 
2 .  S T U D Y  O B J E C T I V E S  A N D  E N D P O I N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1 
3 .  S T U D Y  D E S I G N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3 
4 .  S U B J E C T  E L I G I B I L I T Y  C R I T E R I A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 
4 . 1 .  I n c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 
4 . 2 .  E x c l u s i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7 
4 . 3 .  R a n d om i z a t i o n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2 
4 . 4 .  L i f e s t y l e  R e q u i r em e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2 
4 . 4 . 1 .  C o n t r a c e p t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3 
4 . 4 . 2 .  V a c c i n e  a n d  E x p o s u r e  t o  I n f e c t i o n s  G u i d e l i n e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 
4 . 4 . 2 . 1 .  S u b j e c t  S p e c i f i c  R e c omm e n d a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 
4 . 4 . 2 . 2 .  G u i d a n c e  R e g a r d i n g  H o u s e h o l d  C o n t a c t  V a c c i n e -R e l a t e d  
E x p o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 
4 . 4 . 3 .  S u r g e r y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5 
4 . 5 .  S p o n s o r ’ s  Q u a l i f i e d  M e d i c a l  P e r s o n n e l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  65 .  S T U D Y  T R E A TM E N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6 
5 . 1 .  A l l o c a t i o n  t o  T r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6 
5 . 2 .  B r e a k i n g  t h e  B l i n d . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7 
5 . 3 .  S u b j e c t  C om p l i a n c e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7 
5 . 4 .  I n v e s t i g a t i o n a l  P r o d u c t  S u p p l i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8 
5 . 4 . 1 .  D o s a g e  F o rm ( s )  a n d  P a c k a g i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8 
5 . 4 . 2 .  P r e p a r a t i o n  a n d  D i s p e n s i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8 
5 . 5 .  A dm i n i s t r a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8 
5 . 6 .  I n v e s t i g a t i o n a l  P r o d u c t  S t o r a g e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 9 
5 . 7 .  I n v e s t i g a t i o n a l  P r o d u c t  A c c o u n t a b i l i t y. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0 
5 . 7 . 1 .  D e s t r u c t i o n  o f  I n v e s t i g a t i o n a l  P r o d u c t  S u p p l i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0 
5 . 8 .  C o n c om i t a n t  T r e a tm e n t ( s ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0 
5 . 8 . 1 .  P e rm i t t e d  C o n c om i t a n t  M e d i c a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1 
5 . 8 . 2 .  P r o h i b i t e d  M e d i c a t i o n s  a n d  T r e a tm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2 
6 .  S T U D Y  P R O C E D U R E S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2 
6 . 1 .  V i s i t  1 ,  S c r e e n i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3 
6 . 2 .  T r e a tm e n t  P e r i o d . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6 
6 . 2 . 1 .  V i s i t  2 ,  D a y  1 /W e e k  0  ( B a s e l i n e ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6 
6 . 2 . 2 .  V i s i t  3 ,  D a y  8 /W e e k  1  ( 1  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7 
6 . 2 . 3 .  V i s i t  4 ,  D a y  1 5 /W e e k  2  ( 1  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7 
6 . 2 . 4 .  V i s i t  5 ,  D a y  2 9 /W e e k  4  ( 2  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8 
6 . 2 . 5 .  V i s i t  6 ,  D a y  4 3 /W e e k  6  ( 3  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9 
6 . 2 . 6 .  V i s i t  7 ,  D a y  5 7 /W e e k  8  ( 3  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0 
6 . 2 . 7 .  V i s i t  8 ,  D a y  8 5 /W e e k  1 2  ( 3  d a y s )  o r  E a r l y  T e rm i n a t i o n  V i s i t . . . . . . . . . . . . . . . . . 6 1 
6 . 3 .  F o l l o w -u p  V i s i t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2 
6 . 3 . 1 .  V i s i t  9 ,  D a y  1 2 0 /W e e k  1 6  ( 3  d a y ). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2 
6 . 4 .  S u b j e c t  W i t h d r a w a l . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3 
7 .  A S S E S SM E N T S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5 
7 . 1 .  P r e g n a n c y  T e s t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5 
7 . 3 .  S a f e t y  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7 
7 . 3 . 1 .  V i t a l s  S i g n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 7 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  77 . 3 . 2 .  M e d i c a l  H i s t o r y ,  P h y s i c a l  E x am i n a t i o n ,  H e i g h t ,  a n d  W e i g h t . . . . . . . . . . . . . . . . . . . . 6 8 
7 . 3 . 3 .  C h e s t  X -R a y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9 
7 . 3 . 4 .  T u b e r c u l o s i s  T e s t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9 
7 . 3 . 5 .  E l e c t r o c a r d i o g r am . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0 
7 . 3 . 6 .  S p e c i a l  S a f e t y  A s s e s sm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0 
7 . 4 .  S k i n  T y p e  A s s e s sm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 0 
7 . 5 .  A s s e s sm e n t  o f  S u i c i d a l  I d e a t i o n  a n d  B e h a v i o r . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 5 . 1 .  C o l um b i a  S u i c i d e  S e v e r i t y  R a t i n g  S c a l e  ( C -S S R S ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 5 . 2 .  S u i c i d a l  B e h a v i o r s  Q u e s t i o n n a i r e -R e v i s e d  ( S B Q -R ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 5 . 3 .  P a t i e n t  H e a l t h  Q u e s t i o n n a i r e  –8  i t em s  ( P H Q - 8 ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 6 .  C l i n i c a l  L a b o r a t o r y  T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 6 . 1 .  B l o o d  V o l um e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 6 . 2 .  L a b o r a t o r y  T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1 
7 . 6 . 2 . 1 .  H e p a t i t i s  T e s t i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 3 
7 . 6 . 2 . 2 .  V a r i c e l l a  Z o s t e r  V i r u s  ( V Z V )  I g G  A n t i b o d y  ( A b )  T e s t i n g . . . . . . 7 4 
7 . 6 . 2 . 3 .  B a s e l i n e  V i r a l  S c r e e n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
7 . 7 .  E f f i c a c y  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
7 . 7 . 1 .  R a t e r  Q u a l i f i c a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
7 . 7 . 2 .  I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t  ( I G A ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4 
7 . 7 . 3 .  E c z em a  A r e a  a n d  S e v e r i t y  I n d e x  ( E A S I ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 5 
7 . 7 . 3 . 1 .  B o d y  S u r f a c e  A r e a  –E f f i c a c y  ( B S A  E f f i c a c y ) . . . . . . . . . . . . . . . . . . . . . . . . . 7 8 
7 . 7 . 4 .  S c o r i n g  A t o p i c  D e rm a t i t i s  ( S C O R A D ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 8 
7 . 7 . 5 .  P h o t o g r a p h y  o f  R e p r e s e n t a t i v e  A D  L e s i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 9 
7 . 8 . 2 .  N i g h t  T im e  I t c h  S c a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 0 
 
 C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  8 
7 . 9 .  P h a rm a c o k i n e t i c s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3 
7 . 9 . 1 .  P l a sm a  f o r  A n a l y s i s  o f  P F -0 4 9 6 5 8 4 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 3 
7 . 9 . 2 . S h i pm e n t  o f  P h a rm a c o k i n e t i c  S am p l e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 
8 .  A D V E R S E  E V E N T  R E P O R T I N G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 
8 . 1 .  R e q u i r em e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 4 
8 . 1 . 1 .  A d d i t i o n a l  D e t a i l s  o n  R e c o r d i n g  A d v e r s e  E v e n t s  o n  t h e  C R F . . . . . . . . . . . . . . . . . . . 8 5 
8 . 1 . 2 .  E l i c i t i n g  A d v e r s e  E v e n t  I n f o rm a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 5 
8 . 1 . 3 .  W i t h d r a w a l  f r om  t h e  S t u d y  D u e  t o  A d v e r s e  E v e n t s  ( s e e  a l s o  t h e  
S u b j e c t  W i t h d r a w a l  S e c t i o n ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 5 
8 . 1 . 4 .  T im e  P e r i o d  f o r  C o l l e c t i n g  A E / S A E  I n f o rm a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 6 
8 . 1 . 4 . 1 .  R e p o r t i n g  S A E s  t o  P f i z e r  S a f e t y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 6 
8 . 1 . 4 . 2 .  R e c o r d i n g  N o n -s e r i o u s  A E s  a n d  S A E s  o n  t h e  C R F . . . . . . . . . . . . . . . . . 8 6 
8 . 1 . 5 .  C a u s a l i t y  A s s e s sm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 6 
8 . 1 . 6 .  S p o n s o r ’ s  R e p o r t i n g  R e q u i r em e n t s  t o  R e g u l a t o r y  A u t h o r i t i e s . . . . . . . . . . . . . . . . . . 8 7 
8 . 2 .  D e f i n i t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7 
8 . 2 . 1 .  A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 7 
8 . 2 . 2 .  A b n o rm a l  T e s t  F i n d i n g s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 8 
8 . 2 . 3 .  S e r i o u s  A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 8 
8 . 2 . 4 .  H o s p i t a l i z a t i o n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 9 
8 . 3 .  S e v e r i t y  A s s e s sm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
8 . 4 .  S p e c i a l  S i t u a t i o n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
8 . 4 . 1 .  P r o t o c o l - S p e c i f i e d  S e r i o u s  A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
8 . 4 . 2 .  P o t e n t i a l  C a s e s  o f  D r u g -I n d u c e d  L i v e r  I n j u r y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 0 
8 . 4 . 3 .  E x p o s u r e  t o  t h e  I n v e s t i g a t i o n a l  P r o d u c t  D u r i n g  P r e g n a n c y  o r  
B r e a s t f e e d i n g ,  a n d  O c c u p a t i o n a l  E x p o s u r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2 
8 . 4 . 3 . 1 .  E x p o s u r e  D u r i n g  P r e g n a n c y . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 2 
8 . 4 . 3 . 2 .  E x p o s u r e  D u r i n g  B r e a s t f e e d i n g . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 4 C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [IP_ADDRESS]. Occupational Exposure .............................................................94
8.4.4. Medication Errors .......................................................................................94
[IP_ADDRESS]. Medication Errors ......................................................................94
9. DATA ANALYSI S/STA TISTICAL  METHODS ...............................................................[ADDRESS_80778] KEEPI[INVESTIGATOR_1645] ...........................................................100
11.1. Case Report Forms/Electronic Data Record .......................................................[ADDRESS_80779]/Ethics Committee ....................................................[ADDRESS_80780] OF TABLES
Table 1. Objectives and Endpoints: ....................................................................................[ADDRESS_80781] Administration ................................................................49
Table 3. Investigator’s Global Assessment (IGA) Score ....................................................75
Table 4. Clinical Sign Severity  Scoring Criteria for the Eczema Area and Severit y 
Index (EASI) .........................................................................................................76
Table 5. Handprint Determination of Bod y Surface Area (BSA) .......................................77
Table 6. Eczema Area and Severity  Index (EASI) Area Score Criteria .............................77
Table 7. Eczema Area and Severity Index (EASI) Bod y Region Weighting .....................[ADDRESS_80782] OF FIGURES
Figure 1. Study  Design Schematic .......................................................................................34
Figure 2. Schematic for Multiple Testing Procedure ...........................................................97
APPENDICES
Appendix 1. Abbreviations ................................ ................................ ................................ ....110
Appendix 2. Diagnostic Criteria for A topic Dermatitis .........................................................115
Appendix 3. Prohibited Concomitant Medications ................................................................116
Appendix 4. Guidelines for Monitoring and Discontinuatio
n ...............................................117
Appendix 5. Fitzpatrick Skin Ty pe
........................................................................................119
Appendix 6. Pruritus Severity and Frequency  (Pruritus NRS) ..............................................120
Appendix 7. Night Time Itch Scale .......................................................................................121
Appendix 8. Patient Global Assessment (PtGA) ...................................................................122
Appendix 9. European Quality  of Life 5
-Dimension 5 -Level Scale (EQ -5D-5L) and 
European Quality  of Life 5-Dimension Youth Scale (EQ -5D-Y)......................123
Appendix 10. Dermatology  Life Qualit y Index (DLQI ) and Children’s Dermatology  
Life Qualit y Index (CDLQI) ...............................................................................127
Appendix 11. Patient
-Oriented Eczema Measure (POEM) ................................ ................... 129
Appendix 12.Hospi[INVESTIGATOR_74017] (HADS) ...........................................130
Appendix 13. Pruritus and Sy mptoms Assessment for Atopic Dermatitis (PSAAD) 
Symptom Diary ................................ ................................ ................................ ...132
Appendix 14. SF -36v2, Acute ................................ ................................ ............................... 136

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 11Appendix 15. Work Productivity  and Activity  Impairment Questionnaire: Atopic 
Dermatitis ...........................................................................................................142
Appendix 16. FACI T
-F and Peds- FACIT -F..........................................................................144
Appendix 17. C
-SSRS – Columbia Suicide Severity  Rating Scale .......................................146
Appendix
18. SBQ -R –Suicide Behaviors Questionnaire –Revised ...................................149
Appendix 19. Patient Health Questionnaire –8 items ...........................................................150

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 12PROTOCOL SUMMARY
Background and Rationale:
Atopic dermatitis (AD), also known as atopic eczema, is a common, chronic, inflammatory
skin disorder characterized by [CONTACT_74053], intense pruritus, and a general deterioration
in quality of life.  Over the past 50 years, AD has become more prevalent, especiall y in 
industrialized, temperate countries such as the [LOCATION_002] (US).1,2Earlier reports indicated 
that, in up to 70% of cases, the disease greatl y improves or resolves by[CONTACT_74054], 
however more recent findings suggest that disease activity  remains manifest for a prolonged 
period of time.  Based on a total of 7157 patients enrolled in the Pediatric Eczema Elective 
Registry  (PEER) study , comprising a total of 22,[ADDRESS_80783] well into the second decade of a child’s life 
and likely  longer.3  At every  age, more than 80% of PEER study  subjects had sy mptoms of 
AD and/or were using medication to treat their AD.
There area limited number of treatments available for AD. Current treatments 
include 
emollients, topi[INVESTIGATOR_11930] (eg, betamethasone, clobetasol, fluocinonide), topi[INVESTIGATOR_74018] (eg, pi[INVESTIGATOR_031], tacrolimus), and coal tar preparations.  Crisaborole 
was approved as a topi[INVESTIGATOR_74019] 2016 by [CONTACT_2165] 
(FDA) for use in patients with mild to moderate AD.  Additional treatments generall y 
reserved f or severe AD include phototherapy (eg, ultraviolet A light [UVA] with or without 
psoralen, ultraviolet B light [UVB] narrowband or broadband) and s ystemic agents (eg, 
corticosteroids, cy closporine, recombinant interferon gamma (IFN-, mycophenolate mofetil , 
methotrexate [MTX], azathioprine, intravenous immunoglobulin).4  Of the currentl y 
available therapi[INVESTIGATOR_014], none offers a cure; therefore, the
main aims of existing treatments are to 
reduce the occurrence of acute flares, to increase the time between relapses, and to reduce 
pruritus and the resulting sleep disturbance.5,6
Other s ystemic agents to treat AD are under clinical dev elopment or recently  approved.  
Dupi[INVESTIGATOR_12458], an injectable human monoclonal antibody targeting interleukin (IL) -4 
and -13,was approved by  [CONTACT_69391] 2017 and received marketing authorization in 
Europe in September 2017, and offers a novel mechanism of action for the treatment of 
moderate to severe AD.  However, the approved dosing for dupi[INVESTIGATOR_74020] 
2x 300 mg subcutaneous injections followed by 300 mg every  other week injections may  
limit the desirability  of this route of treatment.
Key cytokines implicated in the pathophy siology of AD include IL-4,IL-5,IL-13,IL-31,
and IFN -, require Janus kinase 1 (JAK1) for signal transduction; this suggests that selective
JAK1 inhibitors that modulate the activity ofthese cytokines represent a compelling
approach to the treatment of inflammatory skin diseases such as AD.7
PF-04965842 is an orall y bioavailable small molecule that selectively  inhibits JAK1 by
[CONTACT_74055] (ATP) binding site. PF-[ADDRESS_80784] other kinases: 28- fold selectivity over JAK2, >340 -fold over JAK3 and 
43-fold over t yrosine kinase 2 (TYK2), as well as a good selectivity profile over the broader 
range of human kinases. The selective inhibition of JAK1 will lead to modulation of 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 m u l t i p l e  c y t o k i n e  p a t h w a y s  i n v o l v e d  i n  t h e  p a t h o p h y s i o l o g y o f  A D , i n c l u d i n g 
I L - 4 , I L - 5 , I L -1 3 ,  I L -3 1  a n d  I F N -.   D a t a  f r om  a  P h a s e 2 b  p r o o f  o f  c o n c e p t  ( P O C )  s t u d y  
( B 7 4 5 1 0 0 6 )  t h a t  e v a l u a t e d  s u b j e c t s  w i t h  m o d e r a t e  t o  s e v e r e  A D  h a v e  s h o w n  p o s i t i v e  
e f f i c a c y ,  a s  w e l l  a s  a n  a c c e p t a b l e  s a f e t y  p r o f i l e ,  s u f f i c i e n t  t o  s u p p o r t  f u r t h e r  c l i n i c a l  
d e v e l o pm e n t  i n  a  l a r g e r  P h a s e 3  p r o g r am . 
O b j e c t i v e s  a n d  E n d p o i n t s   
P r im a r y  O b j e c t i v e : 
T o  a s s e s s  t h e  e f f i c a c y  o f  P F - 0 4 9 6 5 8 4 2  c om p a r e d  w i t h  p l a c e b o  i n  s u b j e c t s  a g e d  
1 2 y e a r s  a n d  o l d e r  w i t h  m o d e r a t e  t o  s e v e r e  A D . 
S e c o n d a r y  O b j e c t i v e : 
T o  e v a l u a t e  t h e  e f f e c t  o f  P F - 0 4 9 6 5 8 4 2  o n  a d d i t i o n a l  e f f i c a c y  e n d p o i n t s  a n d  
p a t i e n t -r e p o r t e d  o u t c om e s  o v e r  t im e  i n  s u b j e c t s  a g e d  1 2 y e a r s  a n d o l d e r  w i t h  
m o d e r a t e  t o  s e v e r e  a t o p i c  d e rm a t i t i s . 
S a f e t y  O b j e c t i v e :
T o  e v a l u a t e  t h e  s a f e t y  a n d  t o l e r a b i l i t y  o f  P F -0 4 9 6 5 8 4 2  i n  s u b j e c t s  a g e d  1 2 y e a r s  a n d  
o l d e r  w i t h  m o d e r a t e  t o  s e v e r e  a t o p i c  d e rm a t i t i s  f o l l o w i n g  1 2 w e e k s  o f  t r e a tm e n t . 
P h a rm a c o k i n e t i c  O b j e c t i v e :  
T o  e v a l u a t e  t h e  p h a rm a c o k i n e t i c s  ( P K ) o f  P F -0 4 9 6 5 8 4 2  i n  s u b j e c t s  a g e d  1 2 y e a r s  a n d  
o l d e r  w i t h  m o d e r a t e  t o  s e v e r e  a t o p i c  d e rm a t i t i s  f o l l o w i n g  1 2 w e e k s  o f  t r e a tm e n t . 
 
 
 
E n d p o i n t s 
P r im a r y  E f f i c a c y E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  t h e  I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t  ( I G A )  s c o r e  o f  c l e a r  ( 0 )  o r  
a lm o s t  c l e a r  ( 1 )  ( o n  a  5 -p o i n t  s c a l e )  a n d  a  r e d u c t i o n  f r om  b a s e l i n e  o f  2p o i n t s  a t  
W e e k 1 2 .   T h e  b a s e l i n e  w i l l  b e  d e f i n e d  a s  t h e  I G A  s c o r e  o n  D a y 1  p r e -d o s e ; 
R e s p o n s e  b a s e d  o n  t h e  E c z em a  A r e a  a n d  S e v e r i t y  I n d e x  7 5%  im p r o v em e n t  f r om  
b a s e l i n e  ( E A S I -7 5 )  r e s p o n s e  a t  W e e k 1 2 .   T h e  b a s e l i n e  w i l l  b e  d e f i n e d  a s  t h e  E A S I  
s c o r e  o n  D a y 1  p r e -d o s e .   C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 K e y  S e c o n d a r y  E f f i c a c y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a t  l e a s t  4 p o i n t s  im p r o v em e n t  i n  t h e  s e v e r i t y  o f p r u r i t u s  n um e r i c a l  
r a t i n g  s c a l e  ( N R S )  f r om  b a s e l i n e  a t  W e e k s 2 ,  4 ,  a n d  1 2 ; 
C h a n g e  f r om  B a s e l i n e  i n  P r u r i t u s  a n d  S y m p t om s  A s s e s sm e n t  f o r  A t o p i c  D e rm a t i t i s  
( P S A A D )  t o t a l  s c o r e a t  W e e k 1 2 . 
S e c o n d a r y  E f f i c a c y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a t  l e a s t  4 p o i n t s  im p r o v em e n t  i n  t h e  s e v e r i t y  o f p r u r i t u s  n um e r i c a l  
r a t i n g  s c a l e  ( N R S )  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  o t h e r  t h a n  W e e k s2 ,  4  
a n d  1 2 ;  
T im e  t o  a c h i e v e  a t  l e a s t 4p o i n t sim p r o v em e n t  i n  t h e  s e v e r i t y  o f  p r u r i t u s  N R S  s c a l e  
f r om  b a s e l i n e  b y  D a y  1 5 ; 
R e s p o n s e  b a s e d  o n  t h e  E A S I -7 5  a t  a l l  s c h e d u l e d  t im e  p o i n t s  e x c e p t  W e e k 1 2 ; 
R e s p o n s e  b a s e d  o n  t h e  I G A  o f  c l e a r  ( 0 )  o r  a lm o s t  c l e a r  ( 1 )  a n d  2p o i n t  r e d u c t i o n  
f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  e x c e p t  W e e k 1 2 . 
O t h e r  E f f i c a c y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a  5 0%  a n d  9 0%  im p r o v em e n t  i n  t h e  E A S I  t o t a l  s c o r e  
( E A S I - 5 0 a n d  E A S I -9 0 )  a t  a l l  s c h e d u l e d  t im e  p o i n t s ; 
C h a n g e  f r om  b a s e l i n e  i n  t h e  p e r c e n t a g e  B o d y  S u r f a c e  A r e a  ( B S A )  a f f e c t e d  a t  a l l  
s c h e d u l e d  t im e  p o i n t s ; 
R e s p o n s e  b a s e d  o n  a  5 0%  a n d  7 5%  im p r o v em e n t  i n  S c o r i n g  A t o p i c  D e rm a t i t i s  
( S C O R A D )  ( S C O R A D - 5 0 ,  S C O R A D -7 5 )  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s ; 
C h a n g e  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  i n  S C O R A D -s u b j e c t i v e  
a s s e s sm e n t s  o f  i t c h  a n d  s l e e p  l o s s . 
 
 
 
 
 
 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 5  
 
 
 
 
 
 
 
 
S a f e t y  E n d p o i n t s : 
I n c i d e n c e  o f  t r e a tm e n t  em e r g e n t  a d v e r s e  e v e n t s ; 
I n c i d e n c e  o f  S e r i o u s  A d v e r s e  E v e n t  ( S A E ) s  a n d  A d v e r s e  E v e n t  ( A E ) s  l e a d i n g  t o  
d i s c o n t i n u a t i o n ; 
T h e  i n c i d e n c e  o f  c l i n i c a l  a b n o rm a l i t i e s  a n d  c h a n g e  f r om  b a s e l i n e  i n  c l i n i c a l  
l a b o r a t o r y  v a l u e s ,  e l e c t r o c a r d i o g r am  ( E C G )  m e a s u r em e n t s ,  a n d  v i t a l  s i g n s . 
P h a rm a c o k i n e t i c  E n d p o i n t : 
P o p u l a t i o n  P K  c h a r a c t e r i z a t i o n  i n  s u b j e c t s  a g e d  1 2  y e a r s  a n d  o l d e r w i t h  m o d e r a t e  t o  
s e v e r e  a t o p i c  d e rm a t i t i s .  
 
 
 C
C
I
C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 16Study Design
This is a randomized, double -blind, placebo -controlled, parallel -group, Phase 3 study  to 
evaluate the efficacy  and safet y of PF -04965842 monotherap y in subjects aged 12 years and 
older with moderate to severe AD and a bod y weight  40kg.  The treatment duration is 
12weeks.  Subjects will be screened within [ADDRESS_80785] selection criteria for the study .  A total of 
approximately  375
subjects will be enrolled from approximately 85sites located globall y.  
Adolescent subjects below the age of 18 years old (or country -specific age of majority )will
only be enrolled in this study  if instructed b y the sponsor and approved b y the country  or 
regulatory /health authority .  If these approvals have not been granted, onl y subjects aged 
18years(or country -specific age of majority )and older will be enrolled.
Qualified subjects completing the [ADDRESS_80786] the option 
to enter a long -term extension (L TE) study  B7451015.  Subjects discontinuing earl y from 
treatment, or who are otherwise ineligible for the LTE stud y will undergo a [ADDRESS_80787] ch ronic moderate to severe AD as defined per the inclusion criteria will 
be randomized to receive 200 mg or 100 mg PF-04965842 once dail y (QD), or matching 
placebo.  Investigators, subjects, and the sponsor study  team will be blinded as to treatment 
group.
After providing informed consent, subjects will be assessed for stud y eligibility  at the 
screening visit.  For subjects younger than 18 years old(or country -specific age of majority ),
their parent(s)/legal guardian will provide supplementary  or sole writte n consent and minor 
children will provide assent, according to local regulations and rules regarding ability  to give 
assent and consent.  Subjects will undergo screening within 28 days prior to randomization.  
During the screening period, treatments for AD will be washed out, as applicable, according 
to eligibility  requirements.  Subjects may  be re -screened once if they  fail the screening 
evaluation for reasons related to incidental transitory  conditions, unless the reason for the 
screen failure is the dise ase severit y inclusion criteria. 
Subjects who continue to meet eligibility  criteria at baseline will undergo Day 1/baseline 
assessments and be randomized in a 2:2:1 ratio to receive 200 mg PF -04965842 (N=150) or 
100mg PF -04965842 QD (N=150) or matching p lacebo (N=75) from Day 1. 
Randomization will be stratified b y baseline disease severit y (moderate [IGA = 3] vs. severe 
[IGA = 4] AD), and, age <18 and 18.  Eligible subjects must have a documented history  of 
inadequate response or intolerance to treatmen t with topi[INVESTIGATOR_74021].
Study Treatments
Doses of PF -04965842 will be 200 mg or 100 mg taken QD orall y, or matching 
placebo. 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 17Treatment duration will be 12 weeks (randomized period).
Subjects who do not enroll into the long term extension study , B7451015, will enter a 
4week follow -up post treatment period.
Statistical Methods
A total sample of [ADDRESS_80788] bo (2:2:1 randomization) would provide at least 95% power to 
detect a difference of at least 20% in IGA response rate between PF -04965842 200 mgQD 
(or PF -04965842 100 mg QD) and placebo, assuming the placebo response rate is 6% at 
Week 12.
Furthermore, th is will also provide at least 99% power to detect a difference of at least 
30% in EASI -75 response rate between PF -04965842 200 mgQD(or PF -04965842 100 mg 
QD) and placebo, assuming the placebo response rate is 15% at Week 12.
These two endpoints are co-primary  and both must achieve statistical significance to meet the 
primary  objective.
There are five key  hypotheses to be tested for each of the two PF -04965842 doses 
(200 mgQD and 100 mgQD) versus placebo, for the co -primary  endpoints and two key  
seconda ry endpoints.  For these hy potheses, the family wise Ty pe
-I error rate will be strongl y 
controlled at 5% using a sequential, Bonferroni -based iterative multiple testing procedure.  
This is described in further detail in the statistical anal ysis section of t he protocol and in the 
statistical analy sis plan (SAP).
For analy sis of the co- primary  endpoints, the (Cochran- Mantel -Haenszel) test adjusted by  
[CONTACT_68485] (baseline disease severit y and age) will be used.  If a subject withdraws 
from the study , then this subject will be counted as a non-responder for endpoints after 
withdrawal. 
For continuous endpoints, a mixed -
effect model with repeated measures (MMRM) will be 
used.  This model will include the factors (fixed effects) for treatment group, rando mization 
strata (age group, disease severit y), visit, treatment- by-visit interaction, and relevant baseline 
value.  Within the framework of MMRM, the treatment difference will be tested at the 
pre-specified primary  time point, Week 12, as well as at the other time points by  [CONTACT_74056] -specific contrasts from the MMRM model.
All subjects who receive investigational product (safet y population) will be included in the 
safet y analyses.  All the safet y data will be summarized descriptively through appropriate 
da
ta tabulations, descriptive statistics, categorical summaries, and graphical presentations.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 18SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMEN TSsections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed on the schedule of activities table, in order to 
conduct evaluations or assessments required to protect the well -being of the subject.
Visit IdentifieraDay -28
ScreeningDay 1
Week 0
BaselineDay 8
Week 1
CallDay 15
Week 2Day 29
Week 4Day 43
Week 6
CallDay 57
Week 8Day 85
Week 12 
(EOT/ET) EOS, 
Follow -up
Week 16
(4 Weeks 
after EOT or 
ET)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Visit Window None None 1 Day 1 Days 2 
Days3 Days3 Days 3 Days [ADDRESS_80789] using IRT system X
Inclusion/Exclusion Criteria X X
Demographics, Medical History, Tobacc o 
and Alcohol History, Atopic Dermatitis 
Disease HistorybX
Review Prior/Concomitant Medications & 
TreatmentsX X X X X X X X X
Dispense e -Diary and instruct subjects on use X
Provide Patient Emergency Contact [CONTACT_74057] X
Medical Procedures
Complete Physical ExamcX X X
Targeted Physical ExamcX X X X
Vital SignsdX X X X X X X
Additional Blood Pressure and Pulse Rate 
(post dose)dX X
Weight X X X
Height X X
Chest X -rayeX

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 9 V i s i t  I d e n t i f i e r aD a y  -2 8 
S c r e e n i n g Da y  1 
W e e k  0 
B a s e l i n e D a y  8 
W e e k  1 
C a l l D a y  1 5 
W e e k  2 D a y  2 9 
W e e k  4 D a y  4 3 
W e e k  6 
C a l l D a y  5 7 
W e e k  8 D a y  8 5 
W e e k  1 2  
( EO T / E T )  EO S ,  
F o l l o w -u p 
W e e k  1 6 
( 4  W e e k s  
a f t e r  EO T  o r  
E T ) 
V i s i t  1 V i s i t  2 V i s i t  3 V i s i t  4 V i s i t  5 V i s i t  6 V i s i t  7 V i s i t  8 V i s i t  9 
V i s i t  W i n d o w N o n e N o n e 1  D a y  1  D a y s 2  
D a y s 3  D a y s 3  D a y s 3  D a y s 3  D a y s 
E C G  ( 1 2 -l e a d ) XfX X  X X  X X
L a b o r a t o r y  A s s e s sm e n t s  
S e r um  c h em i s t r y  a n d  h em a t o l o g y  ( i n c l u d i n g  
c o a g u l a t i o n  p a n e l ) gX X X  X X  X X
L i p i d  P a n e lgX X X X
U r i n a l y s i s X X X  X X  X X
S e r um  F S H  (W O N C B P  o n l y )  o r  P r e g n a n c y  
T e s t hX
U r i n e  P r e g n a n c y  T e s t  ( c o n d u c t e d  a t  s t u d y  
s i t e ) iX X  X X  X X
H I V T e s t i n g kX
H e p a t i t i s B  S u r f a c e  A n t i g e n  ( H B s A g ) ,  
H e p a t i t i s  B  S u r f a c e  A n t i b o d y  ( H B s A b ) ,  
H e p a t i t i s  B  C o r e  A n t i b o d y  ( H B c A b ) ,  
H e p a t i t i s  C  A n t i b o d y  ( H C V  A b ) ,  H e p a t i t i s  
C  V i r a l  R N A  ( H C V  R N A ) lX
H B V  D N A  (f o r  C h i n a ,  J a p a n  a n d  R e p u b l i c  
o f  K o r e a o n l y ) b b X X
V a r i c e l l a  Z o s t e r  V i r u s  ( V Z V  I g G  A b )  
( a d o l e s c e n t s  o n l y ,  i f  a p p l i c a b l e ) mX
T u b e r c u l o s i s  T e s t nX
P h a r m a c o k i n e t i c  
P h a rm a c o k i n e t i c  B l o o d  S am p l i n g  ( P r e - d o s e ) oX
P h a rm a c o k i n e t i c  B l o o d  S am p l i n g  
( P o s t -d o s e ) pX
T r i a l  T r e a t m e n t  
R a n d om i z a t i o n  X
D r u g  D i s p e n s i n g X X X
I n v e s t i g a t i o n a l  P r o d u c t  A c c o u n t a b i l i t y   X  X X  X C
C
I
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 20Visit IdentifieraDay -28
ScreeningDay 1
Week 0
BaselineDay 8
Week 1
CallDay 15
Week 2Day 29
Week 4Day 43
Week 6
CallDay 57
Week 8Day 85
Week 12 
(EOT/ET) EOS, 
Follow -up
Week 16
(4 Weeks 
after EOT or 
ET)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Visit Window None None 1 Day 1 Days 2 
Days3 Days3 Days 3 Days 3 Days
Investigational Treatment Administrationq      X--------------------------------------------------------------------------------------------- X
Review eDiary to assess completion X X X X X X
Assess eligibility for B7451015rX
Clinical Assessments 
Fitzpatrick Skin Type Assessment X
Investigator’s Global Assessment (IGA) X X X X X X X
SCORing Atopic Derm atitis (SCORAD) X X X X X X X
Eczema Area and Severity Index (EASI) X X X X X X X
Body Surface Area (BSA from EASI) X X X X X X X
C-SSRSsX
SBQ -RsX
PHQ -8sX
Photography of representative AD lesionstX X X X X X
Patient -reported Outcome 
Pruritus Numerical Rating Scale (NRS)uX------------------ X X ----------------------------------------- X X X X X
Night Time Itch ScaleuX------------------ X X ----------------------------------------- X X X X X
Pruritus and Symptoms Assessment for 
Atopic Dermatitis (PSAAD)vX ---------------- -X X---------------------------------------------------------------------------------------------------------------------X
Patient Global Assessment (PtGA) X X X X X X
Dermatology Life Quality Index (DLQI or 
CDLQI)wX X X X X X
Patient -Oriented Eczema Measure (POEM) X X X X X X
Hospi[INVESTIGATOR_5620] 
(HAD S)X X X X X X
EQ-5D-5L (adults) or EQ -5D-Y (ages 12 -17 
years)X X X X X X
SF-36v2, AcutexX X X
Work Productivity and Activity Impairment 
Questionnaire: Atopic Dermatitis 
(WPAI:AD)xX X X
FACIT -F or Peds -FACIT -FyX X X

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 21Visit IdentifieraDay -28
ScreeningDay 1
Week 0
BaselineDay 8
Week 1
CallDay 15
Week 2Day 29
Week 4Day 43
Week 6
CallDay 57
Week 8Day 85
Week 12 
(EOT/ET) EOS, 
Follow -up
Week 16
(4 Weeks 
after EOT or 
ET)
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Visit Window None None 1 Day 1 Days 2 
Days3 Days3 Days 3 Days 3 Days
Safety
Serious and non -serious adverse event 
monitoringX X X X X X X X X
Contraception CheckzX X X X X X X X X
Serum Sample for Baseline Viral ScreenaaX
Abbreviations: AD = atopic dermatitis; BSA = body surface area; CDLQI = Children’s Dermatology Life Quality Index; C -SSRS = Columbia Suicide Severity 
Rating Scale; DLQI =Derm atology Life Quality Index; EASI = Eczema Area and Severity Index ; ECG =electrocardiogram; EOS =End of Study; EOT = End 
of Treatment; ET = early termination; EQ -5D-5L = EuroQol Quality of Life 5 -Dimension 5 -Level Scale; EQ -5D-Y = EuroQol Quality of Life 5 -Dimension, 
Youth Scale; FACIT -F = Functional Assessment of Chronic Illness Therapy Fatigue Scale; FSH = follicle stimulating hormone; GGT = gamma- glutamyl 
transferase; HADS= Hospi[INVESTIGATOR_74022] D epression Scale ; HBsAg =hepatitis B surface antigen; HBsAb = hepatitis B surface antibody; HBcAb = hepatitis B 
core antibody; HBV DNA = hepatitis B virus deoxyribonucleic acid; HCVAb = hepatitis C antibody; HCV RNA = Hepatitis C Viral RNA; HIV =human 
immunodeficiency virus; HSV -1 = herpes simplex virus type 1; HSV2 = herpes simplex virus type 2; IGA =Investigator’s Global Assessment; IRT = Interactive 
Response System; LLQ = lower limit quantification; NRS = numerical rating scale; Peds -FACIT -F = Pediatri c Functional Assessment of Chronic Illness Therapy 
Fatigue Scale; PHQ -8 = Patient Health Questionnaire 8 items; POEM =Patient -Oriented Eczema Measure; PSAAD =Pruritus and Symptoms Assessment for 
Atopic Dermatitis; PtGA = Patient Global Assessment; RNA = Ribonucleic acid; SBQ -R = Suicide Behaviors Questionnaire -Revised; SCORAD = SCORing 
Atopic Dermatitis; SF -36v2 = Short Form -36 Health Survey Version 2; VZV = varicella zoster virus; VZV IgG Ab = varicella zoster virus immunoglobulin G 
antibody; WPAI:AD = Wo rk Productivity and Activity Impairment Questionnaire: Atopic Dermatitis; WONCBP =women of non -childbearing potential.
a.Day relative to start of study treatment (Day 1).
b.Atopic Dermatitis Disease History includes collection of details of AD: AD diagnosis and duration , the use of topi[INVESTIGATOR_12969], systemic treatments and 
other treatments for AD. 
c.Com plete physical examinations must be performed by [CONTACT_093], sub investigator or a qualified health professional per local guidelines.  Complete 
physical examinations consist of assessments of general appearance; skin; head, eyes, ears, nose and throat (HEENT); mouth, heart; lun gs; breast (optional); 
abdomen; external genitalia (optional); extremities; neurologic function; and lymph nodes.  Targeted physic al examinations must be performed by [CONTACT_1275], sub -investigator or a qualified health professional per local guidelines and should include skin, heart, lungs, and abdomen and e xamination of 
body systems where there are symptom complaints by [CONTACT_74058].
d.Vital Signs include sitting blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature measured after at least [ADDRESS_80790].  

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  2 2 e . C h e s t  X -r a y  o r  o t h e r  a p p r o p r i a t e  d i a g n o s t i c  im a g e  ( i e ,  C T  o r  M R I )  m a y  b e  p e r f o rm e d  u p  t o  1 2 w e e k s  p r i o r  t o  D a y 1 .   C h e s t  X -r a y s  ( p o s t e r i o r -a n t e r i o r  a n d  
l a t e r a l  v i e w s )  a r e  r e q u i r e d  f o r  a d u l t s  a n d  r e c omm e n d e d  f o r  a d o l e s c e n t s  a s  p e r  l o c a l  g u i d e l i n e s  a n d  s t a n d a r d  o f  c a r e . O f f i c i a l  r e a d i n g  m u s t  b e  l o c a t e d  a n d  
a v a i l a b l e  i n  t h e  s o u r c e  d o c um e n t a t i o n . 
f . A  s i n g l e  1 2 -l e a d  E C G  w i l l  b e  p e r f o rm e d  a t  s c r e e n i n g  a n d  a l l  o t h e r  o n -s i t e  v i s i t s  a n d  i n t e r p r e t e d  b y  a  c e n t r a l  r e a d e r .   C l i n i c a l l y  s i g n i f i c a n t  o r  e x c l u s i o n a r y  
E C G  f i n d i n g s  a t  t h e  s c r e e n i n g  o r  b a s e l i n e  v i s i t s  w i l l  r e q u i r e  s c r e e n  f a i l u r e .   
g . S e r um  c h em i s t r y  i n c l u d e s :  b l o o d  u r e a  n i t r o g e n  ( B U N ) ,  s e r um  c r e a t i n i n e ,  c r e a t i n e  p h o s p h o k i n a s e ,  g l u c o s e ,  C a + + ,  N a + ,  K + ,  C l -,  t o t a l  C O 2 ,  a s p a r t a t e  
am i n o t r a n s f e r a s e  ( A S T ) ,  a l a n i n e  am i n o t r a n s f e r a s e  ( A L T ) ,  g amm a -g l u t am y l  t r a n s f e r a s e  ( G G T ) ,  t o t a l ,  i n d i r e c t  a n d  d i r e c t  b i l i r u b i n ,  a l k a l i n e  p h o s p h a t a s e ,  
l a c t a t e  d e h y d r o g e n a s e ,  u r i c a c i d ,  a l b um i n  a n d  t o t a l  p r o t e i n .   T h e  l i p i d  p r o f i l e  p a n e l  w i l l  i n c l u d e  t o t a l  c h o l e s t e r o l ,  l o w -d e n s i t y  l i p o p r o t e i n (L D L ) ,  
h i g h -d e n s i t y  l i p o p r o t e i n ( H D L ) ,  a n d  t r i g l y c e r i d e s .   A  m i n im um  o f  8 -h o u r  f a s t i n g  i s  r e q u i r e d  f o r  l i p i d  p r o f i l e  e v a l u a t i o n  a t  D a y 1 ,  W e e k 4 ,  W e e k 1 2  a n d  E O S  
v i s i t s .   H em a t o l o g y  i n c l u d e s :  H em o g l o b i n ,  h em a t o c r i t ,  r e d  b l o o d  c e l l  c o u n t  a n d  i n d i c e s  (M C H ,  M C H C ,  M C V ,  R B C  M o r p h o l o g y ) ,  W B C  c o u n t  w i t h  
d i f f e r e n t i a l ,t o t a l n e u t r o p h i l s  (% , a b s o l u t e ) ,  l ym p h o c y t e s  (% ,  a b s o l u t e ) ,  m o n o c y t e s  (% ,  a b s o l u t e ) ,  e o s i n o p h i l s  (% ,  a b s o l u t e ) ,  b a s o p h i l s  (% ,  a b s o l u t e ) ,  
p l a t e l e t s ,  r e t i c u l o c y t e  c o u n t  a n d  c o a g u l a t i o n  p a n e l .   C o a g u l a t i o n  p a n e l  i n c l u d e s :  A c t i v a t e d  P a r t i a l  T h r om b o p l a s t i n  T im e  ( A P T T ) ,  P r o t h r om b i n  
T im e / I n t e r n a t i o n a l  N o rm a l i z e d  R a t i o  ( P T / I N R ) .   L a b o r a t o r y  t e s t s  w i t h  a b n o rm a l  r e s u l t s  ( p e r S e c t i o n  6 . 1 a n d S e c t i o n  7 . 6 . 2 )m a y  b e  r e p e a t e d  o n c e  d u r i n g  t h e  
s c r e e n i n g  p e r i o d ;  t h e  l a s t  v a l u e  w i l l  b e  u s e d  t o  d e t e rm i n e  e l i g i b i l i t y .  
h . S e r um  p r e g n a n c y  t e s t i n g  a t  s c r e e n i n g  i s  r e q u i r e d  f o r  w o m e n  o f  c h i l d b e a r i n g  p o t e n t i a l ,  i n c l u d i n g  a d o l e s c e n t s  a g e d  1 2  y e a r s  a n d  o l d e r ,  r e g a r d l e s s  o f  w h e t h e r  
t h e y  h a v e  e x p e r i e n c e d  m e n a r c h e .   F o l l i c l e  s t im u l a t i n g  h o rm o n e  ( F S H )  t e s t  t o  b e  p e r f o rm e d  a t  S c r e e n i n g  t o  c o n f i rm  p o s tm e n o p a u s a l  s t a t u s  i n  f em a l e  s u b j e c t s  
w h o  h a v e  b e e n  am e n o r r h e i c  f o r  a t  l e a s t  1 2 c o n s e c u t i v e  m o n t h s . 
i . U r i n e  p r e g n a n c y  t e s t  m u s t  b e  p e r f o rm e d  p r i o r  t o  d o s i n g  w i t h  t h e  i n v e s t i g a t i o n a l  p r o d u c t  f o r  f em a l e  s u b j e c t s  o f  c h i l d b e a r i n g  p o t e n t i a l ,  i n c l u d i n g  a d o l e s c e n t s  
a g e d  1 2  y e a r s  a n d  o l d e r ,  r e g a r d l e s s  o f  w h e t h e r  t h e y  h a v e  e x p e r i e n c e d  m e n a r c h e .  
k . H I V  t e s t i n g  w i l l  b e  p e r f o rm e d  f o r  a l l  s u b j e c t s . S u b j e c t s  w h o  a r e  p o s i t i v e  f o r  H I V  w i l l  b e  s c r e e n -f a i l e d . 
l . H B s A b  r e f l e x  t e s t i n g w i l l  b e  p e r f o rm e d  o n l y  i f  H B s A g  n e g a t i v e  b u t  H B c A b  p o s i t i v e . S u b j e c t s  w h o  a r e  p o s i t i v e  f o r  H C V A b  a n d  H C V  R N A  w i l l  b e  
s c r e e n -f a i l e d . 
m . V Z V  I g G  a n t i b o d y  t e s t i n g  i s  r e q u i r e d  t o  c o n f i rm  e l i g i b i l i t y  i n  a d o l e s c e n t  s u b j e c t s  w h o  h a v e  n o t  r e c e i v e d  a t  l e a s t o n e  d o s e  o f  a  v a r i c e l l a  v a c c i n e . 
n . A  d o c um e n t e d  T B  te s t  p e r f o rm e d  w i t h i n  1 2 w e e k s  p r i o r  t o  D a y 1  i s  a c c e p t a b l e .   S u b j e c t s  w i t h  a  h i s t o r y  o f  t u b e r c u l o s i s  m a y  n o t  r e q u i r e  T B  t e s t i n g  a s  p e r  t h e  
p r o t o c o l  e x c l u s i o n  c r i t e r i a  i n  S e c t i o n 4 . 2 .  P e r f o rm  T B  t e s t  p r o c e d u r e  u s i n g  t h e  Q u a n t i F E R O N -T B  G o l d  I n  T u b e  T e s t  ( o r  P u r i f i e d  P r o t e i n  D e r i v a t i v e ) .   A  
n e g a t i v e  P P D  t e s t  c a n  b e  s u b s t i t u t e d  f o r  t h e  Q u a n t i F E R O N -T B  G o l d  I n -T u b e  t e s t  o n l y  i f  t h e  c e n t r a l  l a b o r a t o r y  i s  u n a b l e  t o  p e r f o rm  t h e  
Q u a n t i F E R O N -T B  G o l d  I n -T u b e  t e s t  o r  c a n n o t  d e t e rm i n e  t h e  r e s u l t s  t o  b e  p o s i t i v e  o r  n e g a t i v e  a n d  t h e  P f i z e r  M e d i c a l  M o n i t o r  a p p r o v e s  i t  o n  a  
c a s e -b y -c a s e  b a s i s .   I n  a d d i t i o n  t o  p r o t o c o l  r e q u i r e d  T B  t e s t i n g ,  s i t e s s h o u l d  f o l l o w  t h e i r  l o c a l  s t a n d a r d s  f o r  T B  s t a t u s  d e t e rm i n a t i o n ,  w h i c h  m a y  i n c l u d e  
c h e s t  X -r a y .   S e e S e c t i o n  7 . 3 . 3 .  F o r  J a p a n  o n l y :  W h i l e  Q u a n t i F E R O N i s  t h e  p r e f e r r e d  t e s t i n g  m e t h o d ,  t h e  T - S P O T .T B t e s t  i s  a c c e p t a b l e  a s  t h e  s c r e e n i n g  
T B  t e s t .T - S P O T .T B t e s t i n g  w i l l  b e  p e r f o rm e d  a t  t h e  s i t e ’ s  l o c a l  l a b o r a t o r y .   B o r d e r l i n e  r e s u l t s  f r om  t h e  T - S P O T .T B t e s t  s h o u l d  b e  c o n s i d e r e d  
e x c l u s i o n a r y .  I f  t h e  t e s t  r e s u l t s  a r e  i n d e t e rm i n a t e ,  t h e  t e s t  s h o u l d  b e  r e p e a t e d .   I f  t h e  r e s u l t  o f  t h e  r e p e a t  t e s t  i s  i n d e t e rm i n a t e , s u b j e c t s  m a y  b e  s c r e e n e d  u s i n g 
t h e  M a n t o u x / P P D  s k i n  t e s tw i t h  P f i z e r  M e d i c a l  M o n i t o r  a p p r o v a l .  S e e S e c t i o n  7 . 3 . 4 .
o . A  p h a rm a c o k i n e t i c  ( P K )  b l o o d  s am p l e  w i l l  b e  c o l l e c t e d  2 . 0  h o u r s  ( 3 0 m i n ) p r i o r  t o  d o s i n g  a t  t h e  s t u d y  s i t e  o n  W e e k 8 . 
p . P K  b l o o d  s am p l e s  w i l l  b e  c o l l e c t e d  a t  1 . 0  h o u r  ( 1 5 m i n )  a n d  2 . 0 h o u r s  ( 3 0 m i n )  p o s t -d o s e  a t  t h e  W e e k 1 2  v i s i t  ( E O T / E T ) .  I f  t h e  E T  v i s i t  o c c u r s  a f t e r  
W e e k 8 ,  c o l l e c t  P K  s am p l e s  o n l y  i f  t h e  s u b j e c t  t a k e s  t h e  i n v e s t i g a t i o n a l  p r o d u c t  a t  t h e  s i t e  v i s i t .  
q . S u b j e c t s  s h o u l d  t a k e  t h e  m e d i c a t i o n  f r om  s t u d y  D a y s 1  t o  8 5 .   S u b j e c t s  w i l l  b e  e n c o u r a g e d  t o  t a k e  t h e  m e d i c a t i o n  i n  t h e  m o r n i n g  w h e n e v e r  p o s s i b l e ;  
h o w e v e r ,  a t  s t u d y  v i s i t  d a y s ,  s u b j e c t s  a r e  t o  b e  i n s t r u c t e d  t o  r e f r a i n  f r om  d o s i n g  a t  h om e ,  a n d  a r e  t o  t a k e  t h e  d o s e  i n  t h e  c l i n i c . C
C
I
PF-[ADDRESS_80791]’s primary care 
physician (PCP) should be informed, and the subject referred to a mental health professional, either by [CONTACT_74059].
t.For subjects a t selected study sites, photographs of treated AD w ill be obtained. Photographs will be utilized for illustrative purposes and not evaluated as an 
endpoint (see Section 7.7.5 ).  
u.Pruritus Numerical Rating Scale (NRS) and Night Time Itch Scale will be assessed using an eDiary, daily during the screening period and from Day [ADDRESS_80792] on how  to complete the items in the daily eDiary, if needed. 
v.Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) will be conducted to assess the severity and frequency of prur itus, symptoms and sleep 
collected dail y in a subject e -diary during the screening period and from Day 1 through the End of Study visit in selected countries (See Section 7.8.8 ).  At 
the Screening visit, site staff w ill dispense the ePRO device and review instructions for completion of the subject eDiary for the PSAAD questionnaire.  
Subjects will be asked to record their assessment in their eDiary once a day before taking the investigational product.  At e very visit, the study coordinator 
will review the eDiary for completeness and counsel the subject on how  to complete the items in the daily eDiary, if needed. 
w.DLQI will be completed by [CONTACT_74060].  Adolescents [ADDRESS_80793] ead. 
x.SF-36v2 and WPAI:AD will be completed by [CONTACT_74060].  Adolescents 12 -17 years of age will not complete these assessments.
y.FACIT -F will be completed by [CONTACT_74060].  Adolescents 12 -17 years of age will complete the Peds -FACIT -F instead. 
z.The contraception check is an opportunity to confirm that contraception, if assigned, is used consistently and correctly.  It also facilitates continual 
reassessment of child -bearing potential in women.  This allows for implementing necessary changes t o contraception; for example, investigators may need to 
ensure alternative contraceptive methods if ne w concom itant disease contraindicates a selected method of contraception, or if a subject is demonstrably no 
longer of child -bearing status (as per protoc ol) then they will no longer require contraception.  Continual reassessment of contraceptive needs is imperative.
aa.A serum sample will be collected at baseline but analyzed only if the subject has suspected varicella or herpes zoster.  In that event, the sa mple would be 
analyzed for HSV1, HSV2 and VZV. 
bb.For China and Republic of Korea only: Subjects who are HBsAg negative , HBcAb positive , HBsAb positive at screening will have reflex testing for HBV 
DNA. Subjects who are HBV DNA negative or below  LLQ will ha ve repeat HBV DNA repeated at Week 12 or early termination .   
For Japan only: In addition to HBsAg and HBcAb, HBsA b testing will be performed at S creening for all subjects rather than as a reflex test. Subjects with 
negative results for HBsAg, HBcAb and H BsAb may be eligible.
  Subjects who are HBsAg negative, HBcAb negative and HBsAb positive and provide 
documen tation of prior HBV vaccination may be eligible and w ill not require HBV DNA monitoring during the study. Subjects who are HBsAg negative, 
HBcAb n egative and HBsAb positive without documentation of prior HBV vaccination AND subjects who are HBsAg negative, HBcAb positive , and 
HBsAb positive at screening will have reflex testing for HBV DNA.  Subjects who are HBV DNA negative or below  LLQ may be rand omized but will have 
HBV DNA repeated at Week 12 or early termination .

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 241.INTRODUCTION
1.1.Mechanism of Action/Indication
PF-04965842 isaJanus kinase 1(JAK1) inhibitor that is being investigated as a treatment for 
patients with Atopic Dermatitis (AD). 
The Janus kinase (JAK) family , including JAK1, JAK2, JAK3 and ty rosine kinase 2 (TYK2), 
is a group of cy toplasmic ty rosine kinases that mediate signal transduction via interactions 
with Ty pe1 and Ty pe2 cytokine receptors critical for leukocy te activation, proli feration, 
survival and function.  Cy tokine receptors demonstrate restricted association with JAKs such 
that different receptors or receptor classes preferentially  utilize a given JAK dimer or trimer 
combination to transduce their signal.  JAK1 pairs with J AK3 to mediate -common cy tokine 
signaling and also with JAK2 or TYK2 to transmit the signals of additional cy tokines 
important in inflammation and immune responses including interleukin 
(IL) -4, -5, -6, -13,-21, - 31, interferon gamma (IFN -), and interfer on alpha (IFN -).  JAK2 
homodimers are critical for the signaling of hematopoietic cy tokines and hormones including 
erythropoietin (EPO), IL -3, granulocy te-macrophage colony -stimulating factor (GM -CSF) 
and prolactin. 
IL-12 and IL -23 are dependent on TYK2 
and JAK2 for transmitting their signals.  Following 
cytokine activation, receptor -associated JAKs are phosphory lated and in turn phosphory late 
specific sites on the receptor intracellular domain.  Phosphory lation of specific sites on the 
intracellular doma in of the receptor allows for the recruitment of signal transducers and 
activators of transcription (STATs) that can subsequently  be phosphory lated by  [CONTACT_74061].  
Phosphory lated STAT molecules are released from the receptor, translocate to the nucleus 
where the y bind to specific sites on the deox yribonucleic acid (DNA) and regulate gene 
transcription. 
Key cytokines implicated in the pathophy siology of AD include IL-4,IL-5,IL-13,IL-31,
and IFN -, require JAK1 for signal transduction; this suggests that select iveJAK1 inhibitors 
that modulate the activity ofthese cytokines represent a compelling approach to the 
treatment of inflammatory skin diseases such as AD.[ADDRESS_80794] other 
kinases: 28- fold selectivity  over JAK2, >[ADDRESS_80795] s involved in the 
pathophy siology of AD, including IL-4,IL-5, IL -13, IL -31 and IFN -.  Data from a Phase 2b 
proof of concept (POC) study  (B7451006) that evaluated subjects with moderate to severe 
AD have shown positive efficacy , as well as an acceptable safet y profile, sufficient to support 
further clinical development in a larger Phase 3 program.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 251.2.Background and Rationale
1.2.1. Drug Development an d Rationale
PF-04965842 is being developed as an oral treatment for patients with moderate to severe 
AD based on its mechanism of action, and the clinical results obtained in Phase 1 and 
Phase 2 studies.  The clinical development program for PF -04965842 includes healthy  
volunteers, subjects with psoriasis and subjects with AD.  
Additional information for this compound may  be found in the single reference safet y 
document (SRSD), which for this study  is the Investigator’s Brochure (IB). 
1.2.2. Atopic Dermatitis
Atopic dermatitis, also known as atopic eczema, is a common, chronic, inflammatory skin 
disorder characterized b y flaky skin lesions, intense pruritus, and a general deterioration in 
the quality  of life.  Over the past [ADDRESS_80796] common, 
chronic, relapsing childhood dermatoses, impacting 15 -30% of all children in the US and 
many  have disease that persists into adulthood 
with a lifetime prevalence of those affected in 
childhood reported to be 34%.8Earlier reports indicated that, in up to 70% of cases, the 
disease greatly  improves or resolves by[CONTACT_74054], however more recent findings suggest 
that disease activity  remains manifest for a prolonged period of time.  Based on a total of 
7157 patients enrolled in the Pediatric Eczema Elective Registry  (PEER) study , comprising a 
total of 22,[ADDRESS_80797] well into the second decade of a child’s life and likel y longer.3  At every  age, more 
than 80% o
f PEER study subjects had s ymptoms of AD and/or were using medication to treat 
their AD.  In 833 AD patients who were aged 20 years or older when they  visited the clinic 
and 45 y ears or older when they  responded to a follow -up questionnaire, 59% responded that 
they had defined persistent AD at some time during the last [ADDRESS_80798] a continued decrease in 
prevalence with older age.10  Adult- onset AD does also occur, though it is less common.  The 
prevalence of AD in adults is estimated to be 10 %.11Recent studies have indicated that 
adults with AD are more likely  to smoke cigarettes, drink alcohol, and have a sedentary  
lifesty le, potentiall y associated with increased comorbidities, such as asthma and 
cardiovascular disease.[ADDRESS_80799] been associated with the Ty pe2 helper T cell (TH2) phenoty pe, 
showing dominance of IL -4, -5, - 13, and - 31 secretion.7,13,14Recent research sh owed that a 
small increase of Ty pe1 helper T cell (TH1)-associated genes has been also detected in acute 
phase.[ADDRESS_80800] the development of atopic skin lesions, chronic 
lesion s show either the coexistence of both IL
-4-producing TH2 and IFN--producing TH1 
cells or TH1 
dominance.13This coexistence of TH2 and TH1 responses or TH1 dominance 
is more likely  to be the underly ing immunop athology  in adult patients who have had AD 
chronicall y or intermittently  since childhood.  Recent evidence also supports IL -31’s role in 
pruritus and inflammation in AD.7,14
There a re a limited number of treatments available for AD.  Current treatments for AD 
include emollients, topi[INVESTIGATOR_11930] (eg, betamethasone, clobetasol, fluocinonide), 
topi[INVESTIGATOR_22726] (eg, pi[INVESTIGATOR_031], tacrolimus), and coal tar preparatio ns.  
Crisaborole was approved as a topi[INVESTIGATOR_74019] 2016 b y the FDA for use 
inpatients with mild to moderate AD.  Additional treatments generally reserved for severe 
AD include phototherap y (eg, ultraviolet A light [UVA] with or without psora len, 
ultraviolet B light [UVB] narrowband or broadband) and s ystemic agents (eg, corticosteroids, 
cyclosporine, recombinant IFN -, mycophenolate mofetil, methotrexate [MTX], 
azathioprine, intravenous immunoglobulin).4  Of the currently  available therapi[INVESTIGATOR_014], none 
offers a cure; therefore, the main aims of existing treatments are to reduce the occurrence of 
acute flares, to increase the time between relapses, reduce pruritus and the resulting sleep 
disturbance.5,[ADDRESS_80801] drawbacks related to the duration of use due to the pote ntial for local and 
systemic side effects (eg, corticosteroid use is limited to 2 to 4 weeks) and to the body  
regions of use (eg, mid -high potency  corticosteroids are not approved for use on the face 
and/or intertriginous areas).  For AD patients not respo
nding to topi[INVESTIGATOR_74023] y, off -label use of systemic agents, which include oral corticosteroids ororal 
immunosuppressants, remain the last viable treatment option.  Sy stemic therapy  options are 
associated with potentially severe adverse effects and require careful monitoring.  The risk of 
toxicity  and side effects remain a concern when s ystemic agents are used.  For these reasons 
the use of these agents is limited to short courses or intermittent therap y.  
Other s ystemic agents to treat AD are under clinical development or recently  approved.  
Dupi[INVESTIGATOR_12458], an injectable human monoclonal antibody targeting interleukin (IL) -4 
and -13,was approved by  [CONTACT_69391] 2017 and received marketing authorization in 
Europe in September 2017, and offers a novel mechanism of action for the treatment of 
moderate to severe AD. However, the approved dosing for dupi[INVESTIGATOR_74020] 
2x 300 mg subcutaneous injections followed by 300 mg every  other week injections may  
limit the desirability  of this route of treatment.
Therefore, the predominant unmet medical need is an oral therap y with an acceptable safety 
profile for long term use which is effective for refractory  AD.  

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  2 7 A s  m e n t i o n e d  a b o v e ,  a  v a r i e t y  o f  p r o -i n f l amm a t o r y  c y t o k i n e s  s u c h  a s  I L -4 ,  I L -1 3 ,  I L - 2 2 ,  
I L -3 1  a n d  I F N -,  h a v e  b e e n  s u g g e s t e d  t o  h a v e  a  r o l e  i n  t h e  p a t h o g e n e s i s  o f  A D .   M a n y  o f  
t h e s e  p a t h o g e n i c  c y t o k i n e s  u s e  t h e  J A K 1  f o r  s i g n a l i n g .   T h e r e f o r e ,  J A K 1  i s  a n  a t t r a c t i v e  
t h e r a p e u t i c  t a r g e t  f o r  A D . 
1 . 2 . 3 . N o n - C l i n i c a l  a n d  P h a s e  1  D a t a  
D a t a  f r om  n o n c l i n i c a l  a n d  P h a s e  1  p r o g r am s  s u p p o r t s  t h e  p l a n n e d  c l i n i c a l  t r i a l s  w i t h  
P F - 0 4 9 6 5 8 4 2  a n d  f u r t h e r  i n f o rm a t i o n  i s  i n  t h e  c u r r e n t  v e r s i o n  o f  t h e  I B . 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  2 8 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  2 9 C C I 
C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  3 0 C C I 
C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  3 1 2 . S T U D Y  O B J E C T I V E S  A N D  E N D PO I N T S 
S t u d y  o b j e c t i v e s  a n d  c o r r e s p o n d i n g  e n d p o i n t s  a r e  p r o v i d e d  i n  T a b l e 1 .  
T a b l e 1 . O b j e c t i v e s  a n d  E n d p o i n t s : 
P r im a r y  O b j e c t i v e P r im a r y  E n d p o i n t s 
T o  a s s e s s  t h e  e f f i c a c y  
o f  P F - 0 4 9 6 5 8 4 2  
c om p a r e d  w i t h  p l a c e b o  
i n  s u b j e c t s  a g e d  
1 2 y e a r s  a n d  o l d e r  w i t h  
m o d e r a t e  t o  s e v e r e  A D . T h e  f o l l o w i n g  c o - p r im a r y  e n d p o i n t s  w i l l  b e  t e s t e d : 
R e s p o n s e  b a s e d  o n  t h e  I n v e s t i g a t o r ’s  G l o b a l  A s s e s sm e n t  ( I G A )  s c o r e  o f  c l e a r  ( 0 )  o r  
a lm o s t  c l e a r  ( 1 )  ( o n  a  5  p o i n t  s c a l e )  a n d  a  r e d u c t i o n  f r om  b a s e l i n e  o f  2p o i n t s  a t  
We e k 1 2 .   T h e  b a s e l i n e  w i l l  b e  d e f i n e d  a s  t h e  I G A  s c o r e  o n  D a y 1  p r e -d o s e ; 
R e s p o n s e  b a s e d  o n  t h e  E c z em a  A r e a  a n d  S e v e r i t y  I n d e x  7 5%  im p r o v em e n t  f r om  
b a s e l i n e  ( E A S I - 7 5 )  r e s p o n s e  a t  W e e k 1 2 .  T h e  b a s e l i n e  w i l l  b e  d e f i n e d  a s  t h e  E A S I  s c o r e  
o n  D a y 1  p r e -d o s e . 
S e c o n d a r y  O b j e c t i v e S e c o n d a r y  E n d p o i n t s 
T o  e v a l u a t e  t h e  e f f e c t  o f  
P F -0 4 9 6 5 8 4 2  o n  
a d d i t i o n a l  e f f i c a c y  
e n d p o i n t s  a n d  p a t i e n t  
r e p o r t e d  o u t c om e s  o v e r  
t im e  i n  s u b j e c t s  a g e d  
1 2 y e a r s  a n d  o l d e r  w i t h  
m o d e r a t e  t o  s e v e r e  
a t o p i c  d e rm a t i t i s . K e y  S e c o n d a r y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a t  l e a s t  4 p o i n t s  im p r o v em e n t  i n  t h e  s e v e r i t y  o f  p r u r i t u s  n um e r i c a l  
r a t i n g  s c a l e  ( N R S )  f r om  b a s e l i n e  a t  W e e k s 2 ,  4 ,  a n d  1 2 ; 
C h a n g e  f r om  B a s e l i n e  i n  P r u r i t u s  a n d  S ym p t om s  A s s e s sm e n t  f o r  A t o p i c  D e rm a t i t i s  
( P S A A D )  t o t a l  s c o r e  a t  W e e k 1 2 .  
S e c o n d a r y  E f f i c a c y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a t  l e a s t  4 p o i n t s  im p r o v em e n t  i n  t h e  s e v e r i t y  o f  p r u r i t u s  n um e r i c a l  
r a t i n g  s c a l e  ( N R S )  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  o t h e r  t h a n  W e e k s 2 ,  4  a n d  
1 2 ;   
T im e  t o  a c h i e v e  a t  l e a s t 4p o i n t sim p r o v em e n t  i n  t h e  s e v e r i t y  o f  p r u r i t u s  N R S  s c a l e  f r om  
b a s e l i n e  b y  D a y  1 5 ; 
R e s p o n s e  b a s e d  o n  t h e  E A S I - 7 5  a t  a l l  s c h e d u l e d  t im e  p o i n t s  e x c e p t  W e e k 1 2 ;  
R e s p o n s e  b a s e d  o n  t h e  I G A o f c l e a r  ( 0 )  o r  a lm o s t  c l e a r  ( 1 )  a n d  2p o i n t  r e d u c t i o n  f r om  
b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  e x c e p t  W e e k 1 2 . 
O t h e r  E f f i c a c y  E n d p o i n t s : 
R e s p o n s e  b a s e d  o n  a  5 0% a n d  9 0%  im p r o v em e n t  i n  t h e  E A S I  t o t a l  s c o r e  ( E A S I -5 0 
a n d  E A S I -9 0 )  a t  a l l  s c h e d u l e d  t im e  p o i n t s ;
C h a n g e  f r om  b a s e l i n e  i n  t h e  p e r c e n t a g e  B o d y  S u r f a c e  A r e a  ( B S A )  a f f e c t e d  a t  a l l  
s c h e d u l e d  t im e  p o i n t s ; 
R e s p o n s e  b a s e d  o n  a  5 0%  a n d  7 5%  im p r o v em e n t  i n  S C O R A D  ( S C O R A D 5 0 ,  
S C O R A D 7 5 )  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s ; 
C h a n g e  f r om  b a s e l i n e  a t  a l l  s c h e d u l e d  t im e  p o i n t s  i n  S C O R A D  s u b j e c t i v e  a s s e s sm e n t s  o f  
i t c h  a n d  s l e e p  l o s s . 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  3 2 Sa f e t y  O b j e c t i v e S a f e t y  E n d p o i n t s 
T o  e v a l u a t e  t h e  s a f e t y  
a n d  t o l e r a b i l i t y  o f  
P F - 0 4 9 6 5 8 4 2  i n  
s u b j e c t s  a g e d  1 2 y e a r s  
a n d  o l d e r  w i t h  m o d e r a t e  
t o  s e v e r e  a t o p i c  
d e rm a t i t i s  f o l l o w i n g  
1 2 w e e k s  o f  t r e a tm e n t . I n c i d e n c e  o f  t r e a tm e n t  em e r g e n t  a d v e r s e  e v e n t s ; 
I n c i d e n c e  o f  S A E s  a n d  A E s  l e a d i n g  t o  d i s c o n t i n u a t i o n ; 
T h e  i n c i d e n c e  o f  c l i n i c a l  a b n o rm a l i t i e s  a n d  c h a n g e  f r om  b a s e l i n e  i n  c l i n i c a l  l a b o r a t o r y  
v a l u e s ,  E C G  m e a s u r em e n t s ,  a n d  v i t a l  s i g n s . 
PK  O b j e c t i v e PK  E n d p o i n t 
T o  e v a l u a t e  t h e  P K  o f  
P F - 0 4 9 6 5 8 4 2  i n  
s u b j e c t s  a g e d  1 2y e a r s  
a n d  o l d e r  w i t h  m o d e r a t e  
t o  s e v e r e  a t o p i c  
d e rm a t i t i s  f o l l o w i n g  
1 2 w e e k s  o f  t r e a tm e n t . P o p u l a t i o n  P K  c h a r a c t e r i z a t i o n  i n  s u b j e c t s  a g e d  1 2  y e a r s  a n d  o l d e rw i t h  m o d e r a t e  t o  
s e v e r e  a t o p i c  d e rm a t i t i s . C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  3 3 E x p l o r a t o r y  
O b j e c t i v e sE x p l o r a t o r y  E n d p o i n t s 
 
 
 
 
 
 
 
 
 
  
 
 
 
A D  =  A t o p i c  d e rm a t i t i s ;  A E  =  A d v e r s e  E v e n t ;  B S A  =  B o d y  S u r f a c e  A r e a  ;  C D L Q I  =  C h i l d r e n ’ s  D e rm a t o l o g y  L i f e  
Q u a l i t y  I n d e x ;  D L Q I =D e rm a t o l o g y  L i f e  Q u a l i t y  I n d e x ;  E A S I  =  E c z em a  A r e a  a n d  S e v e r i t y  I n d e x ;  E C G  =  
E l e c t r o c a r d i o g r am ; E Q -5 D - 5 L  =  E u r o Q o l ;  Q u a l i t y  o f  L i f e  m e a s u r e ;  5 - D im e n s i o n  5 -L e v e l  S c a l e ;  E Q -5 D -Y  =  E u r o Q o l  
Q u a l i t y  o f  L i f e  5 - D im e n s i o n  Y o u t h  S c a l e ;  F A C I T - F   =  F u n c t i o n a l  A s s e s sm e n t  o f  C h r o n i c  I l l n e s s  T h e r a p y  F a t i g u e  S c a l e ;  
P e d s -F A C I T -F  =  P e d i a t r i c  F A C I T -F ;  H A D S  =  H o s p i t a l A n x i e t y  a n d  D e p r e s s i o n  S c a l e ;  I G A  =  I n v e s t i g a t o r ’ s  G l o b a l  
A s s e s sm e n t ;  N R S  =  p r u r i t u s  n um e r i c a l  r a t i n g  s c a l e ;  P K  =  p h a rm a c o k i n e t i c s ;  S C O R A D  =  S c o r i n g  A t o p i c  D e rm a t i t i s ;  
P O EM =P a t i e n t - O r i e n t e d  E c z em a  M e a s u r e ;  P t G A  =  P a t i e n t  G l o b a l  A s s e s sm e n t ;  P S A A D  =  P r u r i t u s  a n d  S ym p t om s  
A s s e s sm e n t  f o r  A t o p i c  D e rm a t i t i s ;  S F -3 6 v 2 =  S h o r t  F o rm -3 6 V e r s i o n  2 ;  S A E  =  S e r i o u s  A d v e r s e  E v e n t 
3 . S T U D Y  D E S IG N 
T h i s  i s  a  r a n d om i z e d ,  d o u b l e -b l i n d ,  p l a c e b o -c o n t r o l l e d ,  p a r a l l e l -g r o u p ,  P h a s e 3  s t u d y  t o  
e v a l u a t e  t h e  e f f i c a c y  a n d  s a f e t y  o f  P F -0 4 9 6 5 8 4 2  m o n o t h e r a p y  i n  s u b j e c t s  a g e d  1 2 y e a r s  a n d  
o l d e r  w i t h  m o d e r a t e  t o  s e v e r e  A D  a n d  a  b o d y  w e i g h t  4 0 k g .   T h e  t r e a tm e n t  d u r a t i o n  i s  
1 2 w e e k s .   S u b j e c t s  w i l l  b e  s c r e e n e d  w i t h i n  2 8 d a y s  p r i o r  t o  t h e  f i r s t  d o s e  o f  i n v e s t i g a t i o n a l  
p r o d u c t  t o  c o n f i rm  t h a t  t h e y  m e e t  t h e  s u b j e c t  s e l e c t i o n  c r i t e r i a  f o r  t h e  s t u d y .   A  t o t a l  o f  
a p p r o x im a t e l y  3 7 5 s u b j e c t s  w i l l  b e  e n r o l l e d  f r om  a p p r o x im a t e l y  8 5 s i t e s  l o c a t e d  g l o b a l l y .  
A d o l e s c e n t  s u b j e c t s  b e l o w  t h e  a g e  o f  1 8  y e a r s  o l d  ( o r  c o u n t r y -s p e c i f i c  a g e  o f  m a j o r i t y )  w i l l  
o n l y  b e  e n r o l l e d  i n  t h i s  s t u d y  i f  i n s t r u c t e d  b y  t h e  s p o n s o r  a n d  a p p r o v e d  b y  t h e  c o u n t r y  o r  
r e g u l a t o r y / h e a l t h  a u t h o r i t y .   I f  t h e s e  a p p r o v a l s  h a v e  n o t  b e e n  g r a n t e d ,  o n l y  s u b j e c t s  a g e d  
1 8 y e a r s  ( o r  c o u n t r y -s p e c i f i c  a g e  o f  m a j o r i t y )  a n d  o l d e r  w i l l  b e  e n r o l l e d . A  s t u d y  d e s i g n  
s c h em a t i c  i s  p r e s e n t e d  i n  F i g u r e  1.C C I 
PF-[ADDRESS_80802] the option 
to enter a long -term extension (L TE) study  B7451015.  Subjects discontinuing earl y from 
treatment, or who are otherwise ineligible for the LTE stud y will undergo a [ADDRESS_80803] chronic moderate to severe AD as defined per the i nclusion criteria will 
be randomized to receive 200 mg or 100 mg PF-04965842 once dail y (QD), or matching 
placebo. Investigators, subjects, and the sponsor study  team will be blinded as to treatment 
group.
After providing informed consent, subjects will b e assessed for stud y eligibility  at the 
screening visit.  For subjects younger than 18 years old (or country -specific age of majority ), 
their parent(s)/legal guardian will provide supplementary  or sole written consent and minor 
children will provide assent, according to local regulations and rules regarding ability  to give 
assent and consent.  Subjects will undergo screening within 28 days prior to randomization.  
During the screening period, treatments for AD will be washed out, as applicable, according 
toeligibility  requirements.  Subjects may  be re -screened once if they  fail the screening 
evaluation for reasons related to incidental transitory  conditions, unless the reason for the 
screen failure the disease severit y inclusion criteria. 
Subjects who cont inue to meet eligibility  criteria at baseline will undergo Day 1/baseline 
assessments and be randomized in a 2:2:1 ratio to receive 200 mg PF -04965842 (N=150) or 
100mg PF -04965842 QD (N=150) or matching placebo (N=75) from Day 1. 

PF-[ADDRESS_80804] ratified b y baseline disease severit y (moderate [IGA = 3] vs. severe 
[IGA=4] AD), and, age <18 and  18.  Eligible subjects must have a documented history  of 
inadequate response or intolerance to treatment with topi[INVESTIGATOR_74021].
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the stu dy is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol. 
Subject eligibility should be reviewed and documented by  [CONTACT_74062]’s stud y team before subjects are included in the study. 
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated informed consent document indicating that 
the subject or their parent(s)/legal guardian, if applicable, have been informed of all 
pertinent aspects of the study . 
2.Male or female subjects of 12 years of age or older, at the time of informed consent 
and body  weight 40kg.  Adolescent subjects below the age of 18 y ears old (or 
country -specific age of majority )will onl y be enrolled in this study  if instructed by  
[CONTACT_74063] /health authorit y.  If these 
approvals have not been granted, onl y subjects aged 18 years(or country -specific age 
of majority )and older will be enrolled.
3.Meet all the following atopic dermatitis criteria:
Clinical diagnosis of chronic atopic dermatitis (also known as atopic eczema) for 
at least 1 year prior to Day 1 and has confirmed atopic dermatitis at the screening 
and baseline visits according to Hanafin and Rajka criteria for AD16(see 
Appendix 2).
Documente d recent history
 (within 6 months before the screening visit) of 
inadequate response to treatment with topi[INVESTIGATOR_74024] 4 weeks, or 
for whom topi[INVESTIGATOR_74025] (eg, because of 
important side effects or sa fety risks), or who have required systemic therapi[INVESTIGATOR_74026].
Moderate to severe AD (affected BSA ≥10%, IGA ≥ 3, EASI  ≥16, and Pruritus 
NRS severity  score ≥ 4 on the day  of the baseline visit).

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 364.Willing and able to comply  with scheduled v isits, treatment plan, laboratory tests and 
other study  procedures.
5. Female subjects who are of child- bearing potential (which includes all adolescents
aged [ADDRESS_80805] experienced menarche) must 
not be intending to b ecome pregnant, currentl y pregnant, or lactating.  The following 
conditions apply :
a.Female subjects of childbearing potential must have a confirmed negative 
pregnancy  test prior to randomization;
b. Female subjects of childbearing potential must agree to use a highl y effective 
method of contraception (as per Section 4.4.1) for the duration of the active 
treatment period and for at least [ADDRESS_80806].
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with 
study  treatments) may  obviate the need for contraception ONLY if this is the 
preferred and usual lifesty le of the subject. 
6.Female subjects of non -
childbearing potential must meet at least 1 of the following 
criteria: 
Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ;
Have medically  confirmed ovarian failure; o r
Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least [ADDRESS_80807] a serum follicle- stimulating hormone (FSH) level 
confirming the postmenopa usal state.
All other female subjects (including female subjects with tubal ligations) are 
considered to be of childbearing potential.
7. Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sun 
lamps or other ultraviolet light sou rces during the study .
8.If receiving concomitant medications for an y reason other than AD, must be on a 
stable regimen, which is defined as not starting a new drug or changing dosage within 
7days or 5 half-lives (whichever is longer) prior to Day 1 and thr ough the duration of 
the study .

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 374.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1.Other acute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or active su icidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study  participation or investigational product 
administration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigato r, would make the subject inappropriate for entry  into this 
study .
2.Any psychiatric condition including recent or active suicidal ideation or behavior that 
meets an y of the following criteria: 
Suicidal ideation associated with actual intent and a method or plan in the past 
year: “Yes” answers on items 4 or 5 of the Columbia suicide severit y rating scale 
(C-SSRS) ( Appendix 17);
Previous history  of suicidal behaviors in the past 5 y ears: “Yes” answer (for 
events th at occurred in the past 5 y ears) to any  of the suicidal behavior items of 
the C -SSRS;
Any lifetime history  of serious or recurrent suicidal behavior;
Suicidal behaviors questionnaire –revised (SBQ -R) total score 8
(Appendix 18);
Clinically  significant depression: patient health questionnaire 
–8 items (PHQ -8) 
total score  15 (Appendix 19);
The presence of an
y current major psychiatric disorder that is not explicitly 
permitted in the inclusion/exclusion criteria;
In the opi[INVESTIGATOR_22747] (or designee) exclusion is required.
3.A current or past medical history  of conditions associated with thrombocy topenia, 
coagulopathy or platelet dysfunction.
4.Receivi ng anti -coagulants or medications known to cause thrombocy topenia, (unless 
considered safe to stop and washout for the duration of the study ).
5.Currently  have active forms of other inflammatory skin diseases, ie, not AD or have 
evidence of skin conditions ( eg, psoriasis, seborrheic dermatitis, Lupus) at the time of 
Day [ADDRESS_80808].
7.Adolescent subjects 12 to <[ADDRESS_80809] evidence of prior exposure to 
varicella zoster virus (VZV) based on serological testing (ie, varicell a zoster virus 
immunoglobulin G antibody  [VZV IgG Ab]) at screening.
8.Subjects who have received prior treatment with any  JAK inhibitors.
9. Participation in other studies involving investigational drug(s) within 8 weeks or 
within 5 half -lives (if known) which ever is longer, prior to study  entry  and/or during 
study  participation.
Note: Any  investigational or experimental therapy taken or procedure performed for 
AD, psoriasis, psoriatic arthritis or rheumatoid arthritis in the previous 1 year should 
be discussed with the [COMPANY_007] Medical Monitor (or designee).  Subjects cannot 
participate in studies of other investigational or experimental therapi[INVESTIGATOR_74027] y time during their participation in this study .
10.Have received an y of the following treatment regi mens specified in the timeframes 
outlined below:
Within [ADDRESS_80810]:
Prior treatment with non B cell -specific l ymphocyte depleting agents/therapi[INVESTIGATOR_014] 
(eg, alemtuzumab [CAMPATH], alky lating agents [eg, cy clophosphamide or 
chlorambucil], total ly mphoid irradiation, etc.).  Subjects who have received 
rituximab or other selective B lymphocy te depleting agents (including 
experimental agents) are eligible if they  have not received such therapy  for at 
least [ADDRESS_80811] normal cluster of differentiation ( CD)
19/20+ counts by  [CONTACT_74064] -activated cell sorting (FACS) analy sis.
Within [ADDRESS_80812]:
Other biologics: within [ADDRESS_80813] dose of investigational produ ctor 
5half-lives (if known), whichever is longer.
Within [ADDRESS_80814]:
Use of dupi[INVESTIGATOR_12458].

PF-[ADDRESS_80815]: 
Use of oral immunosuppressive drugs (eg, cy closporine A [CsA], azathiop rine, 
methotrexate, sy stemic corticosteroids, my cophenolate -mofetil, IFN -) within 
4weeks of first dose of investigational product or within 5 half-lives (if known), 
whichever is longer; 
Phototherapy  narrowband UVB ( NB-UVB) or broad band phototherap y;
Regular use (more than 2 visits per week) of a tanning booth/parlor;
Herbal medications with unknown properties or known beneficial effects for AD.
Within [ADDRESS_80816]:
Anti- platelet drugs. 
Note: low dose acety l salicy lic acid (100mg QD) is permitted, for the purpose of 
cardiovascular proph ylaxis, at the discretion of the investigator.
Within [ADDRESS_80817]:
Topi[INVESTIGATOR_74028] (eg, corticosteroids, 
calcineurin inhibitors, tars, antibiotic creams, topi[INVESTIGATOR_12669]).
Note: Corticosteroid inhalers and intranasal spray s are allowed for stable asthma 
patients.
11.Have a history  of any  lymphoproliferative disorder such as Epstein Barr Virus (EBV) 
related l ymphoproliferative disorder, history  of lymphoma, leukemia, or signs or 
symptoms suggestive of current l ymphatic or l ymphoid disease.
12.Infection History :
a.Have a history  of sy stemic infection requiring hospi[INVESTIGATOR_059], parenteral 
antimicrobial therap y, or as otherwise judged clinically  significant by  [CONTACT_23514] [ADDRESS_80818] known to be infected with Human 
Immunodeficiency Virus (HIV), 
Hepatitis B, or Hepatitis C (Section 7.6.2).
For China and Republic of Korea only: Subjects who are HBsAg negative, 
HBcAb positive, and HBsAb positive at 
Screening will have reflex testing for 
Hepatitis B virus deox yribonucleic acid (HBV DNA ). Subjects who have HBV 
DNA above the lower limit of quantification (LLQ) will be excluded.  Subjects 
who are HBV DNA negative or below LLQ may  be randomized but will have 
repeat HBV DNA testing at Week 12 (or earl y termination).  

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 40For Japan only : Subjects with negative results for HBsAg, HBc Ab and HBsAb 
may be eligible. Subjects who are HBsAg negative, HBcAb negative and HBsAb 
positive and provide documen tation of prior HBV vaccination may be eligible and 
will not require HBV DNA monitoring during the study .Subject s who are 
HBsAg negative, HBcAb negative and HBsAb positive without documentatio n of 
prior HBV vaccination AND subjects who are HBsAg negative, HBc Ab positive, 
and HBsAb positive at screening will have reflex testing for HBV DNA.  Subjects 
who are HBV DNA negative or below LLQ may be randomized but will have 
repeat HBV DNA testing at Week 12 (or earl y termination).
d.Have a history  (single epi[INVESTIGATOR_1865]) of disseminated herpes zoster or disseminated 
herpes simplex, or a recurrent (more than one epi[INVESTIGATOR_44715]) localized, dermatomal 
herpes zost er.
13.Have a history  of alcohol or substance abuse within 6 months prior to Day 1 that in 
the opi[INVESTIGATOR_22751] .
14.A Screening 12 -lead ECG that demonstrates clinically  significant abnormalities 
requiring treat ment (eg, acute my ocardial infarction, serious tachy -or 
brady-arrhy thmias) or that are indicative of serious underly ing heart disease 
(eg,cardiomy opathy , major congenital heart disease, low voltage in all leads, 
Wolff -Parkinson- White sy ndrome) or criteri a associated with Q wave interval 
(QT)/ Fridericia -corrected Q wave interval (QTcF) abnormalities including:
A marked prolongation of QTcF interval (>450 milliseconds [ms]) on the 
screening ECG;
A history  of additional risk factors for Torsade de Pointes ( TdP) (eg, heart failure, 
hypokalemia, famil y history of Long QT S yndrome);
Use of concomitant medications that prolong the QT/QTcF interval.
15.Have a known immunodeficiency  disorder or a first -degree relative with a hereditary  
immunodeficiency .
16.Have an y malignancies or have a history  of malignancies with the exception of 
adequatel y treated or excised non -
metastatic basal cell or squamous cell cancer of the 
skin, or cervical carcinoma in situ.
17.Require treatment with prohibited concomitant medication(s) ( Section 5.8.2 and 
Appendix 3) or have received a prohibited concomitant medication within the 
specified time frame prior to the first dose of study  medication.
18.Have evidence of active or latent or inadequatel y treated infection with 
Mycobacterium tuberculosis (TB) as defined by  [CONTACT_716]:

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 41A positive QuantiFERON-TB Gold (QFT -G) In -Tube test or positive 
Mantoux/Purified Protein Derivative ([COMPANY_003]) tuberculin skin test (if appropriate per 
Section 7.3.4) performed at or within the 12 weeks prior to Day 1 is exclusionary ; 
a negative test is required for eligibility . It is recommended that subjects with a 
history  of Bacille Calmette Guérin (BCG) vaccination be tested with the QFT -G 
test since the Mantoux/[COMPANY_003] tuberculin skin test may  be positive due to 
vaccination.  See 
Section 7.3.4 for requirements for Mantoux/[COMPANY_003] tuberculin skin 
testing.  A QFT -G or Mantoux/[COMPANY_003] tuberculin skin test is not required if the 
subject has previously received a documented adequate course of therap y for 
either latent or active T Binfection.
For Japan only : While QuantiFERONis the preferred testing method, the 
T-SPOT.TBtest is also acceptable as the screening TB test .Borderline results 
from the T- SPOT.TBtest should be considered exclusi onary .If the test results
are ind eterminate, the test should be repeated.  If the result of the repeat test is 
indeterminate, subjects may  be screened using the Mantoux/[COMPANY_003] skin test with 
[COMPANY_007] Medical Monitor approval .  See Section 7.3.4 .
A history  of either untreated or inadequately  treated latent or active TB infection;
If a subject has previously  received an adequate course of therapy  for either latent 
(9months of isoniazid in a locale where rates of primary  multi
-drug T B resistance 
are <5% or an acceptable alternative regimen) or active (acceptable multi -drug 
regimen) TB infection, neither a QFT -G test , T-SPOT.TBtest (Japan only) nor a 
Mantoux/[COMPANY_003] tuberculin skin test is needed, but a chest radiograph(s) is required 
for adults, and recommended for adolescents per local standard/guidelines, if not 
performed within 12 weeks prior to Day 1.  To be considered eligible for the 
study , the radiograph(s) must be negative for active tuberculosis infection as 
determined b y a qual ified radiologist.  Documentation of adequate treatment for 
TB and negative chest radiograph(s) results must be obtained prior to Day 1.  If 
the current incidence rates of multi- drug resistant TB infection in the locale are 
unavailable, an adequate treatme nt regimen should be defined as the regimen 
recommended b y the health ministry  or expert panel in the locale;
A subject who is currently being treated for active TB infection is to be excluded.
19.ANY of the following abnormalities in clinical laboratory  tests at screening, as 
assessed b y the stud y-specific laboratory  and confirmed by  a single repeat, if deemed 
necessary :
Absolute neutrophil count of <1.2 x 109/L(<1200/mm3);
Hemoglobin <10.0 g/dL or hematocrit <30%;
Platelet count of <150 x 109/L (<150,000/mm3);

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 42Absolute ly mphocy te count of <0.50 x 109/L (<500/mm3);
For the Voluntary  Harmonisation Procedure (VHP) participating member 
states (Czech Republic, German y, Hungary, Latvia, Poland, [LOCATION_008]) 
only, the following absolute ly mphocy te count thresho lds apply :
<0.95 x 109/L (<950/mm3) for subjects 12-17 years of age;
<0.91 x 109/L (<910/mm3) for subjects 18-59 years of age ;
<0.80 x 109/L (<800/mm3) for subjects  60years of age .
Estimated Creatinine Clearance <40 mL/min based on the age appropriate
calculation, or serum creatinine >1.5 times the upper limit of normal (ULN);
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values 
>2times the ULN;
Total bilirubin 1.5times the ULN; subjects with a history of Gilbert’s s yndrome 
may have a direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin is ULN.
20.In the opi[INVESTIGATOR_26335], have any  uncontrolled clinically  
significant laboratory  abnormality  that would affect interpretatio n of study  data or the 
subject’s participation in the study .
21.Have undergone significant trauma or major surgery  within [ADDRESS_80819] of the study . 
4.3. Randomization Criteria 
Subjects will be randomized into the study  provided they  or their parent(s)/legal guardian, if 
applicable, have signed an informed consent document to participate in the study , have 
undergone all screening procedures, and have met all inclusion and none of the exclusion 
criteria for part icipation in the study  at Day 1.  A computer -generated randomization 
schedule will be used to assign subjects to the treatment groups using an Interactive 
Response Technology  (IRT).
4.4.Lifestyle Requirements 
In order to participate in the study , subjects mus t be aware of the following life style
guidelines and restrictions that apply during and after the treatment period.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 43On study  visit day s (Day 1, Weeks 4, 12 and End of Study  [EOS]), subjects must 
comply  with fasting requirement for at least 8 hours prior to the visit.  Water and 
permitted non -study  medications are allowed (see Section 5.8.1).
On study  visit day s, subjects must not smoke or ingest caffeine during the 30 minutes 
prior to blood pre ssure and heart rate measurements.
On study  visit day s, subjects must not take the dose of investigational product until 
instructed to do so by  [CONTACT_74065].
On study  visit day s, showering or bathing is permitted prior to attending the study  
visit, but subjects must not moisturize or apply  emollient.  Non -medicated emollient 
is allowed after the visit.  Discontinue and avoid using certain medications and 
treatments ( Section 4.2, Section 5.8.2 , and Appendix 3).
Agree to use one highly
 effective method of contraception (as spe cified in 
Section 4.4.[ADDRESS_80820] experienced menarche, who are, in the opi[INVESTIGATOR_13046], sexually active and at risk for pregnancy  with their partner(s) must agree to 
use a highly effective method of contraception consistently  and correctly  for the duration of 
the act ive treatment period and for at least [ADDRESS_80821] of contraception methods (see 
below) and will confirm that the subject has been instructed in its consistent and correct use.  
At time points indicated in the Schedule of Activities, the investigator or designee will 
inform the subject of the need to use highly  effective contraception consistently and correctly  
and document the conversation and the subject’s affirmation in the subject’s chart (subjects 
needs to affirm their consistent and correct use of at least 1 of the selected methods of 
contraception).  In addition, the investigator or designee will instruct the subject to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or
suspected in the subject or the partner. 
Highl y effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following :
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) provided the subject 
plans to remain on the same treatment throughout the entire study  and has been using 
that hormonal contraceptive for an adequate period of time to ensure effectiveness.
2.Correctly placed copper -containing intrauterine device (IUD). 

PF-[ADDRESS_80822] (ie, foam, 
gel, film, cream, or supposi tory).  For countries where spermicide is not available or 
condom plus spermicide is not accepted as highl y effective contraception, this option 
is not appropriate.
4.Male sterilization with absence of sperm in the post -vasectom y ejaculate.
5.Bilateral tubal l igation/bilateral salpi[INVESTIGATOR_74029] 
(provided that occlusion has been confirmed in accordance with the device’s label).
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual inte rcourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
The contraception check is an opportunity  to confirm that contraception, if assigned, is used 
consistently  and correctly .  It also facilitates continual reassessment of child bearing potential 
in women.  This allows for implementing necessary changes to contraception; for example, 
investigators may  need to ensure al ternative contraceptive methods if new concomitant 
disease contraindicates a selected method of contraception, or if a subject is demonstrably  no 
longer of child bearing status (as per protocol) then they  will no longer require contraception.  
Continual re assessment of contraceptive needs is imperative.
For countries in the EU:
Highl y effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) provided the subject 
plans to remain on the same treatment throughout the e ntire study  and has been using 
that hormonal contraceptive for an adequate period of time to ensure effectiveness.
2.Correctly placed copper -containing intrauterine device (IUD).
3.Male sterilization with absence of sperm in the post -vasectom y ejaculate.
4.Bilat eral tubal ligation/bilateral salpi[INVESTIGATOR_8820] y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heter osexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 454.4.2. Vaccine and Exposure to Infections Guidelines
[IP_ADDRESS]. Subject Specific Recommendations
It is recommended that all subjects should be up- to-date with respect to standard of care 
vaccinations (as defined by  [CONTACT_74066] ) or AD guidelines.  Vaccination of 
subjects with live components is prohibited within the [ADDRESS_80823] one dose of the varicella vaccine or those who are without evidence of 
previous varicella zoster exposure as co nfirmed by  [CONTACT_74067]. 
[IP_ADDRESS]. Guidance Regarding Household Contact [CONTACT_74068] -Related Exposure
Current routine household contact [CONTACT_74069] a risk during treatment and for 6 weeks following 
completion of the study .  Some of these vaccines include varicella (“chickenpox”) vaccine, 
oral polio vaccine, and the inhaled flu vaccine.  Following vaccination with live component 
vaccines, the virus may  be shed in bodily  fluids, including stool, and there is a potential risk 
that the virus may  be transmitted.  General guidelines for immunosuppressed subjects 
suggest that exposure (through routine contact) should be avoided following vaccination (of 
others) with these vaccines for the stated time period:
a.Varicella or attenuated typhoid fever vaccination for [ADDRESS_80824](inhaled flu vaccine) for [ADDRESS_80825] requires surgery  
(including dental surgery) during the study  to determine whether the subject should 
discontinue from the study and/or discontinue investigational product prior to the surgical 
procedure.  In general, planned surgical proce dures should not be performed unless the 
investigational product has been discontinued for at least 28 days (unless otherwise advised 
by [CONTACT_74070]).  The [COMPANY_007] Medical Monitor or designee should 
be notified as soon as possible if a subject undergoes a surgical procedure without first 
informing the stud y staff.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 464.5.Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_74071]’s manual and in the 
study  portal.
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided with a contact [CONTACT_1137].  The contact [CONTACT_4662], 
at aminimum, protocol and investigational product identifiers, subject study  numbers, 
contact [CONTACT_22850], and contact [CONTACT_4664] a contact [CONTACT_74072] a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .  The contact [CONTACT_74073]; however, it should be used 
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathway s betw een the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
[CONTACT_74074], and if a subject or their parent(s)/legal 
guardian calls that number, he or she will be directed back to the investigator site.
5.STUDY TREATMENTS 
For this study , the investigational products are PF -
04965842 and placebo.  PF- 04965842 will 
be administered orally  at doses of 100 mg or 200 mg given QD for 12 weeks based on 
treatment assignment.  In addition, one treatment group will be assigned to receive 
PF-04965842-matching placebo. 
For the purposes of this study , and per International Conference on Harmonisation (I CH) 
guidelines, investigational product is defined as a p harmaceutical form of an active 
ingredient or placebo being tested or used as a reference/comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approve d form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (I CH E6 1.33).  
5.1.Allocation to Treatment
Allocation of subjects to treatment groups will proceed through the use of an I nteractive 
Response Te chnology  (IRT) sy stem.  The site personnel (study  coordinator or specified 
designee) will be required to enter or select information including but not limited to the 
user’s identification (ID) and password, protocol number, the subject number and the date of 
birth of the subject.  The site personnel will then be provided with a treatment assignment 
and dispensable unit (DU) or container number when investigational product is being 
supplied via the I RT.  The I RT s ystem will provide a confirmation report cont aining the 
subject number and DU or container number assigned.  The confirmation report must be 
stored in the site’s files. 

PF-[ADDRESS_80826] information and further 
details on the use of the IRT. 
Note: The IRT is the source of the subject number.  The I RT sy stem will provide the subject 
number at the end of the first I RT subject transaction.
5.2.Breaking the Blind
Investigators, subjects and the sponsor study  team will be blinded as to treatment group.  The 
study  will be subject and investigator blinded.  At all times, treatment and randomization 
information will be kept confidential and will not be released to the inv estigator, the study  
staff, or the sponsor’s study  team until following the conclusion of the study , with the 
exception described in this section. 
At the initiation of the study , the study  site will be instructed on procedures for breaking the 
blind.  Bli nding codes should only  be broken in emergency  situations for reasons of subject 
safet y.  The method will be an electronic process.  When the blind for a subject has been 
broken, the reason must be fully  documented and entered on the Case Report Form (CRF).  
Whenever possible, the investigator should contact [CONTACT_74075].  If the 
blind is broken, the investigator should promptly inform the [COMPANY_007] Clinician or Medical 
Monitor.  The subject for whom the blind has been broken will be discon tinued from the 
study  and undergo the early  termination (ET) procedures.
5.3. Subject Compliance
For self -administration of the investigational product at home, compliance will be captured 
and completed b y the subject.  Subjects will be issued an electronic dos ing diary  (eDiary ) and 
will be educated to record the time of their daily  dosing, once they  have taken the 
investigational product. 
When investigational product is administered at the research facility , it will be administered 
under the supervision of study  personnel.
Compliance with the dosing of investigational product will be monitored and verified b y 
delegated site personnel through a combination of the accounting of unused investigational 
product returned b y the subject at the study visits, review of the dosing diary , and discussion 
with the subject which will be documented in the source documents.
Investigational product should be taken in the morning.  Subjects should be instructed that if 
a dose is inadvertentl y missed then it should be taken as s oon as remembered, but not within 
12 hours of the next scheduled dose. 
The following compliance cases will be considered medication errors and will be discussed 
with the sponsor for possible withdrawal from the study :
Subjects interrupting investigational product for more than 4 consecutive day s or for a 
total of more than 7 day s between visits;  

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 48Subjects administering >8 tablets in one day  or administering 4 tablets/day  for 
4consecutive day s;  
Subjects who have an overall compliance of <80% or >120% b etween visits.
Any deviation from protocol specified dosing should be recorded as a protocol deviation and 
the investigator or designee is to counsel the subject and parent(s)/legal guardian (if 
applicable) and ensure steps are taken to improve compliance. In addition, if the compliance 
deviation reaches the thresholds defined above it should also be recorded as a medication 
error (see Section 8.4.4).
5.4.Investigational Product Sup plies
5.4.1. Dosage Form(s) and Packaging
Blinded PF -04965842 and its matched placebo will be provided as 100 mg tablets for oral 
administration.  The 100 mg tablets and their matching placebos will be supplied in separate 
bottles and labeled according to local r egulatory  requirements.
When received b y the pharmacy , PF-
04965842 and matching placebo will be in containers 
that will sufficiently  blind all site staff to content within the bottles (ie, active versus 
placebo).
5.4.2. Preparation and Dispensing
The investigatio nal product should be dispensed using a drug management sy stem at each 
dispensing visit.  A qualified staff member will dispense the investigational product via 
unique container numbers in bottles provided, in quantities appropriate for the study  visit 
schedule.  The subject/caregiver should be instructed to maintain the product in the bottles 
provided throughout the course of dosing and return the bottles to the site at the next study  
visit.
5.5.Administration
Subjects will be dispensed two (2) bottles at eac h dispensing visit and given clear dosing 
instructions to take one tablet from each bottle, once dail y, preferabl y in the morning, at 
approximately  the same time of day .  Subjects should take the investigational product orall y 
once a day  for [ADDRESS_80827] Administration
Treatm ent Assignment QD Dosing*
100mg QD Bottle A 100 mg -1 tablet 
Bottle B Placebo - 1 tablet
200 mg QD Bottle A 100 mg -1 tablet
Bottle B 100 mg -1 tablet
Placebo Bottle A Placebo - 1 tablet 
Bottle B Placebo - 1 tablet
* Bottle A and B designations are used for example purposes o nly.
Subjects will swallow the investigational product whole, and will not manipulate or chew the 
medication prior to swallowing.  Investigational product may  be taken with or without food, 
other than on study  visit day s where fasting is required. 
A guida nce document with detailed dosing instructions will also be provided to subjects to 
support at -home dosing.
5.6.Investigational Product Storage 
The investigator, or an approved representative, eg, pharmacist, will ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements. 
Investigational product should be stored in their original container and in accordance with the 
labels.  See the I nvestigational Product Manual (IP Manual) for storage conditions of the 
product.
Any storage conditions stated in the SRSD will be superseded b y the storage conditions 
stated on the product label.
Site sy stems must be capable of measuring and documenting ( for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room- temperature products).  This should 
be captured from the time of investigational produc t receipt throughout the study .  Even for 
continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business d ay to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non- working day s upon return to normal operations.  The operation of the 
temperature mon itoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they  are maintained in working order. 
Any excursions from the product label storage conditions should be reported to [COMPANY_007] upon 
discovery .  The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible.  Deviations from the storage 
requirements, including any
 actions taken, must be documented and reported to [COMPANY_007].

PF-[ADDRESS_80828] supplies.  All investigational products will be 
accounted for using a drug accountabilit
y form/record.  To ensure adequate records, all drug 
supplies will be accounted for in the drug accountability  inventory  forms as instructed by  
[CONTACT_74076] b y the accounting of unused investigational product returned b y 
the subjects.  At the end of the clinical trial, all drug supplies unallocated or unused by  [CONTACT_74077], or destr oyed in an approved 
manner unless otherwise authorized by  [CONTACT_4618].  In either case, the forms must identify  the 
investigational product, including batch or code numbers, and account for its disposition on a 
subject -by-subject basis, including specific dates and quantities. 
All bottles of investigational product must be brought back to the site at every visit for 
inspection by  [CONTACT_74078]/unused investigational product must be returned to 
the investigator b y the subject at the relevant vis it(s).
5.7.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of unused investigational 
product (eg, at the site).  If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
[CONTACT_4618], and all destruction must be adequatel y documented.
5.8. Concomitant Treatment(s)
Subjects will abstain from all concomitant medications as described in Section 4.2and 
Appendix 3of the protocol.  Medications that a re taken in the Screening/Washout period 
(after informed consent is obtained and before the first dose of investigational product) will 
be documented as prior medications.  Medications taken after the first dose of investigational 
product has been administ ered will be documented as concomitant medications.  All 
concomitant medications taken during the study  must be recorded in study  records with 
indication (if atopic dermatitis), reference to an y associated adverse event, dose, and start and 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 51stop dates of a dministration.  Subjects will be queried about concomitant medication 
(including topi[INVESTIGATOR_74030], over- the-counter and prescription medications 
and treatments, and vaccinations) at each study  visit.  Any  new concomitant medications or 
dose changes to current concomitant medications should be evaluated for potential new or 
worsening adverse events.
5.8.1. Permitted Concomitant Medications
The following concomitant AD therapi[INVESTIGATOR_74031] y:
Oral antihistamines; 
Topi[INVESTIGATOR_15385]
-medi cated emollient. 
The following concomitant medications are permitted during the stud y:
Corticosteroid inhalers and intranasal spray s are allowed for stable asthma patients;
Ophthalmic corticosteroids are allowed for patients receiving a stable dose to tre at 
rhinoconjuntivitis;
Low dose acet yl salicy lic acid (<100 mg QD) is permitted, for the purpose of 
cardiovascular proph ylaxis, at the discretion of the investigator ;
Acetaminophen/paracetamol may  be used intermittently  (not to exceed 1 g/day); 
Vitamin an d mineral supplements of standard potency  are allowed in amounts not 
known to be associated with adverse effects (such as hyper -vitaminosis).
For the purposes of this protocol, dietary  supplements are defined as vitamins, minerals, and 
purified food substa nces.  Vitamins, minerals and purified food substances are allowed in 
amounts not known to be associated with adverse effects (such as h yper-vitaminosis).
Unless a prohibited medication or treatment, subjects may  be administered any other 
medications necessary  for the treatment of concomitant medical disorders as deemed 
necessary  by [CONTACT_74079].  Following Day 1, addition of concomitant medications 
or an y change in the dosage should be limited to those considered medicall y essential.
A subject who is receiving a permitted concomitant medication for an y reason must be on a 
locally -approved medication and dose, and this must be documented in the CRF.  Subjects 
are not allowed an y other investigational drugs or treatments during the study. 
Subjects should refrain from starting new or changing doses of permitted prescription or 
non-prescription drugs, vitamins, and dietary  supplements within 7 days or 5 half-lives 
(whichever is longer) prior to Day [ADDRESS_80829]’s 
record and CRF.
5.8.2. Prohibited Medications and Treatmen ts
Subjects are required to discontinue and avoid using certain medications and treatments (see 
Section 4.2, Inclusion Criteria and Exclusion Criteria , and Appendix 3).  Subjects should be 
instructed at each visit to contact [CONTACT_43038] y site investigator promptly if there are an y 
intended changes or addit
ions to concomitant medications. 
All medications and treatments that could affect atopic dermatitis must be discontinued 
except oral antihistamines.  Due to the potential to affect atopic dermatitis with ultraviolet 
light exposure, subjects must also avoi d prolonged exposure to the sun and not to use tanning 
booths, sun lamps or other ultraviolet light sources during the stud y. 
Subjects who received prior treatment with JAK inhibitors are to be excluded from the stud y. 
Herbal medications with unknown properties or known beneficial effects for AD must be 
discontinued at least [ADDRESS_80830] 8 hours prior to all visits that include lipid profile 
panel testing (Day 1, Week 4, Week 12, and EOS).  During the fasting period, subjects 
should refrain from all food and liquids (water and permitted non -study  medications are 
allowed). 
ECGs will be interpreted by  a central reader for all visits.

PF-[ADDRESS_80831] safety  monitoring and discontinuation. 
6.1.Visit 1, Screening
Subjects will be screened (Visit 1) within [ADDRESS_80832] selection criteria for the study .  
The investigator (or an appropriate delegate at the investigator site) will obtain informed 
consent from each subject, o r parent(s)/legal guardian (and assent from the subject, as 
appropriate), in accordance with the procedures described in the Subject Information and 
Consent in Section 12.3. 
If the Mantoux [COMPANY_003] tuberculin skin test is given, the subject must return between 
48-[ADDRESS_80833] - injection for induration evaluation.
Screening laboratory  tests with abnormal results may  be repeated once to confirm abnormal 
results; the last value will be used to determine eligibility .  If results return to normal within 
the 4- week screening period, the subject may  enter the study . 
The following procedures will be completed: 
Obtain written informed consent; for su bjects aged less than the legal age of majority  
(legal adulthood) in the subject’s country ,obtain written informed consent from 
parent(s)/ legal guardian, and informed assent from the patient (if age appropriate 
according to local regulations) ;
Register su bject using the I RT s ystem;
Collect demograph y;
Administer C- SSRS, SBQ -R and PHQ -8.  Subjects meeting an y of the criteria 
specified in Exclusion Criterion 2as described in Section 4.2 on the C -SSRS, SBQ -R 
and PHQ -
8 should be excluded from participation; it is recommended the subject’s 
primary  care ph ysician (PCP) should be informed, and the subject referred to a mental 
health professional, either by [CONTACT_74080] t he investigator according to their usual 
practice ;
Complete medical history, including history  of alcohol and tobacco use.  Smoking 
status and average weekly  alcohol consumption (units/week) will also be collected, 
where a unit contains 12 g of pure alcoho l, an amount equivalent to that contained in 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 545oz/150 ml (a glass) of wine, 12 oz/360 ml of beer, or 1.5 oz/45 ml of 90 proof 
(45% alcohol b y volume) of spi[INVESTIGATOR_2120];
Complete AD disease history  includes collection of details of AD: AD diagnosis and 
duration, t he use of topi[INVESTIGATOR_12969], s ystemic treatments and other treatments for 
AD;
Obtain complete medication history  of all prescription or nonprescription drugs, and 
dietary  and herbal supplements taken within [ADDRESS_80834] dose, 
except as noted below:  
The following timeframe prior to the planned first dose must be used for collection of 
the following Current/Prior Medications:
1year: Previous drug treatments for AD including the use of topi[INVESTIGATOR_12969], 
systemic treatments and othe r treatments; 
Any previous history  of intolerance/allergy  to an y drug, regardless of indication.
Obtain vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74032] (after at least [ADDRESS_80835]);
Obtain weight;
Obtain height;
Perform a single 12 -lead electrocardiogram (ECG). Clinically  significant or 
exclusionary  ECG findings require screen failure;  
Conduct complete phy sical examination;
Dispense electronic patient reported outcome (ePRO) handheld device and instruct 
subject in how to use the device.  Instruct the subject to begin dail y completion of the 
PSAAD (in selected countries) and pruritus NRS questionnaire; 
Pruritus NRS 
and Night Time I tch Scale will be collected daily  in a subject eDiary  
during the sc reening period and from Day 1 to 15 and then on study  visit day s; 
PSAAD will be collected daily  in a subject eDiary during the screening period and 
from Day 1 through the End of Study  visit, in selected countries; 
Chest X -ray (posterior -anterior and late ral views) or other appropriate diagnostic 
image (ie, computerized tomography [CT] or magnetic resonance imaging [MRI ]) are 
required for adults and recommended for adolescents (based on local guidelines and 
standard of care). Official reading must be loca ted and available in the source 
documentation. Chest X -ray may  be performed up to 12 weeks prior to Day 1;
Obtain samples for laboratory testing: serum chemistry , hematology  (including 
coagulation panel), urinaly sis, serum FSH (post -menopausal women) or serum 

PF-[ADDRESS_80836] (women of childbearing potential, including adolescents aged [ADDRESS_80837] experienced menarche), HIV, hepatitis B 
surface antigen (HBsAg), hepatitis B core antibody  (HBcAb), hepatitis B surface 
antibody  (HBsAb), hepatitis C viral antibody  (HCV Ab), hepatitis C viral ribonucleic 
acid (HCV RNA) (see Section [IP_ADDRESS]), VZV IgG antibody  testing for adolescent 
subjects who have not received at least one dose of a varicella vaccine ;
For China 
and Republic of Korea only:Subjects who are HBsAg negative , 
HBcAb positive , and HBsAb positive will have reflex testing for HBV DNA;
For Japan only : In addition to HBsAg and HBcAb ,HBsAb t esting will be 
performed at Screening for all subjects rather than as a reflex test. Subjects with 
negative results for HBsAg, HBcAb and HBsAb may  be eligible . Subjects who 
are HBsAg negative, HBcAb negative and HBsAb positive and provide 
documentation o f prior HBV vaccination may  be eligible and will not require 
HBV DNA monitoring during the stud y.Subjects who are HBsAg negative, 
HBcAb negative and HBsAb positive without documentation of prior HBV 
vaccination AND subjects who are HBsAg negative, HBcAb positive, and HBsAb 
positive at screening will have reflex testing for HBV DNA. Subjects who are 
HBV DNA negative or below LLQ may be randomized but will have HB V DNA 
repeated at Week 12 or early  termination .
QuantiFERON–TB Gold test or locally  anal yzed T- SPOT.TBtest (Japan only )
(unless performed within 12 weeks of Day 1).  If 
Mantoux [COMPANY_003] tuberculin skin 
test is required to be performed instead, per Section 7.3.4, the sub ject must return 
between 48- 72hours post -injection for evaluation of induration (see Section 7.3.4
for further details on TB testing);
Conduct clinical evaluations including I GA, SCORAD, EASI  and BSA 
(calculated in the EASI);
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section 4.4).  Establish willingness and abi lity to comply  with lifest yle 
requirements going forward in the study ;
Review Inclusion and Exclusion criteria for subject eligibility ;
Assess for occurrence of Adverse Events: The adverse event and SAE reporting 
period starts with the signing of the infor med consent document;
If the subject is eligible for continued participation, provide subject with 
emergency  contact [CONTACT_1137].

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  5 6 6 . 2 . T r e a tm e n t  P e r i o d 
6 . 2 . 1 . V i s i t  2 ,  D a y  1 /W e e k  0  ( B a s e l i n e ) 
A dm i n i s t e r  p a t i e n t -r e p o r t e d  o u t c om e s  ( P R O s )i n c l u d i n g :  P t G A ,  D L Q I  ( o r  C D L Q I ) ,  
P O EM , H A D S ,  E Q - 5 D - 5 L  ( o r  E Q -5 D -Y ) ,  S F -3 6 v 2 ,  A c u t e ,  W P A I : A D  a n d  F A C I T -F  
( o r  P e d s -F A C I T -F ) .   S F -3 6 v 2  a n d  W P A I : A D  w i l l  b e  c om p l e t e d  b y  a d u l t  s u b j e c t s  
o n l y ;  
A d o l e s c e n t s  1 2 -1 7  y e a r s  o f  a g e  w i l l  n o t  c om p l e t e  t h e  S F -3 6 v 2  o r  W P A I : A D .   
A d o l e s c e n t s 1 2 - 1 7  y e a r s  o f  a g e  w i l l  c om p l e t e  t h e  C D L Q I  i n s t e a d  o f  t h e  D L Q I ,  t h e  
E Q -5 D - Y  i n s t e a d  o f  t h e  E Q - 5 D - 5 L  a n d  P e d s -F A C I T - F  i n s t e a d  o f  t h e  F A C I T - F ; 
R e v i e w  e D i a r y  p r u r i t u s  N R S ,  N i g h t  T im e  I t c h  S c a l e ,  a n d P S A A D  c om p l e t i o n  ( i n  
s e l e c t e d  c o u n t r i e s )  a n d  r e v i e w  e D i a r y  p r o c e d u r e s  w i t h  s u b j e c t  a s  n e c e s s a r y ; 
R e v i e w  a n y  c h a n g e s  i n  t h e  s u b j e c t ’ s  p r i o r  a n d  c o n c om i t a n t  m e d i c a t i o n s  a n d  t r e a tm e n t  
i n f o rm a t i o n ; 
O b t a i n  p r e - d o s e  v i t a l  s i g n s  i n c l u d i n g  p u l s e  r a t e ,  b l o o d  p r e s s u r e ,  r e s p i r a t o r y  r a t e  a n d  
o r a l  o r  t y m p a n i c  t em p e r a t u r e  ( a f t e r  a t  l e a s t  5 m i n u t e s  o f  r e s t ) ; 
O b t a i n  w e i g h t ; 
P e r f o rm  a  s i n g l e  1 2 -l e a d  e l e c t r o c a r d i o g r am  ( E C G ) .  C l i n i c a l l y  s i g n i f i c a n t  o r  
e x c l u s i o n a r y  E C G  f i n d i n g s  r e q u i r e  s c r e e n  f a i l u r e ;  
C o n d u c t  c om p l e t e  p h y s i c a l  e x am i n a t i o n ;  
O b t a i n  f a s t i n g  s am p l e s  f o r  l a b o r a t o r y  t e s t i n g :  s e r um  c h em i s t r y ,  h em a t o l o g y  
( i n c l u d i n g  c o a g u l a t i o n  p a n e l ) ,  l i p i d  p r o f i l e ,  a n d  u r i n a l y s i s ;  
U r i n e  p r e g n a n c y  t e s t  ( f em a l e  s u b j e c t s  o f  c h i l d b e a r i n g  p o t e n t i a l ,  i n c l u d i n g  a d o l e s c e n t s  
a g e d  1 2  y e a r s  a n d  o l d e r ,  r e g a r d l e s s  o f  w h e t h e r  t h e y  h a v e  e x p e r i e n c e d  m e n a r c h e ) .   A  
n e g a t i v e  u r i n e  p r e g n a n c y  t e s t  m u s t  b e  o b t a i n e d  p r i o r  t o  d o s i n g  w i t h  t h e  
i n v e s t i g a t i o n a l  p r o d u c t ;
  
C o l l e c t  s am p l e  f o r  v i r a l  s u r v e i l l a n c e :  H e r p e s  s im p l e x  v i r u s  ( H S V )  H S V -1 ,  H S V - 2  
a n d  V Z V ; 
C o n d u c t  c l i n i c a l  e v a l u a t i o n s  i n c l u d i n g  F i t z p a t r i c k  S k i n  T y p e  A s s e s sm e n t ,  I G A ,  
S C O R A D ,  E A S I  a n d  B S A  ( c a l c u l a t e d  i n  t h e  E A S I ) ; 
P h o t o g r a p h y  o f  A D  l e s i o n s  ( a t  s e l e c t e d  s i t e s ;  S e c t i o n  7 . 7 . 5 ) ; C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 57Assess need for contraception and adherence to applicable lifest yle requirements 
(Section 4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going forward in the study ;
Review of Inclusion/Exclusion Criteria;
If subject continues to meet all Inclusion/Exclusion criteria, officiall y randomize 
subject into the study ;
Dispense investigational product  to the subject;
Administer first dose of investigational product t o subject;
Obtain an additional pulse rate and blood pressure (after at least [ADDRESS_80838]).  
Pulse rate and blood pressure must be performed at least [ADDRESS_80839];
Assess and record an y Adverse Events sin ce the last visit .
6.2.2. Visit 3, Day 8/Week 1 ( 1 day)
Call subject and confirm compliance with dail y completio n of pruritus NRS, Night 
Time I tch Scale, and PSAAD (in selected countries);
Verball y confirm subject has been compliant with study  dosing and entry  in the 
eDiary .  Review eDiary  procedures with subject as necessary ;
Review an y changes in the subject’s concomitant medications and treatment 
information;
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section
4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going forward in the study;
Assess and record an y Adverse Events since the last visit.
6.2.3. Visit 4, Day 15/Week 2 (1 day)
Administer PROs including PtGA, DLQI (or CDLQI), POEM, HADS and EQ -
5D-5L 
(or EQ -5D- Y);  
Adolescents 12- 17 years of age will complete the CDL QI instead of the DLQI and the 
EQ-5D- Y instead of the EQ -5D- 5L;
Review pruritus NRS, Night Time Itch Scal e, and PSAAD completion (in selected 
countries) and review eDiary  procedures with subject as necessary .  Instruct subject 
that pruritus NRS and Night Time Itch Scale will now be completed onl y at visits on 
site and in the eDiary  and will no longer be compl eted on a dail y basis at home;

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 58Urine pregnancy  test (female subjects of childbearing potential, including adolescents 
aged [ADDRESS_80840] experienced menarche).  A 
negative urine pregnancy test must be obtained prior to dosing with the 
investigational product; 
Administer investigational product at clinic;
Perform a single 12 -lead electrocardiogram (ECG);
Conduct targeted ph ysical examination;
Obtain samples for laboratory testing: serum chemistry , hematology  (including 
coagulation panel), and urinaly sis;
Conduct clinical evaluations including IGA, SCORAD, EASI  and BSA (calculated in 
the EASI);
Photograph y of AD lesions (at selected sites; Section 7.7.5); 
Obtain vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74032] (after at least [ADDRESS_80841]).  Vital signs must be performed 
at least [ADDRESS_80842];
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section
4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going f orward in the study ;
Review an y changes in the subject’s concomitant medications and treatments 
information;
Review eDiary  to assess completion;
Perform drug accountability  procedures;
Assess and record an y Adverse Events since the last visit.
6.2.4. Visit 5, Day
29/Week 4 ( 2 day)
Administer PROs including PtGA, DLQI (or CDLQI), POEM, HADS and EQ -5D- 5L 
(or EQ -5D- Y);  
Adolescents 12- 17 years of age will complete the CDL QI instead of the DLQI and the 
EQ-5D- Y instead of the EQ -5D- 5L;
Review PSAAD daily completion ( in selected countries) , Night Time I tch Scale, and 
pruritus NRS completion for this visit in the eDiary; 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 59Perform a single 12 -lead electrocardiogram (ECG);
Conduct targeted ph ysical examination;
Obtain fasting samples for laboratory  testing: serum chemistr y, hematology 
(including coagulation panel), lipid profile, and urinaly sis; 
Urine pregnancy  test (female subjects of childbearing potential, including adolescents 
aged [ADDRESS_80843] experienced menarche).  A 
negative urine pregnancy test must be obtained prior to dosing with the 
investigational product; 
Administer investigational product at clinic; 
Obtain vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74032] (after at lea st 5minutes of rest) and oral or ty mpanic 
temperature.  Vital signs must be performed at least [ADDRESS_80844];
Conduct clinical evaluations including IGA, SCORAD, EASI  and BSA (calculated in 
the EASI);
Photograp hy of AD lesions (at selected sites; Section 7.7.5);
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section
4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going forward in the study;
Review an y changes in the subject’s concomitant medications and treatments 
information;
Review eDiary  toassess completion;
Perform drug accountability  procedures;
Dispense investigational product to the subject;
Assess and record an y Adverse Events since the last visit.
6.2.5. Visit 6, Day 43/Week 6 ( 3 day)
Call subject and confirm compliance with dail y completio n of PSAAD (in selected 
countries);
Verball y confirm subject has been compliant with study  dosing and entry  in the 
eDiary .  Review eDiary  procedures with subject as necessary ;  

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 60Review an y changes in the subject’s concomitant medications and treatment 
information;
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section 4.4).  Establish willingness and abilit y to comply with lifest yle requirements
going forward in the study
;
Assess and record an y Adverse Events since the last visit.
6.2.6. Visit 7, Day 57/Week 8 ( 3 day)
Administer PROs including PtGA, DLQI (or CDLQI), POEM, HADS and EQ -5D- 5L 
(or EQ -5D- Y);
Adolescents 12- 17 years of age will complete the CDL QI instead of the DLQI and the 
EQ-5D- Y instead of the EQ -5D- 5L;
Review PSAAD daily completion (in selected countr ies), Night Time I tch Scale, and 
pruritus NRS completion for this visit in the eDiary; 
Urine pregnancy  test (female subjects of childbearin g potential, including adolescents 
aged [ADDRESS_80845] experienced menarche).  A 
negative urine pregnancy test must be obtained prior to dosing with the 
investigational product; 
Obtain blood samples for PK analy sis 2.0 hours (30min) pre -dose;
Administer investigational product at clinic;
Perform a single 12 -lead electrocardiogram (ECG);
Conduct targeted ph ysical examination;
Obtain samples for laboratory testing: serum chemistry , hematology  (including 
coagulation pane l), and urinaly sis; 
Conduct clinical evaluations including IGA, SCORAD, EASI  and BSA (calculated in 
the EASI);
Photograph y of AD lesions (at selected sites; Section 7.7.5);
Obtain vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74032] (after at least [ADDRESS_80846]).  Vital signs must be performed 
at least [ADDRESS_80847]; 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 61Assess need for contraception and adherence to applicable lifest yle requirements 
(Section 4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going forward in the st udy;
Review an y changes in the subject’s concomitant medications and treatments 
information;
Review eDiary  to assess completion;
Perform drug accountability  procedures;
Dispense investigational product to the subject; 
Assess and record an y Adverse Events 
since the last visit.
6.2.7. Visit 8, Day 85/Week 12 ( 3 days) or Early Termination Visit
Administer PROs including PtGA, DLQI (or CDLQI), POEM, HADS, EQ -5D- 5L (or 
EQ-5D- Y), SF -36v2, Acute, WPAI :AD and FACIT- F (or Peds -FACIT -F).  SF -36v2 
and WPAI :AD will be compl eted by  [CONTACT_74060] ; 
Adolescents 12- 17 years of age will not complete the SF -36v2 or WPAI :AD.  
Adolescents 12-17 years of age will complete the CDL QI instead of the DLQI, the 
EQ-
5D-Y instead of the EQ -5D- 5L and Peds- FACI T-F instead of the FACI T-F;
Review PSAAD daily  completion (in selected countries) , Night Time I tch Scale, and
pruritus NRS completion for this visit in the eDiary; 
Urine pregnancy  test (female subjects of childbearing potential, including adolescents 
aged [ADDRESS_80848] experienced menarche).  A 
negative urine pregnancy test must be obtained prior to dosing with the 
investigational product;
Obtain pre -dose vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74033] t ympanic te mperature (after at least [ADDRESS_80849]);
Obtain weight;
Obtain height;
Perform a single 12 -lead electrocardiogram (ECG);
Conduct complete phy sical examination;
Obtain fasting samples for laboratory  testing: serum chemistry, hematology  
(including coagu lation panel), lipid profile, and urinaly sis; 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  6 2 F o r  C h i n a ,  J a p a n  a n d  R e p u b l i c  o f  K o r e a o n l y :  I n  s u b j e c t s  w h o  h a d  H B V  D N A  t e s t i n g 
a t  S c r e e n i n g ,  c o l l e c t  b l o o d  s am p l e  f o r  r e p e a t  H B V  D N A  t e s t i n g ,  a s  a p p r o p r i a t e ;
 ;
A dm i n i s t e r  i n v e s t i g a t i o n a l  p r o d u c t  a t  c l i n i c ; 
O b t a i n  b l o o d  s am p l e s  f o r  P K  a n a l y s i s  1 . 0 h o u r  ( 1 5 m i n )  a n d  2 . 0 h o u r s  ( 3 0 m i n ) 
p o s t -d o s e .  I f  t h e  E T  v i s i t  o c c u r s  a f t e r  W e e k  8 ,  c o l l e c t  P K  s am p l e s  o n l y  i f  t h e  s u b j e c t  
t a k e s  t h e  i n v e s t i g a t i o n a l  p r o d u c t  a t  t h e s i t e  v i s i t ; 
O b t a i n  a n  a d d i t i o n a l  p u l s e  r a t e  a n d  b l o o d  p r e s s u r e  ( a f t e r  a t  l e a s t  5 m i n u t e s  o f  r e s t ) . 
P u l s e  r a t e  a n d  b l o o d  p r e s s u r e  m u s t  b e  p e r f o rm e d  a t  l e a s t  1  h o u r  f o l l o w i n g  
a dm i n i s t r a t i o n  o f  i n v e s t i g a t i o n a l  p r o d u c t ; 
C o n d u c t  c l i n i c a l  e v a l u a t i o n s  i n c l u d i n g  I G A ,  S C O R A D ,  E A S I  a n d  B S A  ( c a l c u l a t e d  i n  
t h e  E A S I ) ; 
P h o t o g r a p h y  o f  A D  l e s i o n s  ( a t  s e l e c t e d  s i t e s ;  S e c t i o n  7 . 7 . 5 ) ; 
A s s e s s  n e e d  f o r  c o n t r a c e p t i o n  a n d  a d h e r e n c e  t o  a p p l i c a b l e  l i f e s t y l e  r e q u i r em e n t s  
(S e c t i o n 4 . 4 ) .   E s t a b l i s h  w i l l i n g n e s s  a n d  a b i l i t y  t o  c om p l y  w i t h  l i f e s t y l e  r e q u i r em e n t s  
g o i n g  f o r w a r d  i n  t h e  s t u d y ; 
R e v i e w  a n y  c h a n g e s  i n  t h e  s u b j e c t ’ s  c o n c om i t a n t  m e d i c a t i o n  a n d  t r e a tm e n t s  
i n f o rm a t i o n ; 
R e v i e w  e D i a r y  t o  a s s e s s  c om p l e t i o n ; 
P e r f o rm  d r u g  a c c o u n t a b i l i t y  p r o c e d u r e s ; 
A s s e s s  a n d  r e c o r d  a n y  A d v e r s e  E v e n t s  s i n c e  t h e  l a s t  v i s i t ; 
S u b j e c t s  w h o  c om p l e t e  t h e  t r i a l  t o  t h i s  v i s i t  w i l l  b e  a s s e s s e d  f o r  e l i g i b i l i t y  f o r  
p a r t i c i p a t i o n  i n  l o n g -t e rm  e x t e n s i o n  s t u d y  B 7 4 5 1 0 1 5 . S u b j e c t s  w h o  a r e  n o t  e l i g i b l e  
o r  a r e  n o t  i n t e r e s t e d  a r e  t o  c o n t i n u e  t o  V i s i t 9  ( s e e  S e c t i o n  6 . 3 . 1 ) . 
6 . 3 . F o l l o w -u p  V i s i t s 
6 . 3 . 1 . V i s i t  9 ,  D a y  1 2 0 /W e e k  1 6  ( 3  d a y )  
A dm i n i s t e r  P R O s  i n c l u d i n g  P t G A ,  D L Q I  ( o r  C D L Q I ) ,  P O EM ,  H A D S ,  E Q -5 D - 5 L  ( o r  
E Q - 5 D - Y ) ,  S F - 3 6 v 2 ,  A c u t e ,  W P A I : A D  a n d  F A C I T -F  ( o r  P e d s -F A C I T -F ) .   S F - 3 6 v 2  
a n d  W P A I : A D  w i l l  b e  c om p l e t e d  b y  a d u l t  s u b j e c t s  o n l y ;
A d o l e s c e n t s  1 2 -1 7  y e a r s  o f  a g e  w i l l  n o t  c om p l e t e  t h e  S F -3 6 v 2  o r  W P A I : A D .   
A d o l e s c e n t s 1 2 -1 7  y e a r s  o f  a g e  w i l l  c om p l e t e  t h e  C D L Q I  i n s t e a d  o f  t h e  D L Q I ,  t h e  
E Q - 5 D - Y  i n s t e a d  o f  t h e  E Q - 5 D - 5 L  a n d  P e d s -F A C I T - F  i n s t e a d  o f  t h e  F A C I T - F ;  C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 63Review PSAAD daily  completion (in selected coun tries), Night Time I tch Scale, and 
pruritus NRS completion for this visit in the eDiary;
Obtain vital signs including pulse rate, blood pressure, respi[INVESTIGATOR_74032] (after at least [ADDRESS_80850]);
Perform a single 12 -lead electrocardiogram (ECG);
Conduct targeted ph ysical examination;
Obtain fasting samples for laboratory  testing: serum chemistry
, hematology  
(including coagulation panel), lipid profile, and urinaly sis; 
Urine pregnancy  test (female subjects of childbearing potential, including adolescents 
aged [ADDRESS_80851] experienced menarche); 
Conduct clinical evaluations including IGA, SCORAD, EASI  and BSA (calculated in 
the EASI);
Photograph y of AD lesions (at selected sites; Section 7.7.5); 
Assess need for contraception and adherence to applicable lifest yle requirements 
(Section
4.4).  Establish willingness and abilit y to comply with lifest yle requirements 
going forward in the study;
Review an y changes in the subject’s concomitant medications and treatments 
information;
Assess and record an y Adverse Events since the last visi t.
6.4.Subject Withdrawal
Ongoing safety concern at the time of subject withdrawal from the study :
If a subject has a clinically significant, treatment -emergent, abnormality  at the time of 
withdrawal from the study, the [COMPANY_007] Medical Monitor (or designee) sho uld be notified and 
every  effort should be made to arrange follow -up evaluations at appropriate intervals to 
document the course of the abnormalit y.  All abnormal laboratory events of clinical 
significance should be followed until the laboratory  values hav e returned to normal or 
baseline levels or are deemed clinically  stable.  Follow -up for abnormal laboratory  findings 
and adverse events by  [CONTACT_74081] a level acceptable to the invest igator, and [COMPANY_007] concurs with that assessment.  
Refer to 
Appendix 4for Guidelines for Monitoring and Discontinuation. 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 64Withdrawal of consent :
Subjects (or parent(s)/legal guardian, as applicable) who request to discontinue receipt of 
study  treatment will remain in the study .  If this request occurs at a scheduled visit, an end of 
treatment visit should be performed and the subject should enter into the follow -up period, 
with an end of stud y visit scheduled for 4weeks after the end of treatment visit.  I f the 
request occurs outside of a scheduled visit (eg, via telephone contact) the subject should be 
scheduled to return to site for an end of treatment visit within one week, and the subject 
should enter into the follow -up period, with an end of study  visit scheduled for [ADDRESS_80852] (or parent(s)/legal guardian, as applicable) 
specificall y withdraws consent for an y further contact [CONTACT_74082]
m or her or persons previously  
authorized by  [CONTACT_74083].  Subjects (or parent(s)/legal guardian, 
as applicable) should notify  the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possi ble.  The withdrawal of consent should be explained in 
detail in the medical records by [CONTACT_093], as to whether the withdrawal is only  from 
further receipt of investigational product or also from study  procedures and/or posttreatment 
study  follow -up, and entered on the appropriate CRF page.  In the event that vital status 
(whether the subject is alive or dead) is being measured, publicly  available information 
should be used to determine vital status only  as appropriatel y directed in accordance with 
local law.
Lost to follow
-up: 
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status.  This includes follow -up with persons authorized by  [CONTACT_74084].  Lost 
to follow -up is defined by  [CONTACT_74085] a minimum of [ADDRESS_80853]’s medical records.  If it is 
determined that th e subject has died, the site will use locally  permissible methods to obtain 
the date and cause of death.  I f the investigator’s use of a third -party representative to assist 
in the follow -up portion of the study  has been included in the subject’s (or paren t(s)/legal 
guardian, as applicable) informed consent, then the investigator may  use a sponsor -retained 
third- party representative to assist site staff with obtaining the subject’s contact [CONTACT_74086]- up portion of the study .  
The site staff and representative will consult publicly  available sources, such as public health 
registries and databases, in order to obtain updated contact [CONTACT_3031].  If, after all attempts, 
the subject remains lost to follow -up, then the last -known- alive date as determined by  [CONTACT_74087]’s medical records.
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety  (see also the 
Withdrawal From the Study  Due to Adverse Events section) or behavioral reasons, or the 
inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given study site.  Subjects that discontinue study  treatment will remain in the 

PF-[ADDRESS_80854]’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator should inquire 
about the reason for withdrawal, request that the subject return all unused investigational 
product(s), request that the subject return for a final visit, if applicable, and follow up with 
the subject regarding an y unresolved AEs.
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
7.ASSESSMEN TS
Every  effort should be made to ensure that the protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it u nfeasible to 
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safet y and well -being of the subject.  When a protocol -required test cannot be performed, the 
investigator will document the reason for this and any corrective and preventive actions that 
he or she has taken to ensure that normal processes are adhered to as soon as possible.  The 
study  team will be informed of these incidents in a timely  manner.
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact [CONTACT_19987] . 
7.1.Pregnancy Testing
For female subjects of childbearing potential, including adolescents aged [ADDRESS_80855] 25 mIU/mL, will be performed at screening.  A urine pregnancy  test 
with a sensitivity  of at least 25 mIU/mL, will be performed at every  site visit including the 
End of Treatment (EOT) and follow -up visits to confirm the subject has not become pregnant 
during the stud y, and at the follow -up visit. 
A negative pregnancy  test result is required before the subject may  receive the investigational
product.  Pregnancy  tests will also be done whenever 1 menstrual cy cle is missed during the 
active treatment period (or when potential pregnancy  is otherwise suspected).  Pregnancy  
tests may  also be repeated if requested b y institutional review boards (IRBs)/ethics 
committees (Ecs) or if required by  [CONTACT_427]. 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  6 6 U r i n e  p r e g n a n c y  t e s t s  m u s t  b e  s e n s i t i v e  t o  a t  l e a s t  2 5 m I U /m L  a n d  w i l l  b e  c o n d u c t e d  w i t h  t h e  
t e s t  k i t  p r o v i d e d  b y  t h e  c e n t r a l  l a b o r a t o r y  i n  a c c o r d a n c e  w i t h  i n s t r u c t i o n s  p r o v i d e d  i n  i t s  
p a c k a g e  i n s e r t .   S u b j e c t s  w h o  h a v e  m i s s e d  a  m e n s t r u a l  p e r i o d  o r  w h o  s h o w  a n  i n d e t e rm i n a t e  
o r  p o s i t i v e  r e s u l t  o n  t h e  u r i n e  t e s t  m a y  n o t  f u r t h e r  p r o g r e s s  i n  t h e  s t u d y  u n t i l  p r e g n a n c y  i s  
r u l e d  o u t  u s i n g  f u r t h e r  d i a g n o s t i c  t e s t i n g  ( e g , a  n e g a t i v e  q u a n t i t a t i v e  s e r um p r e g n a n c y  t e s t  
c o n d u c t e d  a t  a  c e r t i f i e d  l a b o r a t o r y ) . 
I n  t h e  c a s e  o f  a  p o s i t i v e  c o n f i rm e d  p r e g n a n c y ,  t h e  s u b j e c t  w i l l  b e  w i t h d r a w n  f r om  
a dm i n i s t r a t i o n  o f  i n v e s t i g a t i o n a l  p r o d u c t  b u t  m a y  r em a i n  i n  t h e  s t u d y .
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  6 7  
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
7 . 3 . S a f e t y  A s s e s sm e n t s 
S a f e t y  w i l l  b e  a s s e s s e d  b y  t h e  s p o n t a n e o u s  r e p o r t i n g  o f  A E s ,  p h y s i c a l  e x am i n a t i o n s ,  v i t a l  
si g n s  a n d  c l i n i c a l  l a b o r a t o r y  r e s u l t s  i n  a l l  s u b j e c t s  w h o  r e c e i v e  a t  l e a s t  o n e  d o s e  o f  t h e  
i n v e s t i g a t i o n a l  p r o d u c t .   U n s c h e d u l e d  s a f e t y  a s s e s sm e n t s  m a y  b e  p e r f o rm e d  a t  a n y  t im e  
d u r i n g  t h e  s t u d y  t o  a s s e s s  a n y  p e r c e i v e d  s a f e t y  c o n c e r n s .   I n v e s t i g a t o r s  a n d  P f i z e r  C l i n i c i a n s  
( o r  d e s i g n e e s )  w i l l  r e v i e w  i n d i v i d u a l  s u b j e c t  d a t a  t h r o u g h o u t  t h e  c o n d u c t  o f  t h e  s t u d y  t o  
e n s u r e  s u b j e c t s ’  w e l l -b e i n g . 
7 . 3 . 1 . V i t a l s  S i g n s 
V i t a l  s i g n s  ( s i t t i n g  b l o o d  p r e s s u r e ,  p u l s e  r a t e ,  r e s p i r a t o r y  r a t e s  a n d  t em p e r a t u r e )  w i l l  b e  
m e a s u r e d  a f t e r  5 m i n u t e s  o f  r e s t  a s  i n d i c a t e d  i n  t h e  S c h e d u l e  o f  A c t i v i t i e s .  
B o d y  t em p e r a t u r e  w i l l  b e  c o l l e c t e d  u s i n g  t h e  t y m p a n i c  o r  o r a l  m e t h o d s  a n d  t h e  s am e  m e t h o d  
s h o u l d  b e  u s e d  c o n s i s t e n t l y  t h r o u g h o u t  t h e  s t u d y .  C C I 
C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 68Blood pressure (BP) will be measured using a standard calibrated blood pressure measuring 
device.  A BP device that uses multiple cuff sizes based on the arm circumference is the 
required t ype of device.  The appropriate cuff size for the subject must be used to ensure 
accurate measure ment.  The arm circumference at the midpoint of the length of the upper arm 
should be measured to determine the appropriate cuff size in accordance with the 
specifications of the BP measuring device.  The same properly  sized and calibrated blood 
pressure c uff will be used to measure blood pressure each time. 
Subjects should be seated in a chair, back supported, and arms bared (free of restrictions such 
as rolled-up sleeves, etc.) and supported at heart level.  Measurements should be taken on the 
same arm a t each visit (preferabl y non -dominant).  Subjects should refrain from smoking or 
ingesting caffeine during the [ADDRESS_80856]. 
Heart rate should be measured at approximate ly the same time as BP for a minimum of 
30seconds.  When the timing of BP and pulse (heart) rate measurements coincides with a 
blood collection or other study  procedure, BP and pulse (heart) rate should be obtained first.
7.3.2. Medical History, Physical Examina tion, Height, and Weight
Complete AD disease history  includes collection of details of AD at Screening: AD 
diagnosis, the use of topi[INVESTIGATOR_12969], s ystemic treatments and other treatments for AD.  
Medical history  in addition to AD history  including disea se duration will be collected at 
screening.  Medical history  also includes history  of alcohol and tobacco use.  Smoking status 
and average weekl y alcohol consumption (units/week) will be collected, where a unit 
contains 12 g of pure alcohol, an amount equivalent to that contained in 5 oz/150 mL (a 
glass) of wine, 12 oz/360 mL  of beer, or 1.5 oz/[ADDRESS_80857] wearing shoes.  Height (inches or centimeters) 
and weight (lbs. or kg) will be 
measured and recorded in the source document at the 
screening visit.  Weight (lbs. or kg) will continue to be measured and recorded at various 
time points, see Sched uleof Activities .
Complete phy sical examinations must be performed by [CONTACT_093], sub -investigator or a 
qualified health professional per local guidelines.  Complete phy sical examinations consist of 
assessments of general appearance; skin; head, eyes, ears, nose and throat (HEENT); mouth, 
heart; lungs; breast (opti onal); abdomen; external genitalia (optional); extremities; neurologic 
function; and ly mph nodes.
Targeted ph ysical examinations must be performed by  [CONTACT_093], sub -investigator or a 
qualified health professional per local guidelines and should include skin, heart, lungs, and 
abdomen and examination of body  systems where there are s ymptom complaints by  [CONTACT_1560]. 
Complete and Targeted phy sical examinations are performed at various time points, see 
Schedule of Activities
.

PF-[ADDRESS_80858] radiograph (posterior -anterior and lateral views) are required for adults and 
recommended for adolescents (as per local guidelines and standard of care) or other 
appropriate diagnostic image (ie, c omputed tomograph y[CT] or m agnetic resonance imaging
[MRI ]) with no evidence of current, active TB or previous inactive TB, taken at screening or 
within [ADDRESS_80859] be located and available in the so urce documentation.
7.3.4. Tuberculosis Testing
At the time of screening, all subjects will undergo tuberculosis (TB) testing unless performed 
within 12 weeks of Day  1.  QuantiFERON-TB Gold I n-Tube Test is the preferred testing 
method.  If the QuantiFERON-TB Go ld In-Tube test cannot be performed, or if the results 
cannot be determined b y the reference laboratory  to be either positive or negative, then 
subjects may  be screened using the Purified Protein Derivative ([COMPANY_003]) Tuberculin Skin Test 
(Mantoux method) with approval of the [COMPANY_007] Medical Monitor. 
In addition to TB testing as specified in this clinical protocol, a chest X -ray will be 
performed to aid in TB status determination for all adults, and recommended for adolescents 
according to local guidelines and s tandard of care and/or in countries with a high incidence 
rate of TB. 
QuantiFERON-TB Gold I n-Tube is an in vitro diagnostic test using a peptide cocktail 
simulating ESAT -6, CFP -10and TB 7.[ADDRESS_80860] ion of interferon -gamma b y Enz yme-Linked Immunosorbent Assay  (ELISA) is 
used to identify  in vitro responses to these peptide antigens that are associated with 
Mycobacterium tuberculosis infection.  QuantiFERON-TB Gold In -Tube is an indirect test 
for M.tuberculosis infection (including disease) and is intended for use in conjunction with 
risk assessment, radiography  and other medical and diagnostic evaluations.
A blood sample (approximately  3mL) will be collected at screening for QuantiFERON-TB 
Gold I n-Tube testing.  Following sample processing, the sample will be shipped to the 
sponsor’s designated reference laboratory  for testing.  The procedure for processing and 
preparing the sample for shipment is described fully  in the laboratory  manual, which will be 
provided to investigators.
A negative [COMPANY_003] test can be substituted for the QuantiFERON-TB Gold In -Tube test only  if 
the central laboratory  is unable to perform the QuantiFERON-TB Gold In-Tube test or 
cannot determine the results to be positive or negat ive and the [COMPANY_007] Medical Monitor 
approves it, on a case -by-case basis.  
Japan only : While QuantiFERONis the preferred testing method, the T- SPOT.TBtest is 
also 
acceptable as the screening TB test .Like QuantiFERON, the T- SPOT.TBtest is an in 
vitro diagnostic test for M.tuberculosis 
infection; however, it differs in that it uses a peptide 
cocktail ofESAT -6 and CFP -10 proteins to stimulate peripheral blood mononuclear cells. 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 70T-SPOT.TBtesting will be performed at the site’s local laboratory. Borderline results from 
the 
T-SPOT.TBtest should be considered exclusi onary .If the T -SPOT.TBtest results are 
indeterminat e, the test should be repeated.
If the result of the repeat test is indeterminate, 
subjects may
 be screened using the Mantoux/[COMPANY_003] s kin test with [COMPANY_007] Medical Monitor 
approval.
Purified Protein Derivative ([COMPANY_003]) Test
If the QuantiFERON-TB Gold In- Tube test or the T-SPOT.TBtest (Japan only ) cannot be 
performed, or if the results cannot be determined to be positive or negative, then subjects 
may be screened using the Purified Protein Derivative ([COMPANY_003]) Tuberculin Test (Mantoux 
method), with the approval of the [COMPANY_007] Medical Monitor. 
Subjects must have the [COMPANY_003] test administered and evaluated b y a health care professional 
48to [ADDRESS_80861] should be performed according to local standards with 
induration of <[ADDRESS_80862]’s screening ECG must be within normal limits prior to randomization.
7.3.6. Special Safety Assessment
In the event of a suspected opportunistic infection, effort should be made to identify  the 
pathogen utilizi ng laboratory  or other methods appropriate to the clinical situation. 
In case of a suspected viral skin infection (eg, herpes zoster and herpes simplex or eczema 
herpeticum ), a specimen for viral DNA may be analy zed locally  for confirmation and results 
pr
ovided to the adjudication committee to support evaluation.  
For subjects with a past history  of oral or genital HSV and a presentation consistent to prior 
infections, further laboratory anal ysis may  be performed at the discretion of the investigator. 
7.4.Skin Type Assessment
As part of baseline characteristics, a skin ty pe assessment will be done at the Day 1 visit 
using the Fitzpatrick Skin Ty pe assessment (Refer to Appendix 5).  This is used to classify  a 
person ’s skin ty pe by  [CONTACT_74088] (ie, burning or tanning).

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 717.5.Assessment of Suicidal Ideation and Behavior
Subjects meeting exclusionary  results as described inSection 4.2 on the C -SSRS, SBQ -R and 
PHQ -8 should be excluded from participation; it is recommended the subject’s primary  care 
physician (PCP) should be informed, and the subject referred to a mental health professional, 
either b y the PCP or the investigator according to thei r usual practice .
7.5.1. Columbia Suicide Severity Rating Scale (C -SSRS)
The Columbia Suicide Severit y Rating Scale is a validated tool for investigative staff to use 
to evaluate suicidal ideation and behavior ( Appendix 17).17  At the screening visit, if there 
are “y es” answers on items [ADDRESS_80863]’s eligibility  based on the answers.
7.5.2. Suicidal Behaviors Questionnaire -Revised (SBQ- R)
The Suicidal Behaviors Questionnaire- Revised ( Appendix 18) is a patient -reported 
questionnaire consisting of 4 items to assess suicidal ideation, suicide attempts, threat of 
suicidal behavior, and likelihood of suicidal behavior.  At the Screening Visit, if SBQ -R t
otal 
score 8, the subject will not be included in the study .18  Site staff is to administer the SBQ -R 
to all subjects at screening and score immediately .
7.5.3.
Patient Health Questionnaire –8 items (PHQ -8)
The Patient Healt h Questionnaire – 8 items ( Appendix 19) is a patient -reported questionnaire 
consisting of [ADDRESS_80864]’s depression level.  At Screening Visit, if PHQ -
8 
total score  15, the subject will not be included in the study .19  Site staff is to administer the 
PHQ -8 to all subjects at screening and score immediately .
7.6.
Clinical Laboratory Tests
7.6.1. Blood Volume
Total blood sampling volume planned for this study  is approximately  124 mL.  Further 
details regarding the collection, processing, storage, and shippi[INVESTIGATOR_74034].
7.6.2. Laboratory Tests
The following laboratory tests will be performed at time points identified in the Schedule of 
Activities
.  Unscheduled clinical labs may  be obtained at an y time during the study  to assess 
any perceived safet y concerns at the investigator’s discretion.
Sample collection, labeling, storage, and shippi[INVESTIGATOR_74035] n be found in the laboratory  
manual.  All laboratory  tests with clinically  important changes from baseline identified after 
administration of investigational product will be followed until the value stabilizes.

PF-[ADDRESS_80865] abstain from all food and drink (except water and non- study  medications) for 
an 8-hour overnight fast prior to labs that include the lipid profile panel on Day 1, Week 4, 
Week 12, and EOS.  All other labs do not require fasting.
Laboratory Tests
Hem atology Serum Che mistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count and indices 
(MCH, MCHC, MCV, RBC
Morphology)
Reticulocyte count
Platelet count
WBC count with differential
Total neutrophils (%, Abs)
Eosinophils (%, Abs)
Monocytes (%, Abs)
Basophils (%, Abs)
Lymphocytes (%, Abs)
Coagu lation Panel
Activated Partial 
Thromboplastin Time 
(APTT) 
Prothrombin 
Time/International 
Normalized Ratio 
(PT/INR)BUN and Creatinine
Creatine Phosphokinase
Glucose
Na+, K+, Cl -,Ca++
Total CO2 (Bicarbonate)
AST, ALT
GGT
Total, Indirect & Direct Bilirubin
Alkaline phosphatase
Lactate dehydrogenase 
Uric acid
Albumin
Total protein
Lipid Profile Panelf
Total cholesterol
LDL 
HDL
TriglyceridespH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Microscopy and/or 
culturedHIVa
HBsAga
HBcAba
HBsAbb
HCVAba
HCV RNAb
VZV IgG Abg
Serum FSH (WONCBP 
only) or Pregnancy Testa, c
Urine pregnancy testc
QFT -G or [COMPANY_003] (if 
applicable) or T-SPOT.TB
test(Japan only)e
HSV -1, HSV -2, VZV
HBV DNAh
a.At Screening only. HIV testing will be performed for all subjects.
b.HBsAb reflex testing only if HBsAg negative but HBcAb positive.  HCV RNA is reflex testing only if 
HCVAb is positive. For Japan only: In addition to HBsAg and HBcAb, HBsAb testing will be performed 
at Screening for all subjects rather than as a reflex test.  
c.Pregnancy testing for females of childbearing potential, including adolescents aged [ADDRESS_80866] experienced menarche; serum FSH for w omenwho have been amenorrheic 
for at least 12 consecutive months.
d.Microscopy with culture performed as appropriate. 
e.[COMPANY_003] results should be read w ithin 48 to 72 hours. For Japan only: QFT -G is prefe rred but T-SPOT.TBtest 
may be performed instead through the site’s local laboratory.
f.Lipid Profile Panel requires at least an [ADDRESS_80867] one dose of varicella vaccine.
h.For China and Republic of Korea only: Subjects who are HBsAg negative , HBcAb positive , and HBsAb
positive at Screening will have reflex testing for HBV DNA. Subjects who have HBV DNA above LLQ 
will be excluded. Subjects who are HBV DNA negative or below  LLQ may be randomized but will have 
repeat HBV DNA testing at Week 12 (or early termination ).
For Japan only: Subjects with negative re sults for HBsAg, HBcAb and HBsAb tests may be eligible. 
Subjects who are HBsAg negative, HBcAb negative and HBsAb positive and provide documentation of 
prior HBV vaccination may be eligible and will not require HBV DNA monitoring during the study.
Subjects who are HBsAg negative, HBcAb negative and HBsAb positive without documentation of prior 
HBV vaccination AND subjects who are HBsAg negative, HBcAb positive, and HBsAb positive at 
Screening will have reflex testing for HBV DNA.  Subjects who are HBV DNA negative or below  LLQ 
may be randomized but will have HBV DNA repeated at Week [ADDRESS_80868] results 
determined to be caused from laboratory  error should not be reported as AEs. Clinically  
significant laboratory  findings at the final assessment should be followed to resolution or 
until determined by  [CONTACT_74089].  Repeat tests may  be indicated to 
establish this.  Refer to Appendix 4for Guidelines on Monitoring and Discontinuation.
[IP_ADDRESS]. Hepatitis Testing 
Hepatitis B testing: HB surface antigen ( HBsAg), HB core antibod y (HBcAb ), HB surface 
antibody  (HBsAb ).
Interpretation of Hepatitis B Testing Results:   
HBsAg negative and HBcAb negative: Subject is eligible for the study ;
HBsAg positive and HBcAb negative: Subject is excluded from study participation;
HBsAg negative and HBcAb positive and HBsAb positive: Subject is eligible for 
study ;
HBsAg negative an d HBcAb positive and HBsAb negative: Subject is excluded from 
study  participation.
For China and Republic of Korea only:
Subjects who are HBsAg negative , HBcAb positive , and HBsAb positive at 
Screening 
will have reflex testing for HBV DNA. Subjects who ha ve HBV DNA 
above LLQ will be excluded. Subjects who are HBV DNA negative or below LLQ
may be randomized but will have repeat HBV DNA testing at Week 12 (or earl y 
termination ).
For Japan only:
In addition to HBsAg and HBcAb, HBsAb testing will be performed at Screening for 
all subjects rather than as a reflex test. Subjects with negative results for HBsAg, 
HBcAb and HBsAb may  be eligible. Subjects who are HBsAg negative, HBcAb 
negative and HBsAb positive and provide documentation of prior HBV vaccination
may be eligible and will not require HBV DNA monitoring during the study .
Subjects who are HBsAg negative, HBcAb negative and HBsAb positive without 
documentation of prior HBV vaccination AND subjects who are HBsAg negative, 
HBcAb positive, and HBsAb posi tive at screening will have reflex testing for HBV 
DNA.  Subjects who are HBV DNA negative or below LLQ may  be randomized but 
will have HBV DNA repeated at Week 12 or early  termination .

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 74Hepatitis C testing: Hepatitis C Antibody  (HCV Ab), Hepatitis C Viral RNA (HCV RNA 
for confirmation of positive HCV Ab result).  Interpretation of Hepatitis C Testing Results:
HCV Ab positive and HCV RNA positive: Subject is excluded from study 
participation. 
[IP_ADDRESS]. Varicella Zoster Virus (VZV) IgG Antibody (Ab) Testing
Adolescen t subjects without documented evidence of having received at least a single dose of 
the varicella vaccine in countries where the varicella vaccine is approved and standard of 
care will be tested for varicella zoster virus IgG Ab as described in the lab man ual.  Subjects 
that lack evidence of prior exposure to varicella zoster virus based on serological VZV IgG 
Ab testing are excluded.
[IP_ADDRESS]. Baseline Viral Screen 
A serum sample will be collected at baseline but analy zed onl y if the subject has suspected 
varicella or herpes zoster.  I n that event, the sample would be analyzed for HSV1, HSV2 and 
VZV.  Additional sample collection instructions will be provided in the lab manual ( Schedule 
of Activities).  The retained samples will be destroy ed upon subject completion of this study  
or the long- term extension study . 
7.7.Efficacy Assessments
7.7.1. Rater Qualifications
Clinical evaluations of atopic dermatitis will be performed by[CONTACT_74090] (board certified or equivalent). An experienced and qualified 
non-dermatologist phy sician or experienced medical professional with experience in the
conduct of AD clinical trials may be permitted to perform the clinical evaluations of atopic
dermatitis when designated by  [CONTACT_74091] I nvestigator.  The evaluator must receive and 
document protocol specific and applicable efficacy assessment scales training prior to 
performing these evaluations.  To assure consistency and reduce variability, the same
evaluator must assess all dermatologic al clinical evaluations for any individual subject
throughout the study whenever possible ; a back -
up experienced and qualified, 
protocol -trained evaluator will only be allowed and documented in case of emergency or
special situations when the designated ev aluator is unable to perform the evaluation.
7.7.2. Investigator’s Global Assessment (IGA)
The Investigator’s Global Assessment of atopic dermatitis is scored on a 5-point scale (0 -4), 
reflecting a global consideration of the ery thema, induration and scaling.  Th e clinical 
evaluator of atopic dermatitis will perform an assessment of the overall severity  of atopic 
dermatitis and assign an IGA score and category  as described in 
Table 3.  The assessment 
will be a static evalu ation without regard to the score at a previous visit.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 75Table 3. Investigator’s Global Assessment (IGA) Score
Score Category Description
0 Clear Atopic dermatitis is cleared, except for any residual discoloration 
(post -inflammatory hyperpi[INVESTIGATOR_22758]/or hypopi[INVESTIGATOR_371]).
[ADDRESS_80869] 
ClearOverall, the atopic dermatitis is not entirely cleared and remaining lesions 
are light pi[INVESTIGATOR_8745] (not including post inflammatory hyperpi[INVESTIGATOR_371]) and/or; 
have barely palpable hard thickened skin an d/or papules and/or; have barely 
perceptible lichenification; excoriation and oozing/crusting are absent.
2 Mild Overall, the atopic dermatitis consists of lesions that are light red; with 
slight, but definite hard thickened skin and/or papules; with slig ht, but 
definite linear or pi[INVESTIGATOR_22760]; with 
slight, but definite thickened skin, fine skin markings, and lichenoid scale; 
oozing/crusting is absent.
3 Moderate Overall, the atopic dermatitis consists of lesions that are red; with easily 
palpable moderate hard thickened skin and/or papules; with moderate linear 
or pi[INVESTIGATOR_22760]; with moderate 
thickened skin, coarse skin markings, and coarse lichenoid scale; with slight 
oozing/crust ing.
4 Severe Overall, the atopic dermatitis consists of lesions that are deep, dark red; with 
severe hard thickened skin and/or papules; with severe linear or pi[INVESTIGATOR_22763]; with severe thickened skin with 
very coarse skin markings and lichenoid scale; with moderate to severe 
oozing/crusting.
The IGA will exclude scalp, palms, and soles from the assessment/scoring.
7.7.3. Eczema Area and Severity Index (EASI)
The EASI quantifies the severit y of a subject’s atopic dermatitis based on both severity  of 
lesion clinical signs and the percent of BSA affected.  EASI is a composite scoring b y the 
atopic dermatitis clinical evaluator of the degree of ery thema, induration/papulation, 
excoriation, and lichenification (each scored sep arately ) for each of four body  regions, with 
adjustment for the percent of BSA involved for each body  region and for the proportion of 
the body  region to the whole body .
Lesion Severity by [CONTACT_74092]: The basic characteristics of atopic dermatitis 
lesions-erythema, induration/papulation, excoriation, and lichenification- provide a means for 
assessing the severit y of lesions.  Assessment of these four main clinical signs is performed 
separately  for four body  regions: head and neck, upper limbs, trunk (inc luding axillae and 
groin) and lower limbs (including buttocks).  Average ery thema, induration/papulation, 
excoriation, and lichenification are scored for each body  region according to a 4 point scale: 
0 =absent; 1 =mild; 2 =moderate; 3 =severe.  Morpho logic descriptors for each clinical 
sign severity  score are shown in Table 4.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 76Table 4. Clinical Sign Severity Scoring Criteria for the Eczema Area and Severity 
Index (EASI)
Score Description*
Erythema (E)
0 Absent None; may  have residual discoloration (post -inflammatory  
hyperpi[INVESTIGATOR_22758]/or hy popi[INVESTIGATOR_371]).
1 Mild Light pi[INVESTIGATOR_22759]
2 Moderate Red
3 Severe Deep, dark red
Induration/Papulation (I)
[ADDRESS_80870] thickened skin and/or 
papules
[ADDRESS_80871] thickened skin and/or papules
[ADDRESS_80872] thickened skin and/or papules
Excoriation (Ex)
0 Absent None
1 Mild Slight, but definite l inear or pi[INVESTIGATOR_74036]
2 Moderate Moderate linear or pi[INVESTIGATOR_74037]
3 Severe Severe linear or pi[INVESTIGATOR_74038] (L)
0 Absent None
1 Mild Barel y perceptible to slight, but definite thickened skin, fine skin 
markings, and lichenoid scale
2 Moderate Moderate thickened skin, coarse skin markings, and coarse 
lichenoid scale
3 Severe Severe thickened skin with very coarse skin markings and 
lichenoid scale
The EASI will exclude scalp, palms, and soles from the assessment/scoring.
Percent BSA with Atopic Dermatitis: The number of handprints of skin afflicted with 
atopic dermatitis in a body region can be used to determine the extent (% ) to which a body  
region is involved with atopic dermatitis ( Table 5).  When measuring, the handprint unit 
refers to the size of each individual subject’s hand with fingers in a closed position.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 77Table 5. Handprint Determination of Body Surface Area (BSA)
Body Region Total Number of 
Handprints in Body 
Region*Surface Area of Body 
Region Equivalent of One 
Handprint*
Head and Neck 10 10%
Upper Limbs 20 5%
Trunk (including axillae and 
groin/ge nitals)30 3.33%
Lower Limbs (including 
buttocks)40 2.5%
Handprint refers to the hand size of each individual subject.
* The number of handprints will be for the entire body region; these values will not be adjusted for exclusion 
of scalp, palms, and so les from the BSA assessment.
The extent (%) to which each of the four bod y regions is involved with atopic dermatitis is 
categorized to a numerical Area Score using a non-linear scaling method according to the 
following BSA scoring criteria ( Table 6).
Table 6.Eczema Area and Severity Index (EASI) Area Score Criteria
Percent BSA with Atopic Dermatitis in a Body Region Area Score
0% 0
>0 -<10% 1
10 -<30% 2
30 -<50% 3
50 -<70% 4
70 -<90% 5
90 - 100% 6
Body Region Weighting: Each bod y region is weighted according to its approximate 
percentage of the whole body  (Table 7).
Table 7. Eczema Area and Severity Index (EASI) Body Region Weighting
Body Region Body Region Weighting
Head and Neck 0.1
Upper Limbs 0.2
Trunk (including axillae and 
groin/genitals)0.3
Lower Limbs (including buttocks) 0.4
* No adjustment for body regions excluded for assessment
In each bod y region, the sum of the Clinical Signs Severity  Scores for ery thema, 
induration/papulation, excoriation, and lichenification is multiplied by  [CONTACT_74093] y Region Weighting to provide a bod y region value, which is then summed across all 
four bo dy regions resulting in an EASI  score as described in Equation 3.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 78Equation 3: EASI =0.1Ah(Eh+Ih+Exh+Lh) + 0.2Au(Eu+Iu+ExU+Lu) + 
0.3At(Et+It+Ext+Lt) + 0.4Al(El+Il+Exl+Ll)
A = Area Score; E = ery thema; I =induration/papulation; Ex = excoriation; 
L =lichen ification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs
The EASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores 
representing greater severity  of atopic dermatitis.
[IP_ADDRESS]. Body Surface Area –Efficacy (BSA Effi cacy)
BSA Efficacy  will be derived from the sum of the BSA in handprints across 4 body  regions 
assessed as part of the EASI  assessment ( Table 5).  Handprint refers to that of each 
individual subject for their own m easurement.  The BSA Efficacy  ranges from 0 to 
100%, with higher values representing greater severity  of atopic dermatitis.  Since the scalp, 
palms, and soles will be excluded from the BSA (Efficacy ) assessment, the maximum 
possible value will be less than 100%.
7.7.4. Scoring Atopic Dermatitis (SCORAD)
SCORAD is a validated scoring index for atopic dermatitis, which combines extent (0- 100), 
severit y (0-18), and subjective sy mptoms (0 -20) based on pruritus and sleep loss, each scored 
(0-10). 
Extent (A, maximum sc ore of 100 %)
To determine extent of AD, rule of 9 is used to calculate bod y surface area affected b y AD as 
a percentage of the whole body  surface area.  Body  surface area as percentage of total body  
surface area for each body  region is as follows:
Head and neck 9%; 
Upper limbs 9% each; 
Lower limbs 18% each; 
Anterior trunk 18%; 
Back 18%; 
1% for genitals. 
The score for each bod y region is added up to determine the BSA affected by  [CONTACT_22802] (A), which 
has a possible maximum score of 100%. 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  7 9 S e v e r i t y  ( B ,  m a x im um  s c o r e  o f  1 8 ) 
A  r e p r e s e n t a t i v e  a r e a  o f  A D  i s  s e l e c t e d .   I n  t h i s  a r e a ,  t h e  s e v e r i t y  o f  e a c h  o f  t h e  f o l l o w i n g  
s i g n s  i s  a s s e s s e d  a s  n o n e  ( 0 ) ,  m i l d  ( 1 ) ,  m o d e r a t e  ( 2 )  o r  s e v e r e  ( 3 ) .  
E r y t h em a  ( r e d d e n i n g ) ; 
E d em a  ( s w e l l i n g ) / p a p u l a t i o n ;
O o z i n g / c r u s t i n g ;  
E x c o r i a t i o n  ( s c r a t c h  m a r k s ) ; 
S k i n  t h i c k e n i n g  ( l i c h e n i f i c a t i o n ) ;  
X e r o s i s  ( d r y n e s s )  ( t h i s  i s  a s s e s s e d  i n  a n  a r e a  w h e r e  t h e r e  i s  n o  i n f l amm a t i o n ) . 
T h e  s e v e r i t y  s c o r e s  a r e  a d d e d  t o g e t h e r  t o  g i v e  ' B '  (m a x im um  s c o r e  o f  1 8 ) . 
S u b j e c t i v e  S ym p t om s  ( C ,  m a x im um  s c o r e  o f  2 0 ) 
S u b j e c t i v e  s y m p t om s( i e ,  i t c h  a n d  s l e e p l o s s )  a r e  e a c h  s c o r e d  b y  t h e  s u b j e c t  u s i n g  a  v i s u a l  
a n a l o g  s c a l e  (V A S )w h e r e  “ 0 ”  i s  n o  i t c h  ( o r  n o  s l e e p l o s s )  a n d  “ 1 0 ”  i s  t h e  w o r s t  im a g i n a b l e  
i t c h  ( o r  s l e e p l o s s ) .  T h e  v a l u e  f o r  e a c h  s h o u l d  r e f l e c t  t h e  a v e r a g e  o n  a  1 0  p o i n t  s c a l e  f o r  t h e  
l a s t  3  d a y s / n i g h t s .  T h e s e  s c o r e s  a r e  a d d e d  t o  g i v e  ' C '  (m a x im um  s c o r e  o f 2 0 ) .  
S CO R A D  T o t a l  S c o r e 
T h e  S C O R A D  f o r  a n  i n d i v i d u a l  i s  c a l c u l a t e d  b y  t h e  f o rm u l a :  A / 5  +  7 B / 2  +  C  ( c a n  r a n g e  
f r om  0 t o  1 0 3 ) .  
7 . 7 . 5 . P h o t o g r a p h y  o f  R e p r e s e n t a t i v e  A D L e s i o n s 
F o r  s u b j e c t s  a t  s e l e c t e d  s t u d y  s i t e s ,  p h o t o g r a p h s  o f  t r e a t e d  A D  w i l l  b e  o b t a i n e d  ( a c c o r d i n g  t o  
t h e  s e p a r a t e l y  p r o v i d e d  P h o t o g r a p h y  I n s t r u c t i o n s )  a t  B a s e l i n e / D a y 1 ,  W e e k  2 ,  W e e k  4 ,  
W e e k 8 ,  E O T ,  a n d  E O S .   A r e a s  p h o t o g r a p h e d  s h o u l d  b e  r e c o r d e d  i n  s o u r c e  d o c um e n t s  s o  
t h a t  t h e  s am e  A D  b o d y  r e g i o n ( s )  w i l l  b e  p h o t o g r a p h e d a t  e a c h  t im e  p o i n t .   P h o t o g r a p h s  w i l l  
b e  u t i l i z e d  f o r  i l l u s t r a t i v e  p u r p o s e s  a n d  n o t  f o rm a l l y  e v a l u a t e d  a s  a n  e n d p o i n t  f o r  a n a l y s i s . 
P h o t o g r a p h i c  s e r v i c e s  w i l l  b e  p r o v i d e d  t h r o u g h  a  c e n t r a l  p h o t o g r a p h y  l a b o r a t o r y  s e l e c t e d  b y  
t h e  s p o n s o r .   D e t a i l e d  p r o c e d u r e s  t o  a s s u r e  c o n s i s t e n c y  w i l l  b e  p r o v i d e d  s e p a r a t e l y  i n  a  
c e n t r a l  p h o t o g r a p h y  l a b o r a t o r y  i n s t r u c t i o n  m a n u a l . 
 
  C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  8 0  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
7 . 8 . 2 . N i g h t  T im e  I t c h  S c a l e  
S e v e r i t y  o f  N i g h t  T im e  I t c h 
T h e  s e v e r i t y  o f  i t c h  ( p r u r i t u s )  d u r i n g  t h e  n i g h t  d u e  t o  a t o p i c  d e rm a t i t i s  w i l l  b e  a s s e s s e d  u s i n g  
t h e  N i g h t  T im e  I t c h  S c a l e ,  a  h o r i z o n t a l  N R S  ( A p p e n d i x 7) .  S u b j e c t s  w i l l  b e  a s k e d  t o  a s s e s s  
t h e i r  w o r s t  i t c h i n g  d u e  t o  a t o p i c  d e rm a t i t i s  d u r i n g  t h e i r  m o s t  r e c e n t  n i g h t ’ s  s l e e p  o n  a n  N R S  
a n c h o r e d  b y  t h e  t e rm s  “ n o  i t c h ” ( 0 )  a n d  “ w o r s t  i t c h  im a g i n a b l e ”  ( 1 0 ) .   T h i s  i t em  w i l l  b e  
a dm i n i s t e r e d  t o  a l l  s u b j e c t s .   S u b j e c t s  w i l l  e n t e r  t h e  N i g h t  T im e  I t c h  N R S  a s s e s sm e n t  i n t o  a n  
e D i a r y .C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  8 1 F r e q u e n c y  o f  N i g h t  T im e  I t c h 
T h e  f r e q u e n c y  o f  i t c h  ( p r u r i t u s )  d u r i n g  t h e  n i g h t  d u e  t o  a t o p i c  d e rm a t i t i s  w i l l  b e  a s s e s s e d  
u s i n g  a  h o r i z o n t a l  N R S  ( A p p e n d i x 7) .  S u b j e c t s  w i l l  b e  a s k e d  t o  a s s e s s  f r e q u e n c y  o f  i t c h i n g  
d u e  t o  a t o p i c  d e rm a t i t i s  d u r i n g  t h e i r  m o s t  r e c e n t  n i g h t ’ s  s l e e p  o n  a n  N R S  a n c h o r e d  b y  t h e  
t e rm s  “ n e v e r / n o  i t c h i n g ”  ( 0 ) a n d  “ a l w a y s / c o n s t a n t  i t c h i n g ”  ( 1 0 ) .   T h i s  i t em  w i l l  b e  
a dm i n i s t e r e d  t o  a l l  s u b j e c t s . S u b j e c t s  w i l l  e n t e r  t h e  N i g h t  T im e  I t ch  N R S  a s s e s sm e n t  i n t o  a n  
e D i a r y .
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  8 2  
 
  
 
  
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  8 3  
  
 
   
 
 
7 . 9 . P h a rm a c o k i n e t i c s 
7 . 9 . 1 . P l a sm a  f o r  A n a l y s i s  o f  P F -0 4 9 6 5 8 4 2 
D u r i n g  t h e  s t u d y ,  b l o o d  s am p l e s  ( 3 m L )  t o  p r o v i d e  m i n im um  1 m L  o f  p l a sm a  f o r  P K  a n a l y s i s  
w i l l  b e  c o l l e c t e d  i n t o  a p p r o p r i a t e l y  l a b e l e d  t u b e s  c o n t a i n i n g  p o t a s s i um  
e t h y l e n e d i am i n e t e t r a a c e t i c  a c i d  ( K 2E D T A )  a t  t im e s  s p e c i f i e d  i n  t h e  S T U D Y  P R O C E D U R E S 
s e c t i o n o f  t h e  p r o t o c o l . 
B l o o d  f o r  P K  a n a l y s i s  w i l l  b e  c o l l e c t e d  a t  t h e  s t u d y  s i t e  a t  t h e  f o l l o w i n g  t im e  p o i n t s : 
A t  2 . 0 h o u r s  ( 3 0 m i n )  p r e -d o s e a t  W e e k  8 ;  
A t  1 . 0 h o u r  ( 1 5 m i n )  a n d  2 . 0 h o u r s  ( 3 0 m i n )  p o s t -d o s e  a t  W e e k 1 2 .  
A l l  e f f o r t s  w i l l  b e  m a d e  t o  o b t a i n  t h e  P K  s am p l e s  a t  t h e  e x a c t  n om i n a l  t im e  r e l a t i v e  t o  
d o s i n g .   T h e  e x a c t  t im e  o f  t h e  s am p l e  c o l l e c t i o n  i s  t o  b e  n o t e d  o n  t h e  s o u r c e  d o c um e n t  a n d  
d a t a  c o l l e c t i o n  t o o l  ( e g ,  C R F ) .   S am p l e s  o b t a i n e d  o u t s i d e  t h e  w i n d o w s  s p e c i f i e d  i n  t h e  S O A 
w i l l  b e  c o n s i d e r e d  a  p r o t o c o l  d e v i a t i o n .  F o r  E T  v i s i t s ,  i f  t h e  s u b j e c t  d i s c o n t i n u e s  b e f o r e  
W e e k 8  d o  n o t  c o l l e c t  P K  s am p l e s .   I f  t h e  E T  v i s i t  o c c u r s  a f t e r  W e e k 8 ,  c o l l e c t  P K  s am p l e s  
o n l y  i f  t h e  s u b j e c t  t a k e s  t h e  i n v e s t i g a t i o n a l  p r o d u c t  a t  t h e  s i t e  v i s i t . 
T h e  p l a sm a  w i l l  b e  s t o r e d  i n  a p p r o p r i a t e l y  l a b e l e d  s c r e w -c a p p e d  p o l y p r o p y l e n e  t u b e  
a t  a p p r o x im a t e l y  - 2 0 C  w i t h i n  1 h o u r  o f  c o l l e c t i o n . 
F u r t h e r  d e t a i l s  r e g a r d i n g  t h e  c o l l e c t i o n ,  p r o c e s s i n g ,  s t o r a g e  a n d  s h i p p i n g  o f  t h e  b l o o d  
s am p l e s  w i l l  b e  p r o v i d e d  i n  t h e  l a b  m a n u a l . 
S am p l e s  w i l l  b e  a n a l y z e d  u s i n g  a  v a l i d a t e d  a n a l y t i c a l  m e t h o d  i n  c om p l i a n c e  w i t h  
P f i z e r  s t a n d a r d  o p e r a t i n g  p r o c e d u r e s .  
T h e  P K  s am p l e s  m u s t  b e  p r o c e s s e d  a n d  s h i p p e d  a s  i n d i c a t e d  t o  m a i n t a i n  s am p l e  
i n t e g r i t y .   A n y  d e v i a t i o n s  f r om  t h e  P K  p r o c e s s i n g  s t e p s ,  i n c l u d i n g  a n y  a c t i o n s  t a k e n ,  
m u s t  b e  d o c um e n t e d  a n d  r e p o r t e d  t o  t h e  s p o n s o r .   O n  a  c a s e -b y -c a s e  b a s i s ,  t h e  
s p o n s o r  m a y  m a k e  a  d e t e rm i n a t i o n  a s  t o  w h e t h e r  s am p l e  i n t e g r i t y  h a s  b e e n  
c om p r om i s e d .   A n y  s am p l e  d e em e d  o u t s i d e  o f  e s t a b l i s h e d  s t a b i l i t y ,  o r  o f  q u e s t i o n a b l e  
i n t e g r i t y ,  w i l l  b e  c o n s i d e r e d  a  p r o t o c o l  d e v i a t i o n . C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 84As part of understanding the PKs of the investigational product, samples may  be used 
for metabolite identification and/or evaluation of the bioanal ytical method.  These 
data will be used for internal exploratory  purposes and will not be included in the 
clinical report.
7.9.2. Shipment of Pharmacokinetic Samples
The central laboratory  will provide collection materials and directions for packaging and 
shipment of samples and will forward samples to the contract anal ytical laboratory .  The 
contract anal ytical laboratory  will be pr ovided with randomization codes so that only  samples 
in the PF -[ADDRESS_80873] randomization.  Refer to the central lab vendor manual for 
further information.
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to [COMPANY_007] Safety .  These requirements are delineated for 3 ty pes of events: (1) SAEs; 
(2)non-serious adverse events (AEs); and (3) exposure to the investigational product under 
study  during pregnancy  or breastfeeding, and occupational exposure. 
Safety Event Recorded on the CRF Reported on 
the CT SAE 
Report Form to [COMPANY_007] 
Safety Within [ADDRESS_80874] 
under study  during 
pregnancy  or 
breastfeeding, and 
occupational exposureAll (regardless of whether 
associat ed with an AE), 
except occupational 
exposureExposure during pregnancy , 
exposure via breastfeeding, 
occupational exposure 
(regardless of whether 
associated with an AE)
All observed or volunteered events regardless of treatment group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to [COMPANY_007] Safet y on the CT SAE Report 
Form within [ADDRESS_80875] be made immed iately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 

PF-[ADDRESS_80876] report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determ ine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Even tssection below).  In addition, the investigator may  be 
requested b y [COMPANY_007] Safety to obtain sp ecific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF .  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case an d independent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon a s possible 
to [COMPANY_007] Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to [COMPANY_007] Safet y ONLY upon request.
As part of ongoing saf ety reviews conducted b y the sponsor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by [CONTACT_74094].  To assist 
in the determination of case seriousness, further information may  be requested from the 
investiga tor to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject/parent(s)/legal guardian, if applicable.  In addition, each study 
subject/parent(s)/legal guardian, if applicable, will be questioned about the occurrence of 
AEs in a non- leading manner.
8.1.3. Withdrawal from the Study Due to Adverse Events (see also th e Subject 
Withdrawal Section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 

PF-[ADDRESS_80877] SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Infor mation
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject/parent(s)/legal guardian, if 
applicable, provides informed consent, which is obtained before the subjec t’s participation in 
the study  (ie, before undergoing an y stud y-related procedure and/or receiving investigational 
product), through and including a minimum of 28 calendar day s; except as indicated below 
after the last administration of the investigational product.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a subject during the active collection period are reported to [COMPANY_007] 
Safety  onthe CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to [COMPANY_007] 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to [COMPANY_007] Safety .
Follow up by  [CONTACT_74095] a level acceptable to the investigator, and 
[COMPANY_007] concurs with that assessment.
[IP_ADDRESS]. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  [CONTACT_47610] a level acceptable to the investigator, and [COMPANY_007] concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the inves tigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possib ility that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 87defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated s ection of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance wit h applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Example s of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease; 
Drug abuse;
Drug dependency .
Additionall y, AEs may include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 88Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in stud y dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b ythe investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Even ts
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospi[INVESTIGATOR_1081];
Results in persistent or signif icant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 89Medical and scientific judgment is exercised in deter mining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospi[INVESTIGATOR_059].  However, if it is determined that the event may  jeopardize 
the subject or may  require int ervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; 
or development of drug dependency  or drug abuse.
8.2.4. Hospi[INVESTIGATOR_4589] (even less than 24 hours) in a hospi[INVESTIGATOR_31009] , or any  prolongation of an existi ng admission.  Admission also 
includes transfer within the hospi[INVESTIGATOR_4591]/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessaril y constitute a hospi[INVESTIGATOR_059]; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospi[INVESTIGATOR_4592]:
Rehabilitation facilities;
Hospi[INVESTIGATOR_4593];
Respi[INVESTIGATOR_4594] (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_74039]. Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (e g, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a stud y (eg, for a procedure required by [CONTACT_43038] y 
protocol);

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 90Optional admission not associated with a precipi[INVESTIGATOR_4596] (eg, for elective 
cosmetic surgery );
Hospi[INVESTIGATOR_4597] a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject.
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, a n acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Assessment
If required on the AE page of the CRF, the invest igator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specif ied SAEs in this study.  All SAEs will be reported to [COMPANY_007] 
Safety  by [CONTACT_74096], and will be handled as SAEs in 
the safet y database. 
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show n o sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potent ial outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 91In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBi li) elevations (>2 ×ULN) by  [CONTACT_74097].  The increase in TBili ty pi[INVESTIGATOR_1306] y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, by [CONTACT_22858], AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential D ILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on th e subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal labora tory values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR ALT values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not availab le;
For subjects with baseline AST OR ALT OrTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values a bove the normal range: AST or ALT 
values >2 times the baseline values AND >3
× ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN or if the value reaches >3 ×ULN 
(whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law ca se should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_80878] and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 92anticoagulated tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a co -formula ted product in prescription or over- the-counter medications), 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact [CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  
of liv er or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on repeat testin g as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test (LFT) abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breast feeding and 
occupational exposure are reportable to [COMPANY_007] Safety  within 24 hours of investigator 
awareness.
[IP_ADDRESS]. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact [CONTACT_4490] 
a [COMPANY_007] product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products) ;
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy . 

PF-[ADDRESS_80879]’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
[COMPANY_007] Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a [COMPANY_007] product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by [CONTACT_31061][INVESTIGATOR_4598]) to [COMPANY_007] Safety  using the EDP supp lemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of p regnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Sa fety of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be spe cified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
pre-procedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to [COMPANY_007] Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur with in 1month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after [ADDRESS_80880].
Additional information regarding the EDP may  be requested by  [CONTACT_456].  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, 
the investigator will provide the subject with the Pregnant Partner Release of 
Information Form to deliver to his partner.  The investigator must document in the 
source documents that the subject was given the Pregnant Partner Release of 
Information Form to provide to his partner.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [IP_ADDRESS]. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to [COMPANY_007] Safet y within 24 hours of the investigator’s awareness, using the
CT SAE Report Form.  An exposure during breastfeeding report is not created when a [COMPANY_007] 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE as sociated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional o r otherwise) gets in unplanned direct contact [CONTACT_8898], which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to [COMPANY_007] Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regar dless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site fi le.
8.4.4. Medication Errors 
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Aware ness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an 
SAE
[IP_ADDRESS]. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the w rong time, or at the wrong dosage strength. 
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve t he participating subject;
Refer to Section 5.[ADDRESS_80881].

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 95Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by [CONTACT_1149], as deter mined by  [CONTACT_1275], the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to [COMPANY_007] S afety  within [ADDRESS_80882] SAE Report 
Form onl y when associated with an SAE .
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a stati stical anal ysis plan (SAP), which will be 
maintained by  [CONTACT_456].  The SAP may  modify  what is outlined in the protocol where 
appropriate; however, any  major modifications of the co -primary  endpoint definitions or their 
analyses will also be reflected in a protocol amendment.
9.1.Sample Size Determination
Sample size for the study was based on the co -primary  endpoints.  A total sample of 
375 subjects with 150 subjects randomized to PF - 04965842 200 mg QD, 150 subjects 
randomized to PF -04965842 100 mgQD and 75 subjects randomized to placebo
(2:2:1 randomization) would provide at least 95% power to detect a difference in IGA 
response rate of at least 20% between PF -04965842 200 mgQD (or PF -04965842 
100mgQD) and placebo, assuming the placebo response rate is 6% at Week 12.  
Furthermore, this will also provide at least 99% power to detect a difference in EASI -
[ADDRESS_80883] 30% between PF -04965842 200 mg QD (or PF -04965842 
100mgQD) and placebo, assuming the placebo response rate is 15% at Week 12.
The T ype-I error for testing each individual co -primary  endpoint was fixed at 5%.  Since 
both endpoints are co -primary , the study  will meet its primary
 endpoint only  if both 
hypotheses (corresponding to each co- primary  endpoint) are rejected.  Therefore, the Ty pe-I 
error rate remains controlled at 5% for testing the primary  endpoint.  The power to reject 
both hy potheses when a true difference exists (alternative hy pothesis is true) could be at least 
94% depending on the correlation between the endpoints.
9.2.Efficacy Analysis
9.2.1. Analysis Sets 
The primary  anal ysis population for efficacy  data will be the Full Anal ysis Set (FAS) defined 
as all randomized subjects receiving at least one dose of study  medication.  The primary  
efficacy  endpoint and the key  secondary  efficacy  endpoints will also be analy zed for the 
Per
-Protocol Anal ysis Set (PPAS) defined as a subset of FAS who had no major protocol 
violations.  The subjects excluded from the PPAS will be determined and documented before 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 96the study  is un -blinded.  For a ll analy ses, baseline value will be based on observations 
collected pre -dose.
9.2.2. Testing Procedure for Multiple Comparisons
There are five key  hypotheses to be tested for each of the two PF -04965842 doses 
(200 mgQD and 100 mgQD) versus placebo, for the co -primary  endpoints and two key  
secondary  endpoints.  The family wise Ty pe-I error rate will be strongl y controlled at 
5%using a sequential, Bonferroni -based iterative multiple testing procedure. 
The procedure will first test the co -primary  endpoints (I GA a nd EASI75 at Week 12 for 
200mg QD vs placebo) at the 5% level.  If this hypothesis is not rejected, then no further 
testing will be conducted.  If this hy pothesis is rejected, then testing may  continue on two 
paths:
The hy pothesis for severity  of pruritus (200 mg QD vs placebo at Week 2) will be 
tested at the 2.5% level.  If this hy pothesis is rejected, then the unused alpha level 
of 2.5% will be passed on to the testing for the key  secondary  endpoints and the co -
primary  endpoints for 100 mg QD vs placebo, in the order specified in Sequence A at 
a 5% significance level (see figure below).  Testing stops at an y point where a 
hypothesis cannot be rejected.
If the h ypothesis for severity of pruritus (200 mg QD vs placebo at Week 2) is not 
rejected at the 2.5% level, then the hy potheses for the key  secondary  endpoints and 
the co- primary  endpoints for 100 mg QD vs placebo, in the order specified in 
Sequence A will be tested at a 2.5% significance level (see figure below). If all 
hypotheses in this sequence are r ejected, then the unused alpha level of 2.5% will be 
passed on to the testing of the hy pothesis for severity  of pruritus (200 mgQD vs 
placebo) at Week 2 at the 5% level.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 97Figure 2.Schematic for Multiple Testing Procedure
The fig ure above illustrates the procedure showing the sequence of the tests.  
Hypotheses for all other endpoints not described here are to be tested at the 5% level, without 
making adjustments for multiple comparisons.
9.2.3. Analysis of the Primary Endpoints 
The co -primary  endpoints will be analy zed using the (Cochran -Mantel -Haenszel) test 
adjusted by  [CONTACT_68485] (baseline disease severit y and age) and both must achieve 
statistical significance to meet the primary  objective .  The difference between each acti ve 
group and the placebo group in the proportion of subjects achieving IGA response (similarly 
for EASI75) along with its 95% confidence interval (using the normal approximation for the 
difference in binomial proportions) will be reported.  If a subject wi thdraws from the study , 
then this subject will be counted as non -responder for endpoints after withdrawal.  Additional 
secondary  anal yses will utilize Missing at Random and Not at Random approaches (eg, 
Longitudinal Mixed models and jump to reference anal
yses).
9.2.4. Analysis of Secondary Endpoints
The key  secondary  endpoints which are expressed as proportions such as EASI 50, EASI 90 
and the proportion of subjects achieving a 4 -point improvement from baseline in the pruritus 
NRS measure will be analyzed using the same method as the for co- primary endpoints.  This 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  9 8 w o u l d  a l s o  a p p l y  t o  a n y  o t h e r  b i n a r y  e n d p o i n t  i n  t h e  s t u d y .   E n d p o i n t s  w h i c h  a r e  c o n t i n u o u s  
w i l l  b e  a n a l y z e d  a s  d e s c r i b e d  b e l o w .  
F o r  c o n t i n u o u s  e n d p o i n t s ,  s u c h  a s  p e r c e n t  c h a n g e  f r om  b a s e l i n e  i n  t h e  E A S I  t o t a l  s c o r e ,  a  
m i x e d - e f f e c t  m o d e l  w i t h  r e p e a t e d  m e a s u r e s  (MM RM )  w i l l  b e  u s e d .   T h i s  m o d e l  w i l l  i n c l u d e  
t h e  f a c t o r s  ( f i x e d  e f f e c t s )  f o r  t r e a tm e n t  g r o u p ,  r a n d om i z a t i o n  s t r a t a  ( a g e  g r o u p ,  d i s e a s e  
s e v e r i t y ) ,  v i s i t ,  t r e a tm e n t -b y -v i s i t  i n t e r a c t i o n ,  a n d  r e l e v a n t  b a s e l i n e  v a l u e .   W i t h i n  t h e  
f r am e w o r k  o f  MM RM ,  t h e  t r e a tm e n t  d i f f e r e n c e  w i l l  b e  t e s t e d  a t  t h e  p r e -s p e c i f i e d  p r im a r y  
t im e  p o i n t ,  W e e k 1 2 ,  a s  w e l l  a s  a t  t h e  o t h e r  t im e  p o i n t s  b y  t im e  p o i n t -s p e c i f i c  c o n t r a s t s  f r om  
t h e  MM RM  m o d e l .  
C o n t i n u o u s  e n d p o i n t s  s u c h  a s t h e  c h a n g e  f r om  b a s e l i n e  i  
 
 
  F o r  b i n a r y  
e n d p o i n t s  s u c h  a s  t h e  S C O R A D 5 0  o r  S C O R A D 7 5  o r  t h e  p r o p o r t i o n  o f  s u b j e c t s  w i t h  P t G A  o f  
A D  o f  c l e a r  ( 0 )  o r  a lm o s t  c l e a r  ( 1 )  a n d  2p o i n t  im p r o v em e n t  f r om  b a s e l i n e  o v e r  1 2w e e k s ,  
t h e  s am e  m e t h o d  a s  u s e d  f o r  t h e  b i n a r y  e n d p o i n t s  i n  S e c t i o n  9 . 2 . 3 w i l l  b e  em p l o y e d .   A l l  
s e c o n d a r y  e n d p o i n t s  e x c e p t  t h e  k e y  s e c o n d a r y  e n d p o i n t s  w i l l  b e  e v a l u a t e d  a t  t h e  5%  l e v e l  o f  
s i g n i f i c a n c e ,  w i t h o u t  a d j u s tm e n t s  f o r  m u l t i p l e  c om p a r i s o n s . 
9 . 3 . S a f e t y  A n a l y s i s 
T h e  s a f e t y  d a t a  w i l l  b e  s umm a r i z e d  i n  a c c o r d a n c e  w i t h  P f i z e r  D a t a  S t a n d a r d s .   A l l  s u b j e c t s  
w h o  r e c e i v e  i n v e s t i g a t i o n a l  p r o d u c t  ( s a f e t y  p o p u l a t i o n )  w i l l  b e  i n c l u d e d  i n  t h e  s a f e t y  
a n a l y s e s .   A l l  s a f e t y  d a t a  w i l l  b e  s umm a r i z e d  d e s c r i p t i v e l y  t h r o u g h  a p p r o p r i a t e  d a t a  
t a b u l a t i o n s ,  d e s c r i p t i v e  s t a t i s t i c s ,  c a t e g o r i c a l  s umm a r i e s ,  a n d  g r a p h i c a l  p r e s e n t a t i o n s .   S a f e t y  
e n d p o i n t s  f o r  t h e  s t u d y  i n c l u d e : 
T r e a tm e n t -em e r g e n t  A E s  a n d  S A E s ; 
W i t h d r a w a l s  f r om  a c t i v e  t r e a tm e n t  d u e  t o  A E s ; 
S e r i o u s  i n f e c t i o n s ,  d e f i n e d  a s  a n y  i n f e c t i o n  ( v i r a l ,  b a c t e r i a l ,  a n d  f u n g a l )  r e q u i r i n g  
h o s p i t a l i z a t i o n  o r  p a r e n t e r a l  a n t im i c r o b i a l s ; 
S a f e t y  l a b o r a t o r y  t e s t s  ( e g ,  h em a t o l o g y  [ i n c l u d i n g  c o a g u l a t i o n  p a n e l ] ,  c h em i s t r y  a n d  
l i p i d  p r o f i l e s ) ; 
V i t a l  s i g n s ;
E C G  p a r am e t e r s  i f  a p p l i c a b l e . 
C h a n g e  f r om  b a s e l i n e  o n  l a b o r a t o r y  d a t a  a n d  v i t a l  s i g n s  w i l l  b e  a d d i t i o n a l l y  s umm a r i z e d . 
S u b j e c t  l i s t i n g s  w i l l  a l s o  b e  p r o d u c e d  f o r  t h e s e  s a f e t y  e n d p o i n t s . C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 999.4.Analysis of Pharmacokinetic Endpoints 
Population PK data for PF-04965842 will be summarized through appropriate data 
tabulations, descriptive statistics, and graphical presentation.  A population PK model will be 
developed for the purpose of estimating PK parameters.  Additional details of the 
methodology  will be captured in a separate modeling plan and the results will also be 
reported separatel y.
9.5.External Data Monitoring Committee 
This study  will use an external data monitoring committee (E
-DMC ).  The E -DMC will be 
responsible for ongoing monitoring of the efficacy , safety and PKs of subjects in the study 
according to the charter.  The recommendations made b y the E -DMC to alter the conduct of 
the study  will be forwarded to [COMPANY_007] for final decision.  [COMPANY_007] will forward such decisions, 
which may  include summaries of aggr egate analy ses of endpoint events and of safet y data 
that are not endpoints, to regulatory  authorities, as appropriate.  Composition of the E- DMC 
and processes under which the E -DMC operates will be documented in the E -DMC charter.
9.6.Safety Adjudication Comm ittees
To help assess the specific, complex safet y events related to malignancies, cardiovascular 
events, and opportunistic infection (including eczema herpeticum and other infections of 
special interest) in this study , Safet y Adjudication Committees, consisting of clinical experts 
in each of the relevant clinical areas, will be set up to harmonize and standardize 
assessments.  In order to allow for an unbiased safety assessment, the members of these 
committees will be blinded to treatment assignment.  Furt her information about the Safety  
Adjudication Committees can be found in their respective charters, including a specific 
description of the scope of their responsibilities, a plan where communication timelines are 
defined, and the exact process and definit ions used by  [CONTACT_74098] y events that they will adjudicate.  Other safety  events for adjudication may  be identified 
and included in the remit of the Safet y Adjudication Committees as appropriate.
10.QUALITY CONTROL AND QUALITY ASSURANCE
[COMPANY_007] or its agent will conduct periodic monitoring visits during stud y conduct to ensure that 
the protocol and Good Clinical Practices (GCPs) are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs are accurate.  The 
investigator and institution will allow [COMPANY_007] monitors/auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.  This 
verification may  also occur after study  completion.
During stud y conduct and/or after stud y completion, the investigator site may be subject to 
review b y the IRB/EC, and/or to quality  assurance audits performed by  [CONTACT_4618], or companies 
working with or on behalf of [COMPANY_007], and/or to inspection by  [CONTACT_8901].

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 100The investigator(s) will notify  [COMPANY_007] or its agents immediately  of any  regulatory  inspection 
notification in relation to the study .  Furthermore, the investigator will cooperate with [COMPANY_007] 
or its agents to prepare the investigator site for the inspection and will allow [COMPANY_007] or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject' s medical records.  The investigator will promptl y provide copi[INVESTIGATOR_74040].  Before response submission to the regulatory 
authorities, the investigator will provide [COMPANY_007] or its agents with an opportunity  to review
and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HAN DLING AND RECORD KEE PI[INVESTIGATOR_1645]
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of [COMPANY_007] and should not be made available in any form to 
third parties, except for authorized representatives of [COMPANY_007] or appropriate regulatory  
authorities, without written permission from [COMPANY_007].
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y, and laboratory data entered on the CRFs and any other data collection forms (source 
docum ents) and ensuring that they  are accurate, authentic/original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring, and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to at test that the 
data contained on the CRFs are true.  An y corrections to entries made in the CRFs or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the 
original entry . 
In most cases, the source documents are t he hospi[INVESTIGATOR_74041].  In these 
cases, data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at [COMPANY_007] that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or inspections/audits from regulatory authorities or [COMPANY_007], the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed 
informed consent/assent documents, copi[INVESTIGATOR_4600], safet y reporting form s, source 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 101documents, and detailed records of treatment disposition, and adequate documentation of 
relevant correspondence (eg, letters, meeting minutes, and telephone call reports).  The 
records should be retained by  [CONTACT_74099] g uidelines, according to 
local regulations, or as specified in the clinical study  agreement (CSA), whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period (eg, retirement, relocation ), [COMPANY_007] should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to [COMPANY_007], such as another 
investigator, another institution, or an independent third party  arranged by  [CONTACT_4618]. 
Investigator records must be kept f or a minimum of [ADDRESS_80884] obtain [COMPANY_007]'s written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent/assent documents, and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the 
IRB/EC should be retained in the investigator file.  Copi[INVESTIGATOR_1309] I RB/EC approvals should be 
forwarded to [COMPANY_007].
The only  circumstance in which an amendment may  be initiate d prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and [COMPANY_007] in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International O rganizations of 
Medical Sciences 2002), ICH Guideline for Good Clinical Practice, and the Declaration of 
Helsinki.
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other ident ifiable data in any  reports, publications, or other disclosures, except where 
required b y law. 
When study  data are compi[INVESTIGATOR_47581], subject 
names, addresses, and other identifiable data will be replaced b y nume rical codes based on a 
numbering s ystem provided by  [CONTACT_47617] -identify  study  subjects.  The investigator 
site will maintain a confidential list of subjects who participated in the study, linking each 

PF-[ADDRESS_80885]’s numerical code to his or her actua l identity .  In case of data transfer, [COMPANY_007] will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws.
The informed consent/assent documents and an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws.
The informed consent/assent documents used during the informed consent process and any  
subject recruitment materials must be reviewed and approved b y [COMPANY_007], approved b y the 
IRB/EC before use, and available for inspection.
The investigator must ensure that each study  subject, or his or her parent(s)/legal guardian if 
a minor, is fully  informed about the nature and objectives of the study  and possible risks 
associated with participation. 
Whenever consent is obtained from a subject’s parent(s)/legal guardian, the subject’s assent 
(affirmative agreement) must subsequently  be obtained when the subject has the capacit y to 
provide assent, a s determined by  [CONTACT_1201]/EC.  If the investigator determines that a subject’s 
decisional capacit y is so limited he/she cannot reasonably be consulted, then, as permitted b y 
the IRB/EC and consistent with local regulatory  and legal requirements, the subject’ s assent 
may be waived with source documentation of the reason assent was not obtained.  If the 
study  subject does not provide his or her own consent, the source documents must record 
why the subject did not provide consent (eg, minor, decisionall y impaire d adult), how the 
investigator determined that the person signing the consent was the subject’s parent(s)/legal 
guardian, the consent signer’s relationship to the study  subject (eg, parent, spouse), and that 
the subject’s assent was obtained or waived.  Ifassent is obtained verball y, it must be 
documented in the source documents.
If the stud y includes minor subjects who reach the age of majorit y during the study, as 
recognized under local law, they  must reconsent as adults to remain in the study .  If the 
enrollment of emancipated minors is permitted by  [CONTACT_74100], the I RB/EC, and 
local law, they  must provide documentation of legal status to give consent without the 
permission of a parent or legal guardian. 
The investigator, or a person designat ed by [CONTACT_093], will obtain written informed 
consent from each subject or the subject's parent(s)/legal guardian and the subject’s assent, 
when applicable, before any  study -specific activity  is performed.  The investigator will retain 
the original 
of each subject's signed consent/assent document.
12.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, [COMPANY_007] should be informed immediately. 

PF-[ADDRESS_80886] visit (L SLV).
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opi[INVESTIGATOR_1100]/EC, or investigational product safety  problems, or at the 
discretion of [COMPANY_007].  In addition, [COMPANY_007] retains the right to discontinue development of 
PF-[ADDRESS_80887] all participating subjects and the hospi[INVESTIGATOR_4601]  
(if applicable) within [ADDRESS_80888] extent pos sible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by [CONTACT_74101].clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
[COMPANY_007] posts clinical trial US Basic Results on www.clinicaltrials.gov for [COMPANY_007] -sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
[COMPANY_007] product, regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within [ADDRESS_80889]
[COMPANY_007] posts European Union (EU) Basic Results on EudraCT for all [COMPANY_007] -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
[COMPANY_007] posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov.
15.2. Publications by [CONTACT_74102] (PI) of the results of the study based on information collected or 
generated b y the PI, whether or not the results are favorable to the [COMPANY_007] product.  However, 
to ensure against inadvertent disclosure of confidential information or unprotected 
inventions, the investigator will provide [COMPANY_007] an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study (collectively, “publ ication”) 
before it is submitted or otherwise disclosed.
The investigator will provide any  publication to [COMPANY_007] at least [ADDRESS_80890] to the other 
requirements of this section.
For all publications relating to the stud y, the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  [CONTACT_4717].

PF-[ADDRESS_80891] between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will control as to all other 
issues.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [ZIP_CODE].REFERENCES
1. Eichenfield LF, Ellis CN, Mancini AJ, et al. Atopic dermatitis: epi[INVESTIGATOR_74042]. Semin Cutan Med Surg 2012;31([ADDRESS_80892])(Sep):S3 -5.
2. Leicht S, Hanggi M. Atopic dermatitis. How to incorporate advances in management. 
Postgrad Med 2001;109(6)(Jun):119-27.
3.
Margolis JS, Abuabara K, Bilker W, et al. Persistence of mild to moderate atopic 
dermatitis. JAMA Dermatol 2014;150(6):593-600.
4. Slater NA, Morrell DS. Sy stemic th erapy of childhood atopic dermatitis. Clin Dermatol 
2015;33(3): 289 -299.
5. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003;361(9352):151-160.
6. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic 
dermatitis) part I. J Eur Ac ad Dermatol Venereol  2012;26(8):1045 -60.
7. Auriemma M, Vianale G, Amerio P, et al. Cy tokines and T cells in atopic dermatitis Eur 
Cytokine Netw 2012; 24(1):37 -44.
8. Mortz C, Andersen K, Dellgren C, et al. Atopic dermatitis from adolescents to 
adulthood in the TOACS cohort: prevalence, persistence and comorbidities. Allergy  
2015;70:836 -45. 
9. Sandstrom M., Faergemann J. Prognosis and prognostic factors in adult patients with 
atopic dermatitis: a long -term follow -up questionnaire study . British J. of Dermatology  
2004;150:102 - 10.
10. Deckers I, McLean AS, Linssen S, Mommers M, et al. Investigating international time 
trends in the incidence and prevalence of atopic eczema 1990- 2010: a sy stematic review 
of epi[INVESTIGATOR_74043] 2012;7(7):e39803.
11. Silverberg J I, Hanifin JM. Adult eczema prevalence and associations with asthma and 
other health and demographic factors: a US population
-based study . J Allergy  Clin 
Immunol 2013;132(5): 1132-1138.
12. Lee CH, Chuang HY, Hong CH, Huang SK, et al. Lifetime exposure to cigaret te 
smoking and the development of adult -onset atopic dermatitis.Br J Dermatol 
2011;164(3): 483 -9.
13. Homey  B, Steinhoff M, Ruzicka T, et al. Cy tokines and chemokines orchestrate atopic 
skin inflammation.J Allergy  Clin Immunol 2006;118(1):178 -89.
14. Cornelissen C , Luscher -Firzlaff J, Baron JM, et al. Signaling b y IL-31 and functional 
consequences. Eur J Cell Biol 2012;91(6- 7):552- 66.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [ZIP_CODE]. Gittler JK, Shemer A, Suarez -Farinas M, Fuentes -Duculan J, et al. Progressive 
activation of T(H)2/T(H)22 cy tokines and selective epi [INVESTIGATOR_74044]. J Allergy  Clin I mmunol 2012;130(6):1344 -54.
16. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 
1980;92(suppl):44-7.
17. Posner K, Oquendo MA, Gould M, et al. Colu mbia Classification Algorithm of Suicide 
Assessment (C -CASA): classification of suicidal events in the FDA's pediatric suicidal 
risk anal ysis of antidepressants. Am J Psy chiatry  2007;164(7):1035-43.
18. Osman A, Bagge CL, Gutierrez PM, et al. The Suicidal Beha viors 
Questionnaire -Revised (SBQ -R): validation with clinical and nonclinical samples. 
Assessment. 2001; 8(4):[ADDRESS_80893] 2009;114(1- 3);163–73. 
20. Yosipovitch G, Reaney  M, Mastey  V, et al. Validation of the peak pruritus numerical 
rating scale: Results from clinical studies of dupi[INVESTIGATOR_74045] -to-severe atopic dermatitis: 5063. Journal of the American Aca demy  of 
Dermatology . 2017 Jun 1;76(6):AB278.
21. Rabin R, Gudex C, Selai C, et al. From translation to version management: a history  and 
review of methods for the cultural adaptation of the EuroQol five -dimensional 
questionnaire. Value in Health 2014;17(1):70 -6.  
22. Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ -5D- 5L: mappi[INVESTIGATOR_74046] -5D- 5L to EQ -5D- 3L value sets. Value in Health 2012;15(5):708 -15.  
23. Ramos -Goñi JM, Pi[INVESTIGATOR_1946] -Prades J L, Oppe M, et al. Valuation and modeling of EQ -5D- 5L 
health states using a h ybrid approach. Medical care 2017;55(7):e51 -8.  
24. Yang Y, Brazier J, L ongworth L . EQ-5D in skin conditions: an assessment of validity  
and responsiveness. Eur J Health Econ. 2015;16(9):927-939.
25. Janssen MF, Pi[INVESTIGATOR_19370], Golicki D, et al. Measurement properties of the EQ -5D- 5L 
compared to the EQ -5D- 3L across eight patient groups: a multi -country  study . Quality  
of Life Research. 2013;22(7):1717 -27.  
26. Herdman M, Gudex C, Lloy d A, et al. Development and preliminary  testing of the new 
five-level version of EQ-5D (EQ -5D- 5L). Quality  of life research 2011;20(10):1727-36. 
27. Agborsangay a CB, Lahtinen M, Cooke T, Johnson JA. Comparing the EQ -5D 3L and 
5L: measurement properties and association with chronic conditions and multimorbidity  
in the general population. Health and qualit y of life outcomes 2014;12(1):74.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [ZIP_CODE]. Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, Egmar AC, Greiner W, 
Gusi N, Herdman M, Jelsma J  Development of the EQ -5D- Y: a child -friendly  version 
of the EQ -5D.  Qual Life Res 2010 Aug;19( 6):875 -886. 
29. Ravens -Sieberer U, Wille N, Badia X, et al. Feasibility , reliability , and validity  of the 
EQ-5D- Y: results from a multinational study . Qual L ife Res 2010;19(6):887 -97. 
30. EuroQol Group. EuroQolea new facilit y for the measurement of health -relate d quality  
of life. The EuroQol Group. Health Policy  1990;16:199 -208.
31. Simpson EL , Gadkari A, Worm M, et al. Dupi[INVESTIGATOR_74047]-reported outcomes (PROs): A phase IIb, 
randomized, placebo -controlled, clinic al trial in adult patients with moderate to severe 
atopic dermatitis (AD). J Am Acad Dermatol. 2016;75(3):506-515.
32. Simpson EL , Bieber T, Guttman -Yassk y E, et al. Two Phase 3 trials of dupi[INVESTIGATOR_74048]. N Engl J Med. 2016;375:23 35-2348.
33.
Poole CD, Chambers C, Sidhu MK, et al. Health- related utility  among adults with 
atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therap y over 
the long term: findings from the Protopic CONTROL  study . Br J Dermatol 
2009;161(6): 1335-40.
34.
Kim C, Park KY, Ahn S, et al. Economic impact of atopic dermatitis in Korean patients. 
Ann Dermatol. 2015;27(3):298-305. 
35. Finlay  AY, Khan GK. Dermatology  Life Quality  Index (DLQI): A simple practical 
measure for routine clinical use. Clinical and Experimental Dermatology  1994;19: 
210-216.
36. Basra MK, Salek MS, Camilleri L , et al. Determining the minimal clinically  important 
difference and responsiveness of the Dermatology  Life Qualit y Index (DLQI): further 
data. Dermatology . 2015;230(1):27
-33.
37. Lewis -Jones MS, Finlay  AY. The Children's Dermatology  Life Quality  Index (CDL QI): 
Initial validation and practical use. British Journal of Dermatology  1995;132:942 -49. 
38. Ersser SJ, Cowdell F, L atter S, et al. Psy chological and educational interventions for 
atopic eczema in children. The Cochrane Library . 2014;Jan 1. 
39. Schmitt J, Langan S, Williams H, et al. What are the best outcome measurements for 
atopic eczema? A sy stematic review. J Allergy  Clinical I mmunol 2007;120(6):1389 -98. 
40. White D, L each C, Sims R, et al. Validation of the Hospi[INVESTIGATOR_74049]. Br J Psy chiatry  1999;175(5):452-4.  

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page [ZIP_CODE]. Ware J, Kosinski M, Bjorner J, et al. Determining important differences in scores. 
User's Manual for the SF -36v2® Health Survey . Lincoln (RI): Quality Metric 
Incorporated; 2007:125-33.
42. Reilly  MC, Tanner A, Meltzer EO. Work, classroom and activity  impairment 
instruments. Validation studies in allergic rhinitis. Clin Drug Invest 1996;11(5):278 -
288.
43. Reilly  MC, Zbrozek AS, Dukes EM. The Validit y and Reproducibility  of a Work 
Productivity  and Activit y Impairment Instrument. PharmacoEconomics 1993;4(5):353-
365.
44. Reilly  MC, Lavin PT, Kahler KH, et al. Validation of the Dermatology  Life Quality  
Index (DLQI) and the Work Productivity  and Activity  Impairment: Chronic Hand 
Dermatitis Questionnaire (WPAI -ChHD) in Chronic Hand Dermatitis (ChHD). J Am 
Academ y Dermatol. 2003;48:128 -30.
45. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in 
the general [LOCATION_002] population. Cancer 2002;94(2):5 28 -38. 
46. Lai J, Cella D, Holm S, et al, Measuring Fatigue for Children with Cancer: 
Development and Validation of the Pediatric Functional Assessment of Chronic I llness 
Therap y Fatigue (PEDSFACI T-F). J Pediatr Hematol Oncol 2007;29(7): 471-9.

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 1 0 A p p e n d i x 1 . A b b r e v i a t i o n s  
T h i s  f o l l o w i n g  i s  a  l i s t  o f  a b b r e v i a t i o n s  t h a t  m a y  b e  u s e d  i n  t h e  p r o t o c o l .  
A b b r e v i a t i o n T e rm 
A D a t o p i c  d e rm a t i t i s 
A E a d v e r s e  e v e n t 
A L T a l a n i n e  am i n o t r a n s f e r a s e 
A S T a s p a r t a t e  am i n o t r a n s f e r a s e 
A T P a d e n o s i n e  t r i p h o s p h a t e 
A U C A r e a  u n d e r  t h e  c u r v e 
A U C i n f a r e a  u n d e r  t h e  c u r v e  f r om  t im e  z e r o  e x t r a p o l a t e d  t o  i n f i n i t y 
A U C l a s t a r e a  u n d e r  t h e  c u r v e  f r om  t im e  z e r o  t o  l a s t  q u a n t i f i a b l e 
A U C t a u a r e a  u n d e r  t h e  c u r v e  o v e r  d o s i n g  i n t e r v a l  t a u 
B B S B i o s p e c im e n  B a n k i n g  S y s t em 
B C G B a c i l l e  C a lm e t t e  G u é r i n 
B I D t w i c e  a  d a y 
B P b l o o d  p r e s s u r e 
B S A b o d y  s u r f a c e  a r e a 
Cm a x m a x im um  c o n c e n t r a t i o n  
C D c l u s t e r  o f  d i f f e r e n t i a t i o n 
C F B c h a n g e  f r om  b a s e l i n e 
C I c o n f i d e n c e  i n t e r v a l 
C L / F c l e a r a n c e / f r a c t i o n  o f  d o s e  a b s o r b e d 
C O 2 c a r b o n  d i o x i d e 
C K c r e a t i n e  k i n a s e 
C R F c a s e  r e p o r t  f o rm 
C S A c l i n i c a l  s t u d y  a g r e em e n t 
C s A c y c l o s p o r i n e A
C S c l i n i c a l l y  s i g n i f i c a n t 
C S F c e r e b r o s p i n a l  f l u i d 
C S R c l i n i c a l  s t u d y  r e p o r t 
C - S S R S C o l um b i a  S u i c i d e  S e v e r i t y  R a t i n g  S c a l e 
C T c l i n i c a l  t r i a l 
C T A c l i n i c a l  t r i a l  a p p l i c a t i o n 
C T C A E C omm o n  T e rm i n o l o g y  C r i t e r i a  f o r  A d v e r s e  E v e n t s 
C V C o e f f i c i e n t  o f  v a r i a t i o n 
D I L I d r u g -i n d u c e d  l i v e r  i n j u r y 
DM C d a t a  m o n i t o r i n g  c omm i t t e e 
D N A d e o x y r i b o n u c l e i c  a c i d 
D U d i s p e n s a b l e  u n i t 
E A S I E c z em a  A r e a  a n d  S e v e r i t y  I n d e x C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 1 1 A b b r e v i a t i o n T e rm 
E A S I - 7 5 E c z em a  A r e a  a n d  S e v e r i t y  I n d e x  7 5%  im p r o v em e n t  f r om  
b a s e l i n e 
E B V E p s t e i n  B a r r  v i r u s 
E C e t h i c s  c omm i t t e e 
E C G e l e c t r o c a r d i o g r am 
e - D i a r y e l e c t r o n i c  d i a r y 
E - DM C e x t e r n a l  d a t a  m o n i t o r i n g c omm i t t e e  
E D P e x p o s u r e  d u r i n g  p r e g n a n c y 
E L I S A E n z y m e -L i n k e d  Im m u n o s o r b e n t  A s s a y 
EM A E u r o p e a n  M e d i c i n e s  A g e n c y 
E O S e n d  o f  s t u d y 
E O T e n d  o f  t r e a tm e n t 
E P O e r y t h r o p o i e t i n 
e P R O e l e c t r o n i c  P a t i e n t  R e p o r t e d  O u t c om e  
E T e a r l y  t e rm i n a t i o n  
E U E u r o p e a n  U n i o n 
E u d r a C T E u r o p e a n  C l i n i c a l  T r i a l s  D a t a b a s e 
F A C s f l u o r e s c e n c e - a c t i v a t e d  c e l l  s o r t i n g 
F A S f u l l  a n a l y s i s  s e t 
F D A F o o d  a n d  D r u g  A dm i n i s t r a t i o n  
F S H f o l l i c l e -s t im u l a t i n g  h o rm o n e 
G C P G o o d  C l i n i c a l  P r a c t i c e 
G G T G amm a -g l u t am y l  t r a n s f e r a s e 
GM -C S F g r a n u l o c y t e -m a c r o p h a g e  c o l o n y -s t im u l a t i n g  f a c t o r 
H B s A b h e p a t i t i s  B  s u r f a c e  a n t i b o d y 
H B s A g h e p a t i t i s  B  s u r f a c e  a n t i g e n 
H B c A b  h e p a t i t i s  B  c o r e  a n t i b o d y
H B V h e p a t i t i s  B  v i r u s 
H B V  D N A h e p a t i t i s  B  v i r u s  d e o x y r i b o n u c l e i c  a c i d 
H C V h e p a t i t i s  C  v i r u s 
H C V A b  h e p a t i t i s  C  a n t i b o d y 
H C V  R N A h e p a t i t i s  C  v i r a l  r i b o n u c l e i c  a c i d 
H D L h i g h -d e n s i t y  l i p o p r o t e i n  
H E E N T h e a d ,  e y e s ,  e a r s ,  n o s e  a n d  t h r o a t 
H I V h um a n  imm u n o d e f i c i e n c y  v i r u s 
H R Q L h e a l t h -r e l a t e d  q u a l i t y  o f  l i f e 
h s C R P h i g h -s e n s i t i v i t y  C - r e a c t i v e  p r o t e i n 
H S V h e r p e s  s im p l e x  v i r u s 
H T A h e a l t h  t e c h n o l o g i e s  a s s e s sm e n t  C C I 
C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 1 2 A b b r e v i a t i o n T e rm 
I B I n v e s t i g a t o r ’ s  B r o c h u r e 
I C H I n t e r n a t i o n a l  C o n f e r e n c e  o n  H a rm o n i s a t i o n 
I D i d e n t i f i c a t i o n 
I F N i n t e r f e r o n 
I F N - i n t e r f e r o n -a l p h a 
I F N - i n t e r f e r o n -g amm a 
I G A I n v e s t i g a t o r ’ s  G l o b a l  A s s e s sm e n t 
I g E  Imm u n o g l o b u l i n  E 
I g G imm u n o g l o b u l i n  G 
I I V i n t e r  i n d i v i d u a l  v a r i a b i l i t y 
I L i n t e r l e u k i n 
I N D i n v e s t i g a t i o n a l  n e w  d r u g  a p p l i c a t i o n 
I N R i n t e r n a t i o n a l  n o rm a l i z e d  r a t i o 
I P i n v e s t i g a t i o n a l  p r o d u c t 
I R B i n s t i t u t i o n a l  r e v i e w  b o a r d 
I R C i n t e r n a l  r e v i e w  c omm i t t e e 
I R T i n t e r a c t i v e  r e s p o n s e  t e c h n o l o g y 
I U D i n t r a u t e r i n e  d e v i c e 
IW R i n t e r a c t i v e  w e b  r e s p o n s e 
J A K J a n u s  k i n a s e 
J A K 1 J a n u s  k i n a s e  1 
K2E D T A d i p o t a s s i um  e t h y l e n e d i am i n e t e t r a a c e t i c  a c i d 
L D L l o w -d e n s i t y  l i p o p r o t e i n 
L F T l i v e r  f u n c t i o n  t e s t 
L L Q l o w e r  l im i t  o f  q u a n t i f i c a t i o n 
L S L V la s t  s u b j e c t  l a s t  v i s i t  
L T E l o n g -t e rm  e x t e n s i o n 
M A A m a r k e t i n g  a u t h o r i s a t i o n  a p p l i c a t i o n 
M C H m e a n  c o r p u s c u l a r  h em o g l o b i n 
M C H C m e a n  c o r p u s c u l a r  h em o g l o b i n  c o n c e n t r a t i o n 
M C V m e a n  c o r p u s c u l a r  v o l um e 
MM RM m i x e d -e f f e c t  m o d e l  w i t h  r e p e a t e d  m e a s u r e s 
M n B m e n i n g i t i d i s  s e r o g r o u p  B 
M R I m a g n e t i c  r e s o n a n c e  im a g i n g 
M T X m e t h o t r e x a t e 
N / A n o t  a p p l i c a b l e 
N B -U V B n a r r o w b a n d  u l t r a v i o l e t  B  l i g h t 
N R S  n um e r i c a l  r a t i n g  s c a l e 
P C D p r im a r y  c om p l e t i o n  d a t e 
P C P p r im a r y  c a r e  p h y s i c i a n 
P D P h a rm a c o d y n am i c s 
P E E R  S t u d y P e d i a t r i c  E c z em a  E l e c t i v e  R e g i s t r y  S t u d y 
 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 1 3 A b b r e v i a t i o n T e rm 
P F S p r e f i l l e d  s y r i n g e 
P G I C P a t i e n t  G l o b a l  I m p r e s s i o n  o f  C h a n g e 
P G I S P a t i e n t  G l o b a l  I m p r e s s i o n  o f  S e v e r i t y 
P G x P h a rm a c o g e n om i c s 
PH Q 8 P a t i e n t  H e a l t h  Q u e s t i o n n a i r e  -8  i t em s 
P I p r i n c i p a l  i n v e s t i g a t o r 
P K P h a rm a c o k i n e t i c s 
P O C p r o o f  o f  c o n c e p t 
P P A S p e r - p r o t o c o l  a n a l y s i s  s e t 
P P D p u r i f i e d  p r o t e i n  d e r i v a t i v e  t e s t 
P T p r o t h r om b i n  t im e 
 
Q D o n c e  d a i l y
Q F T - G Q u a n t i F E R O N -T B  G o l d 
Q T Q  w a v e  i n t e r v a l 
Q T c c o r r e c t e d  Q  w a v e  i n t e r v a l 
Q T c F F r i d e r i c i a  c o r r e c t e d  Q  w a v e  i n t e r v a l 
Ra c a c c um u l a t i o n  r a t i o  
R B C r e d  b l o o d  c e l l 
R N A r i b o n u c l e i c  a c i d 
S A E s e r i o u s  a d v e r s e  e v e n t 
S A P s t a t i s t i c a l  a n a l y s i s  p l a n 
S B Q - R S u i c i d e  B e h a v i o r s  Q u e s t i o n n a i r e - R e v i s e d 
S C O R A D  S c o r i n g  A t o p i c  D e rm a t i t i s 
S O C s y s t em  o r g a n  c l a s s 
S O P s t a n d a r d  o p e r a t i n g  p r o c e d u r e 
S R S D s i n g l e  r e f e r e n c e  s a f e t y  d o c um e n t 
S T A T s i g n a l  t r a n s d u c e r s  a n d  a c t i v a t o r s  o f  t r a n s c r i p t i o n 
S U S A R s u s p e c t e d  u n e x p e c t e d  s e r i o u s  a d v e r s e  r e a c t i o n 
t½ H a l f -l i f e 
Tm a x t im e  t o  m a x im um  a b s o r p t i o n 
T A R C t h y m u s  a n d  a c t i v a t i o n  r e g u l a t e d  c h em o k i n e 
T B t u b e r c u l o s i s 
T B i l i t o t a l  b i l i r u b i n 
T d P T o r s a d e  d e  P o i n t e s 
T H 1 t y p e  1  h e l p e r  T  c e l l 
T H 2 t y p e  2  h e l p e r  T  c e l l 
T Y K 2 t y r o s i n e  k i n a s e  2 C C I 
C C I 
C C I 
C C I 
C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 1 4 A b b r e v i a t i o n T e rm 
U L N u p p e r  l im i t  o f  n o rm a l 
U S U n i t e d  S t a t e s 
U V A u l t r a v i o l e t  A  l i g h t 
U V B u l t r a v i o l e t  B  l i g h t 
V A S v i s u a l  a n a l o g  s c a l e 
V / F v o l um e  o f  d i s t r i b u t i o n / f r a c t i o n  a b s o r b e d 
V H P V o l u n t a r y  H a rm o n i s a t i o n  P r o c e d u r e 
V Z V  v a r i c e l l a  z o s t e r  v i r u s 
W B C w h i t e  b l o o d  c e l l 
W O N C B P  w om e n  o f  n o n - c h i l d b e a r i n g  p o t e n t i a l 
 C C I 
PF-[ADDRESS_80894] a clinical diagnosis of atopic dermatitis 
according to the criteria of Hanifin and Rajka.16
Hanifin and Rajka’s Diagnostic Criteria for Atopic Dermatitis
Must have three or more basic features described below:
Pruritus
Typi[INVESTIGATOR_74050]:
Flexural lichenific ation in adults
Facial and extensor eruptions in infants and children
Chronic or chronically -relapsing dermatitis
Personal or famil y history of atop y (asthma, allergic rhinitis, atopic dermatitis)
Must have three or more following minor features:
Xero sis
Ichthy osis/palmar hy perlinearity , keratosis pi[INVESTIGATOR_74051] (t ype 1) skin test reaction
Elevated serum IgE
Early age of onset
Tendency  toward cutaneous infections (esp. staph. aureus and herpes simplex), impaired 
cell-mediated immunity
Tendency toward non- specific hand or foot dermatitis
Nipple eczema
Cheilitis
Recurrent conjunctivitis
Dennie -Morgan infraorbital fold
Keratoconus
Anterior subcapsular cataracts
Orbital darkening
Facial pallor, facial ery thema
Pi[INVESTIGATOR_74052] b y environmental and emotional factors
White dermographism, delay ed blanch

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 116Appendix 3.Prohibited Concomitant Medications
CYP2C19 Inhibitors CYP2C19 Inducers
Amitripty line (Elavil) Enzalutamide (Xtandi)
Clomipramine (Anafranil) Rifampin
Fluconazole (Diflucan)
Fluvoxamine (L uvox)
Imipramine (Tofranil)
Ticlopi[INVESTIGATOR_5325] (Ticlid)
Esomeprazole (Nexium)
Fluoxetine (Prozac)
Moclobemide
Omeprazole (Prilosec)
Voriconazole (Vfend)
CYP2C9 Inhibitors CYP2C9 Inducers
Fluconazole (Diflucan) Carbamazepi[INVESTIGATOR_050] (Tegretol)
Amiodarone (Cordarone) Enzalutamide (Xtandi)
Fluvoxamine (L uvox) Rifampin
Miconazole
Oxandrolone (Oxandrin)
Voriconazole (Vfend)

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 117Appendix 4.Guidelines for Monitoring and Discontinuation 
Monitoring Criteria 
The following laboratory abnormalities require prompt retesting:
Neutrophil counts <1000 neutrophils/mm3; confirmed promptly  by [CONTACT_15013], 
ideally  with in 3-5 day s; 
Lym phocy te count <500/mm3
; confirmed promptly b y repeat testing, ideally within 
3-5 day s;
Platelet counts <75,000 platelets/mm3; confirmed promptly  by [CONTACT_15013], ideally  
within 3 -5 day s; 
Any single hemoglobin value < 9.0g/dL or one that drops 
2g/dL below baseline; 
confirmed promptl y by [CONTACT_15013], ideall y within 3- 5 day s; 
Any single AST and/or AL T elevation >3 times the upper limit of normal regardless 
of accompan ying symptoms or the total Bilirubin should prompt repeat testing.  This 
should also prompt review of Section 8.4.2; additional investigations must be 
conducted.
Discontinuation Criteria
Subjects must be permanently  discontinued from treatment if they  meet any of the following 
criteria at an y point in the study:
Marked prolongation of the QTcF interval to >500 ms or >60 ms change from 
screening ECG.
Note: an y quoted lab value below must be confirmed by [INVESTIGATOR_1312] -test, preferably  within 48 hours.
Serious infection (see definition for Serious Adverse Events in Section
8.2.3).
Two sequential platelet counts <50,000/mm3.  If the subject has a platelet count 
<25,000/mm3, investigat ional product should be discontinued pending the 
confirmatory  retest.  If the subject has a platelet count <50,000/mm3 and the 
confirmatory  retest cannot be obtained within [ADDRESS_80895]. 
Any platelet count reduction thought to be associated with a bleeding event per the 
judgement of the investigator ( or, if necessary /desired, following discussion with 
sponsor) .
Two sequential neutrophil counts <500/mm3.

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 118Two sequential l ymphocy te co unts <500/mm3.
Two sequential hemoglobin assessments <8.0 g/dL or a decrease of more than 
30% from baseline value (either criteria or both) .
Any of the following:
Two sequential AST or AL T elevations >[ADDRESS_80896] one Tot al Bilirubin value >2 times the upper limit of normal.
Two sequential AST or AL T elevations >3 times the upper limit of normal with an 
abnormal INR.
Two sequential AST or AL T elevations >3 times the upper limit of normal 
accompanied b y symptoms consistent with hepatic injury .
Two sequential AST or AL T elevations >5 times the upper limit of normal, regardless 
of Total Bilirubin or accompany ing s ymptoms.
Two sequential increases in serum creatinine that are >50% over the average of 
screening and baseline valu es AND an absolute increase in serum creatinine 
0.5mg/dL.  At the time of study  completion or discontinuation, if a patient should 
exhibit elevations in serum creatinine 33% above the average of screening and 
baseline values, they  will be re -tested ever y 1 to 2 weeks until the serum creatinine 
elevation is fully  reversed to within 10% of the average of screening and baseline 
values or has stabilized.
Other adverse event, per judgment of the investigator, requiring discontinuation from 
treatment (or, if n ecessary /desired, following discussion with sponsor).

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 119Appendix 5.Fitzpatrick Skin Type 

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 120Appendix 6. Pruritus Severity and Frequency (Pruritus NRS)
Severity of Pruritus
On a scale of 0 to 10, with 0 being “no itch” and 10 being “worst itch imaginable”, how 
would y ou rate y ouritch at the worst moment during the previous 24 hours? 
Frequency of Pruritus
Select the number that best describes frequency  of itching due to Atopic Dermatitis over the 
past 24 hours (check one number only ).[ADDRESS_80897] 
itch
imaginable
10 9 8 7 6 5 4 3 2 1 010 9 8 7 6 5 4 3 2 1 0
Never /No 
itchingAlway s/constant 
itching

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 121Appendix 7. Night Time Itch Scale
Severity of Night Time Itch  
On a scale of 0 to 10, with 0 being “no itch” and 10 being “worst itch imaginable” , how 
would y ou rate y our itch at the worst moment during your most recent night’s sleep ?      
(select one number onl y)
□  □ □ □ □ □ □ □ □ □ □
[ADDRESS_80898] itch 
itch imaginable 
Frequency of Night Time Itch
On a scale of 0 to 10, with 0 being “no itching” and 10 being “constant itching”, how would 
you rate the frequency  of itching during your most recent night’s sleep (select one number 
only)
□  □ □ □ □ □ □ □ □ □ □
0 1 2 3 4 5 6 7 8 9 10
Never/No Alway s/Constant 
itching itching 

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 2 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 3  
 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 4 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  12 5 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 6 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 7 A Y  F i n l a y ,  G K  K h a n ,  A p r i l  1 9 9 2 ,  T h i s  m u s t  n o t  b e  c o p i e d  w i t h o u t  t h e  p e rm i s s i o n  o f  t h e  a u t h o r s . C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 128

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 2 9 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 0 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 1 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 2 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 3 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 4 C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 135

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 6 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 7 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 3 8 C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 139

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 140

P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 1 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 2 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 3 W P A I : A D  v 2 . 0  ( U S  E n g l i s h ) C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 4 C C I 
P F -0 4 9 6 5 8 4 2 
B 7 4 5 1 0 1 3 
F i n a l  P r o t o c o l  Am e n dm e n t  3 ,  0 6  D e c em b e r  2 0 1 8 
P a g e  1 4 5 C C I 
PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 146Appendix 17. C- SSRS – Columbia Suicide Severity Rating Scale

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 147

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 148

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 149Appendix 18.SBQ -R –Suicide Behaviors Questionnaire –Revised

PF-04965842
B7451013
Final Protocol Amendment 3, 06 December 2018
Page 150Appendix 19. Patient Health Questionnaire – 8 item s
